MITOGEN-ACTIVATED PROTEIN KINASE KINASE (MEK) DEGRADATION COMPOUNDS AND METHODS OF USE

Abstract

This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

Description

BACKGROUND

There is a need in the art for compounds, compositions, and methods of use of the compounds for the treatment of diseases in a subject in need thereof.

SUMMARY

This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use of the heterobifunctional compounds for the treatment of certain diseases in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

According to the first aspect of the present disclosure, a heterobifunctional compound disclosed herein comprises a mitogen-activated protein kinase kinase (MEK) Ligand conjugated to a Degradation Tag through a Linker, which comprises a moiety of FORMULA I:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof.

In another embodiment, the MEK Ligand moiety in FORMULA I is capable of binding to a MEK protein comprising a MEK mutant, MEK deletion, or a MEK fusion protein.

In another embodiment, the MEK Ligand moiety in FORMULA I is capable of binding to a MEK protein comprising MEK1 and/or MEK 2.

In another embodiment, the MEK Ligand moiety in FORMULA I is a MEK inhibitor or a portion of MEK inhibitor.

In one embodiment, the MEK Ligand moiety in FORMULA I binds to an allosteric site of MEK.

In another embodiment, the MEK Ligand moiety in FORMULA I binds to the ATP-binding site of MEK.

In another embodiment, the MEK Ligand moiety in FORMULA I is selected from the group consisting of PD0316684, PD184352, Cobimetinib, Binimetinib, GDC-0623, G-573, CH5126766, Trametinib, TAK-733, MAP855, E6201, and BI-847325.

In another embodiment, Degradation Tag moiety in FORMULA I is capable of binding to a ubiquitin ligase, or a hydrophobic group, or a tag that leads to misfolding of the MEK proteins.

In another embodiment, Degradation Tag moiety in FORMULA I is capable of binding to an E3 ligase.

In another embodiment, the Degradation Tag moiety in FORMULA I is capable of binding to a VHL E3 ligase, a cereblon E3 ligase, an IAP ligase, a MDM2 ligase, a TRIM24 ligase, a TRIM21 ligase, a KEAP1 ligase, DCAF16 ligase, RNF4 ligase, RNF114 ligase, or AhR ligase.

In another embodiment, Degradation Tag moiety in FORMULA I is capable of binding to a VHL E3 ligase or a cereblon E3 ligase.

In another embodiment, Degradation Tag moiety in FORMULA I is capable of binding to a VHL E3 ligase.

In another embodiment, the Degradation Tag moiety in FORMULA I is selected from the group consisting of VHL-1, pomalidomide, thalidomide, lenalidomide, adamantane, 1-((4,4,5,5,5-pentafluoropentyl)sulfinyl)nonane, nutlin-3a, RG7112, RG7338, AMG232, AA-115, bestatin, MV-1, LCL161, CPD36, GDC-0152, CRBN-1, CRBN-2, CRBN-3, CRBN-4, CRBN-5, CRBN-6, CRBN-7, CRBN-8, CRBN-9, CRBN-10, CRBN-11, CRBN-12, CRBN-13, CRBN-14, CRBN-15, or CRBN-16.

In another embodiment, the heterobifunctional compound disclosed herein comprises a moiety of FORMULA I-1:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

i) *, Ar¹, Ar², A, and B are defined as hereinafter;

ii) E3 Ligase Binder moiety is of FORMULAE 6A, 6B, and 6C:

wherein *, R_E¹, R_E², R_E²′, R_E³, R_E⁴, R_E⁴′, R_E⁵, and R_E⁶ are defined as hereinafter;

or,

E3 Ligase Binder moiety is of FORMULA 5:

wherein *, R_E¹, Z_E, ring A_E, and L_E, are defined as hereinafter;

and iii) the Linker moiety is of FORMULA 9:

wherein m_L, A_L¹, W_L² and B_L are defined as hereinafter.

In some embodiments, the compound comprises any one of the compounds in Table 1.

In some embodiments, the heterobifunctional compound is selected from the group consisting of CPD-001 to CPD-097 or a pharmaceutically acceptable salt or analog thereof.

In some embodiments, the heterobifunctional compound is selected from the group consisting of CPD-11, CPD-13, CPD-14, CPD-24, CPD-31, CPD-33, CPD-35, CPD-36, CPD-37, CPD-38, CPD-39, CPD-41, CPD-43, CPD-45, CPD-46, CPD-50, CPD-51 and a pharmaceutically acceptable salt or analog thereof.

In some embodiments, the heterobifunctional compound is selected from the group consisting of CPD-31, CPD-37, CPD-38, and a pharmaceutically acceptable salt or analog thereof.

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-17-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,15-dioxo-3-oxa-2,7,16-triazaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (CPD-11).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-19-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,17-dioxo-3-oxa-2,7,18-triazaicosan-20-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-13).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-14).

In one embodiment, the heterobifunctional compound is N-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-24).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-031).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,19-dioxo-3-oxa-2,7,20-triazadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-33).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,8,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-35).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-19-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,17-dioxo-3-oxa-2,7,18-triazaicosan-20-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-36).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-7-methyl-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5- yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-037).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-22-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,20-dioxo-3-oxa-2,8,21-triazatricosan-23-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-038).

In one embodiment, the heterobifunctional compound is (2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,19-dioxo-3-oxa-2,8,20-triazadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-39).

In one embodiment, the heterobifunctional compound is N-(3-((3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)propyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-41).

In one embodiment, the heterobifunctional compound is N-(3-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-43).

In one embodiment, the heterobifunctional compound is N-(3-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)heptyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-45).

In one embodiment, the heterobifunctional compound is N-(3-((8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)octyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-46).

In one embodiment, the heterobifunctional compound is N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxa-15-azaoctadecan-18-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-50).

In one embodiment, the heterobifunctional compound is N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxa-18-azahenicosan-21-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-51).

According to the 2nd aspect of the present disclosure, a pharmaceutical composition is provided herein comprising a compound according to the 1^st aspect of the present disclosure, and one or more pharmaceutically acceptable carriers.

In one embodiment, the pharmaceutical composition further comprising one or more additional therapeutic agent.

In one embodiment, the additional therapeutic agent is selected from the group consisting of anti-cancer or anti-tumor agents, or the combination thereof.

In one embodiment, the additional therapeutic agent is selected from the group consisting of anti-proliferative agent, immunomodulatory agent, or the combination thereof.

In one embodiment, the additional therapeutic agent is selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzyme inhibitors, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.

In one embodiment, the additional therapeutic agent is selected from the group consisting of signaling pathway inhibitor, signaling pathway activator, or the combination thereof.

In one embodiment, the additional therapeutic agent is selected from the group consisting of kinase inhibitor, kinase activator, or the combination thereof.

In one embodiment, the additional therapeutic agent a signaling pathway inhibitor, wherein the signaling pathway is selected from the group consisting of RAS/RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, EGFR pathway, ALK pathway, BCR-ABL pathway, and the combinations thereof.

In one embodiment, the additional therapeutic agent is an inhibitor of PI3K/AKT/mTOR pathway.

In one embodiment, the additional therapeutic agent is an inhibitor of RAS/RAF/MEK/ERK pathway.

In one embodiment, the additional therapeutic agent is an inhibitor of EGFR pathway.

In one embodiment, the additional therapeutic agent is an inhibitor of ALK pathway.

In one embodiment, the additional therapeutic agent is an inhibitor of BCR-ABL pathway.

In one embodiment, the additional therapeutic agent is a kinase inhibitor.

In one embodiment, the additional therapeutic agent is selected from the group consisting of RAF inhibitor, AKT inhibitor, EGFR inhibitor, ALK inhibitor, BCR-ABL inhibitor, PI3K inhibitor, mTOR inhibitor, mTOR activator, RAS inhibitor, RAF inhibitor, MEK inhibitor, ERK inhibitor, and the combinations thereof.

In one embodiment, the additional therapeutic agent is RAF inhibitor and/or AKT inhibitor.

According to the 3rd aspect of the present disclosure, a method of treating and/or preventing a MEK-mediated disease provided herein comprises administering to a subject in need the heterobifunctional compound or a pharmaceutically acceptable salt or analog thereof.

In one embodiment, the subject in need means a subject with one or more MEK-mediated diseases and/or a subject with elevated MEK function.

In one embodiment, the MEK-mediated disease results from MEK expression, mutation, deletion, or fusion.

In one embodiment, the subject with the MEK-mediated disease has an elevated MEK function relative to a healthy subject without the MEK-mediated disease.

In one embodiment, the subject is mammal, preferably, human.

In one embodiment, the heterobifunctional compound is selected from the group consisting of CPD-001 to CPD-097, or analogs thereof.

In one embodiment, the heterobifunctional compound is administered to the subject orally, parenterally, intradermally, subcutaneously, topically, or rectally.

In one embodiment, the method further comprises administering to the subject an additional therapeutic regimen for treating cancer, hyperproliferative disorder, inflammatory disorders, or autoimmune diseases.

In one embodiment, the additional therapeutic regimen is selected from the group consisting of surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, and immunotherapy.

In one embodiment, the MEK-mediated diseases are selected from the group consisting of cancer, hyperproliferative disorder, inflammatory disorders, auto-immune diseases, dermatological disorders, viral infections, dry eye disorders, bone remodeling disorders, organ transplant associated immunological complications, relapsed cancer, or the combination thereof.

In one embodiment, the MEK-mediated cancer is selected from the group consisting of brain cancer, stomach cancer, squamous cell cancer, gastrointestinal tract cancer, liver cancer, biliary passage cancer, breast cancer, ovary cancer, cervix cancer, prostate cancer, testis cancer, penile cancer, genitourinary tract cancer, esophagus cancer, larynx cancer, skin cancer, lung cancer, pancreas cancer, thyroid cancer, gland cancer, bladder cancer, kidney cancer, muscle cancer, bone cancer, head cancer, neck cancer, renal cancer, colorectal cancer, gynecological cancer, cancers of the hematopoietic system, myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, primary myelofibrosis, chronic neutrophilic leukemia, acute lymphoblastic leukemia, Hodgkin's lymphoma, chronic myelomonocytic leukemia, systemic mast cell disease, hyper eosinophilic syndrome, cutaneous T-cell lymphoma, B-cell lymphoma, and myeloma.

In one embodiment, the MEK-mediated non-cancerous hyperproliferative disorder is selected from benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).

In one embodiment, the MEK-mediated disorder is selected from benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)).

In one embodiment, the MEK-mediated disorder is selected from pancreatitis or kidney disease (including proliferative glomemlonephritis and diabetes-induced renal disease)

In one embodiment, the MEK-mediated disorder is pain.

In one embodiment, the MEK-mediated inflammatory disorders are selected from the group consisting of ankylosing spondylitis, Crohn's disease, inflammatory bowel disease, ulcerative colitis, and ischemia reperfusion injuries.

In one embodiment, the MEK-mediated auto-immune diseases are selected from the group consisting of multiple sclerosis, scierodenna, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, psoriasis, myasthenia gravis, type I diabetes, diabetic retinopathy, systemic lupus erythematosus, IgA nephropathy, autoimmune thyroid disorders, alopecia areata, and bullous pemphigoid.

In one embodiment, the MEK-mediated dermatological disorders are selected from the group consisting of atopic dermatitis, pruritus, alopecia areata, psoriasis, skin rash, skin irritation, skin sensitization, chronic mucocutaneous candidiasis, dermatomyositis, erythema multiforme, palmoplantar pustulosis, vitiligo, polyarteritis nodosa, and STING vasculopathy.

In one embodiment, the MEK-mediated diseases are selected from retinopathy of prematurity, age-related macular degeneration, and hemangionia.

In one embodiment, the MEK-mediated disease is a relapsed cancer.

In one embodiment, the MEK-mediated disease is refractory to one or more previous treatments.

According to the 4th aspect of the present disclosure, a use of the compound according to the 1^st aspect of the present disclosure, or a pharmaceutically acceptable salt, or analog thereof, or the pharmaceutical composition according to the 2^nd aspect of the present disclosure in preparing a drug for treating and/or preventing MEK-mediated diseases is provided.

In one embodiment, MEK-mediated diseases are defined as before.

According to the 5th aspect of the present disclosure, a method for identifying a heterobifunctional compound which mediates degradation or reduction of MEK is disclosed. The method comprises:

providing a heterobifunctional test compound comprising an MEK Ligand conjugated to a Degradation Tag through a Linker;

contacting the heterobifunctional test compound with a cell comprising a ubiquitin ligase and MEK;

determining whether MEK level is decreased in the cell; and

identifying the heterobifunctional test compound as a heterobifunctional compound which mediates degradation or reduction of MEK.

In one embodiment, the cell is a cancer cell.

In one embodiment, the cancer cell is a MEK-mediated cancer cell.

According to the 6th aspect of the present disclosure, a method of selectively degrading or reducing MEK is provided comprising contacting cells with a compound of the compound according to the 1^st aspect of the present disclosure, or a pharmaceutically acceptable salt, or analog thereof, or the pharmaceutical composition according to the 2^nd aspect of the present disclosure.

In one embodiment, the cell is a cancer cell.

In one embodiment, the cancer cell is a MEK-mediated cancer cell (such as HT-29 and SK-MEL-28cells).

In one embodiment, the method reduces MEK protein levels in the cells.

In one embodiment, the method is an in vitro non-therapeutic method.

According to the 7^th aspect of the present disclosure, a use of the heterobifunctional compound, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof, is provided in combination with one or more additional therapeutic agents.

In one embodiment, the heterobifunctional compound is of FORMULA I, or I-1.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIG. 1. CPD-001, CPD-014 and CPD-015, but not CPD-19 and CPD-24, reduced MEK1 and MEK2 kinase levels in HT-29 cells.

FIG. 2. PD0325901, CPD-031, and CPD-034 inhibited MEK1 and MEK2 kinase activities.

FIG. 3A-B. CPD-031 reduced MEK1 and MEK2 protein levels, and inhibited phosphorylation of MEK and ERK proteins in a concentration-dependent manner in HT-29 and SK-MEL-28 cells.

FIG. 3C-D. DC₅₀ curves of CPD-031 at the degradation of MEK1 and MEK2 proteins in HT-29 and SK-MEL-28 cells.

FIG. 3E-F. CPD-031, but not PD0325901 and CPD-034, reduced MEK1 and MEK2 protein levels in HT-29 and SK-MEL-28 cells. Compared with CPD-034, CPD-031 is more potent at the inhibition of MEK and ERK phosphorylation.

FIG. 4A-B. CPD-031 reduced MEK1 and MEK2 protein levels, and inhibited phosphorylation of MEK and ERK proteins in a time-dependent manner in HT-29 and SK-MEL-28 cells.

FIG. 5. Pretreatment HT-29 and SK-MEL-28 cells with PD0325901, MG-132, MLN4924 or VH 032 significantly impaired the potency of CPD-031 at the degradation of MEK1 and MEK2 proteins, and the inhibition of MEK phosphorylation.

FIG. 6. CPD-031 selectively degraded MEK1 and MEK2 proteins levels in HT-29 cells in the global proteomic study. And CPD-034 did not significantly modulate protein levels in HT-29 cells.

FIG. 7A-D. CPD-031 is more potent than CPD-034 at the inhibition of the growth of HT-29 and SK-MEL-28 cells.

FIG. 7E-F. shRNA-mediated MEK1 and/or MEK2 knockdown significantly suppressed the growth of HT-29 and SK-MEL-28 cells.

FIG. 8A-B. CPD-037 and CPD-038 degrade MEK1 and MEK2 and inhibit pMEK and pERK in a concentration-dependent manner in HT-29 and SK-MEL-28 cells.

FIG. 9A. CPD-043, CPD-045, CPD-046, CPD-050, and CPD-051, but not CPD-024 and CPD-041, significantly degraded MEK1 and MEK2 protein levels in HT-29 cells.

FIG. 9B. CPD-051 concentration-dependently reduced MEK1 and MEK2 protein levels, and inhibited phosphorylation of MEK and ERK proteins in HT-29 and SK-MEL-28 cells.

FIG. 10. CPD-037, CPD-038, and CPD-051 degrade MEK1 and MEK2 and inhibit pERK signaling in a time-dependent manner in HT-29 and SK-MEL-28 cells.

FIG. 11. Pretreatment HT-29 cells with PD0325901, MG-132, MLN4924, VH 032, or pomalidomide significantly impaired the potency of CPD-037 CPD-038, and CPD-051 at the degradation of MEK1 and MEK2 proteins, and the inhibition of MEK phosphorylation.

FIG. 12. CPD-038 and CPD-051 selectively degraded MEK1 and MEK2 proteins levels in HT-29 cells in the global proteomic study. CPD-052 and CPD-097 did not significantly modulate protein levels in HT-29 cells.

FIG. 13. CPD-037, CPD-038 and CPD-051 significantly suppressed the growth of HT-29 and SK-MEL-28 cells. CPD-053, CPD-052 and CPD-097 did not significantly suppress the growth of HT-29 and SK-MEL-28 cells.

FIG. 14. CPD-037 and CPD-038 are more potent than AZ compound at the growth inhibition of FIT-29, SK-MEL-28, H3122, and SUDHL1 cells.

FIG. 15. Concurrent inhibition of BRAF or PI3K potentiated anti-proliferation potency of CPD-038.

FIG. 16. Plasma concentrations of CPD-031, CPD-037 and CPD-038 in mice following a single intraperitoneal injection.

DETAILED DESCRIPTION

Mitogen-activated protein kinase kinases 1 and 2 (MEK1/2) are critical components of the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling transduction pathway, which transmits extracellular signal into the nucleus through a cascade activation of multiple proteins, including Ras, Raf, MEK, and ERK.^1-3 As crucial proteins in the MAPK/ERK signaling, MEK1/2 are phosphorylated and activated by its upstream RAF kinases.⁴ Activation of MEK1/2 consequently leads to the phosphorylation of ERK at the threonine and tyrosine residues and activation of the ERK signaling.⁵ The MAPK/ERK signaling pathway is associated with a broad array of cellular processes, including cell proliferation, differentiation, cell survival, and apoptosis.^{6, 7} Aberrant regulation of this pathway through hyperactivation and mutation has been implicated in a variety of human cancers, such as melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma.^{1, 8-12}

Pharmacological inhibition of the MAPK/ERK signaling pathway by targeting the catalytic function of Ras, Raf, MEK, and ERK has resulted in multiple FDA approved drugs and many inhibitors in clinic development.^13-20 PD184352 was the first MEK1/2 inhibitor that entered clinical trials.²¹ However, development of PD184352 was terminated due to lack of clinical efficacy.^{22, 23} Optimization of PD184352 led to another clinical MEK1/2 inhibitor PD0325901 (1) (FIG. 1) with improved potency, solubility and metabolic stability.²⁴ PD0325901 is a typical non-ATP competitive MEK1/2 inhibitor, which occupies an allosteric binding pocket adjacent to the ATP binding site.²⁵ Numerous MEK inhibitors have been reported subsequently.²⁶ Although MEK inhibitors can be used as a single agent to treat diseases, the combination of MEK and BRAF inhibitors has shown delayed drug resistance and prolonged progression-free survival.^27-29 As a result, combination therapies, such as MEK inhibitor trametinib (2) (FIG. 1) with BRAF inhibitor dabrafenib, MEK inhibitor cobimetinib with BRAF inhibitor vermurafenib, and MEK inhibitor binimetinib with BRAF inhibitor encorafenib, have been approved by FDA for treating BRAF mutated melanoma.^30-33 These combination therapies have shown good efficacies for treating melanoma patients. However, acquired drug resistance through reactivation and mutation has been reported.^{34, 35} Therefore, new therapeutic strategies to delay or overcome drug resistance are desired.

In addition to the important functions of MEK1/2 in the canonical ERK signaling cascade, MEK1/2 possess other biological roles by phosphorylation of MyoD, HSF1, and β-arrestin 2.^47-49 Furthermore, MEK1/2 have non-catalytic functions, which have been associated with nuclear export of ERK and PPARγ, repression of MyoD transactivation, and regulation of FOXO1 localization.^50-53 Therefore, reduction of MEK1/2 protein levels using PROTACs is expected to diminish both catalytic and non-catalytic functions of the proteins and could have more profound pharmacological effects than inhibition of the kinase activity alone.

Disclosed herein, in some embodiments, are heterobifunctional compounds. In some embodiments, the heterobifunctional compound comprises a chemical structure or formula disclosed herein. The heterobifunctional compound may be or include a MEK degrader. MEK degraders may be characterized by the ability to degrade or reduce cellular protein levels of MEK. Some embodiments relate to a composition that includes the heterobifunctional compound. Some embodiments relate to methods of making the heterobifunctional compound. Some embodiments relate to methods of using the heterobifunctional compound or a pharmaceutical composition of the heterobifunctional compound. For example, the heterobifunctional compound may be used to treat a disorder or a disease. In some cases, the compound is used to treat autoimmune diseases. In some cases, the compound is used to treat inflammatory diseases. In some cases, the compound is used to treat cancers.

This disclosure includes all stereoisomers, geometric isomers, tautomers and isotopes of the structures depicted and compounds named herein. This disclosure also includes compounds described herein, regardless of how they are prepared, e.g., synthetically, through biological process (e.g., metabolism or enzyme conversion), or a combination thereof.

This disclosure includes pharmaceutically acceptable salts of the structures depicted and compounds named herein.

One or more constituent atoms of the compounds presented herein can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the compound does not include any deuterium atoms. In some embodiments, the compound includes at least one deuterium atom. In some embodiments, the compound includes two or more deuterium atoms. In some embodiments, the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 deuterium atoms. In some embodiments, all of the hydrogen atoms in a compound can be replaced or substituted by deuterium atoms. In some embodiments, the compound does not include any fluorine atoms. In some embodiments, the compound includes at least one fluorine atom. In some embodiments, the compound includes two or more fluorine atoms. In some embodiments, the compound includes 1-2, 1-3, 1-4, 1-5, or 1-6 fluorine atoms. In some embodiments, all of the hydrogen atoms in a compound can be replaced or substituted by fluorine atoms.

Heterobifunctional Compounds

Disclosed herein, in some embodiments, are compounds. In some embodiments, the compound comprises a MEK-binding moiety disclosed herein. In some embodiments, the compound comprises a MEK allosteric-site-binding moiety disclosed herein. In some embodiments, the compound comprises a MEK ATP-site-binding moiety disclosed herein. In some embodiments, the compound comprises a Degradation Tag disclosed herein. In some embodiments, the compound comprises a VHL-binding moiety. In some embodiments, the compound comprises a CRBN-binding moiety. In some embodiments, the compound comprises a MEK degrader. For example, the compound may result in MEK degradation. The compound may degrade MEK as a result of hijacking VHL ligase function. The compound may degrade MEK as a result of hijacking CRBN ligase function. The compound may bind to or modulate MEK or VHL. The compound may bind to or modulate MEK or CRBN. In some embodiments, the compound comprises a heterobifunctional compound. In some embodiments, the compound comprises a Linker.

According to the first aspect of the present disclosure, a heterobifunctional compound disclosed herein comprises a mitogen-activated protein kinase kinase (MEK) Ligand conjugated to a Degradation Tag through a Linker, which comprises a moiety of FORMULA I:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULA I-1

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

(i) Ar¹ is selected from the group consisting of optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;

Ar² is selected from the group consisting of optionally substituted monocyclic or bicyclic aryl, optionally substituted monocyclic or bicyclic pyridinone, and optionally substituted monocyclic or bicyclic heteroaryl;

A is bivalent group selected from the group consisting of C(O)NR¹, S(O)NR¹, S(O)₂NR¹, and CO, wherein R¹ is selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted —C═N—, optionally substituted —C(O)N—, optionally substituted C₃-C₈ carbocyclyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; or R1 and Ar², together with the atom(s) and to which they are connected, optionally form an optionally substituted bicyclic heterocyclyl ring, or an bicyclic heteroaryl ring.

B is selected from null or O;

(ii-a) the Degradation Tag is a moiety of FORMULAE 6A, 6B, or 6C:

wherein

* indicates the connection to the Linker moiety of the heterobifunctional compound;

R_E¹ and R_E² are independently selected from the group consisting of hydrogen, hydroxyl, amino, cyano, nitro, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl; optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈ aminoalkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl;

R_E^2′ is a divalent group selected from the group consisting of null, O, NH, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene; optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₁-C₈ aminoalkylene, optionally substituted C₁-C₈alkylaminoC₁-C₈alkylene, optionally substituted C₃-C₁₀ carbocyclyl, and optionally substituted 3-10 membered heterocyclyl;

R_E³ is selected from the group consisting of hydrogen, optionally substituted —C(O)R_E⁷, —C(O)OR_E⁷, —C(O)NR_E⁷R_E⁸, —P(O)(OR_E⁷)₂, and —CR_E⁷R_E⁸—OP(O)(OR_E⁹)₂, wherein

R_E⁷, R_E⁸ and R_E⁹ are independently selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈ aminoalkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted aryl and optionally substituted heteroaryl;

R_E⁴ is selected from the group consisting of —N(R_E¹⁰)R_E¹¹, —OR_E¹⁰, —N(R_E¹⁰)C(O)R_E¹¹, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_E⁴′ is a divalent group selected from the group consisting of —N(R_E¹⁰)R_E¹¹, —OR_E¹⁰, —N(R_E¹⁰)C(O)R_E¹¹, N(R_E¹⁰)C(O)R_E¹¹′—, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_E¹⁰ is selected from the group consisting of hydrogen, optionally substituted C₁-C₈alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted C₁-C₈alkyl-CO, optionally substituted C₁-C₈cycloalkyl-CO, optionally substituted C₃-C₈cycloalkyl-C₁-C₈alkyl-CO, optionally substituted 3-10 membered heterocyclyl-CO, optionally substituted 3-10 membered heterocyclyl-C₁-C₈alkyl-CO, optionally substituted aryl-CO, optionally substituted aryl-C₁-C₈alkyl-CO, optionally substituted heteroaryl-CO, optionally substituted heteroaryl-C₁-C₈alkyl-CO, optionally substituted aryl, and optionally substituted heteroaryl;

R_E¹¹ is selected from the group consisting of hydrogen, optionally substituted C₁-C₈alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C₃-C₈ carbocyclclyl, and optionally substituted C₃-C₈ heterocyclclyl;

R_E¹¹′, at each occurrence, is a divalent group independently selected from the group consisting of null, O, optionally substituted C₁-C₈alkylene, optionally substituted C₃-C₈ cycloalkylene, optionally substituted 3-8 membered heterocycloalkylene, optionally substituted C₃-C₈ carbocylclyl, and optionally substituted C₃-C₈ heterocyclclyl;

R_E⁵ is selected from the group consisting of hydrogen and halogen (such as F); and

R_E⁶ is selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C₁-C₈alkyl, optionally substituted C₁-C₈cycloalkyl, optionally substituted C₁-C₈alkoxy, and optionally substituted C₁-C₈cycloalkoxy, optionally substituted C₁-C₈heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl;

Or, (u-b) the Degradation Tag is a moiety of FORMULA 5, and the Degradation Tag is connected to the Linker moiety of the heterobifunctional compound via Z_E;

wherein

Z_E is a divalent group of —(R_E^z)_nE—; wherein subscript n_E=0, 1, 2, 3, 4, 5 or 6; wherein R_E^Z, at each occurrence, is independently R_E^r, or R_E^w; wherein R_E^w, at each occurrence, is a bond or selected from the group consisting of —CO—, —CR_E⁵R_E⁶—, —NR_E⁵—, —O−, optionally substituted C₁-C₁₀ alkylene, optionally substituted C₁-C₁₀ alkenylene, optionally substituted C₁-C₁₀ alkynylene; and R_E^r, at each occurrence, is a bond, or selected from the group consisting of optionally substituted C₃-C₁₀ carbocyclyl such as 3-13 membered carbocyclyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; with the proviso that —R_E^z—R_E^z— is not —O—O—;

R_E⁵ and R_E⁶, at each occurrence, are independently selected from the group consisting of hydrogen, halogen, oxo, hydroxy, amino, cyano, nitro, optionally substituted C₁-C₆ alkyl, optionally substituted 3 to 8 membered carbocyclyl, and optionally substituted 3 to 8 membered heterocyclyl; or R_E⁵ and R_E⁶ together with the atom(s) to which they are connected form an optionally substituted 3-8 membered cycloalkyl or heterocyclyl ring;

R_E¹ is selected from the group consisting of hydrogen, halogen, cyano, nitro, optionally substituted C₁-C₆ alkyl, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl;

L_E is a divalent group selected from the group consisting of null, —L_E¹—, and —L_E¹—L_E²—; wherein L_E¹ and L_E² are independently selected from the group consisting of —CO—, —O—, —CR_E¹⁰R_E¹¹— and —NR_E¹⁰—, with the proviso that —L_E¹—L_E²— is not —O—O—; wherein R_E¹⁰ and R_E¹¹ are independently selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkoxy, and optionally substituted C₁-C₆ alkylamino;

Ring A_E is a divalent group selected from the group consisting of FORMULA A_E 1, A_E2, A_E3, A_E4 and A_E5:

wherein

* indicates the attachment to L_E, and Z_E is attached to any possible position on the Ring A_E, indicates a single bond or a double bond;

V_E¹, V_E², V_E³, V_E⁴ and V_E⁵, at each occurrence, are each independently selected from the group consisting of a bond, C, CR_E², S, N, and NR_E²; or V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴, or V_E⁴ and V_E⁵ are combined together to optionally form C₆ aryl ring or a 5 or 6 membered heteroaryl ring;

R_E², at each occurrence, is independently selected from the group consisting of absent, hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkenyl, optionally substituted C₁-C₆ alkynyl, optionally substituted C₁-C₆ alkoxy, optionally substituted C₁-C₆ alkylamino, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl; or R_E² and another R_E² together with the atom(s) to which they are connected form optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl ring, optionally substituted aryl, and optionally substituted heteroaryl;

W_E¹, W_E², W_E³ and W_E⁴ are each independently selected from the group consisting of —N═, —C≡, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—; or W_E¹ and W_E², W_E² and W_E³, or W_E³ and W_E⁴ are combined together to optionally form C₆ aryl ring or a 5, 6 or 7 membered heteroaryl ring;

R_E³ and R_E⁴, at each occurrence, are independently selected from the group consisting of absent, hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted 3 to 8 membered carbocyclyl, and optionally substituted 3 to 8 membered heterocyclyl; or R_E³ and R_E⁴, on the same atom or on the adjacent atoms, together with the atom(s) to which they are connected form an optionally substituted 3-8 membered cycloalkyl or heterocyclyl ring;

and, (iii) the Linker moiety is of FORMULA 9:

wherein

A_L, W_L¹, W_L², and B_L, at each occurrence, are bivalent moieties independently selected from the group consisting of null, R_L^d—R_L^e, R_L^dCOR_L^e, R_L^dC(O)OR_L^e, R_L^dC(O)N(R_L¹)R_L^e, R_L^dC(S)_N(R_L¹)R_L^e, R_L^dOR_L^e, R_L^dSR_L^e, R_L^dSOR_L^e, R_L^dSO₂R_L^e, R_L^dSO₂N(R_L¹)R_L^e, R_L^dN(R_L¹)COR_L^e, R_L^dN(R_L¹)CON(R_L²)R_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, R_L^dN(R_L¹)SO₂N(R_L²)R_L^e, R_L^dN(R_L¹)C(S)R_L^e, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₃-C₁₃ cycloalkyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein

R_L^d and R_L^e, at each occurrence, are independently selected from null, R_L^r, optionally substituted (C₁-C₈ alkylene)-R_L^r, optionally substituted R_L^r—(C₁-C₈ alkylene), optionally substituted (C₁-C₈ alkylene)-R_L^r-(C₁-C₈ alkylene), or a bivalent moiety comprising of optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈alkylaminoC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₃-C₁₃ cycloalkyl, optionally substituted 3-13 membered, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^r, at each occurrence, is selected from optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L¹ and R_L², at each occurrence, are independently selected from the group consisting of hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxyalkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^d and R_L^e, R_L¹ and R_L², R_L^dand R_L¹, R_L^d and R_L², R_L^e and R_L¹, or R_L^e and R_L² together with the atom(s) to which they are connected optionally form a C₃-C₂₀ carbocyclyl or 3-20 membered heterocyclyl ring; and

m_L is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULA I-2

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

Ar², A, B, Linker and Degradation Tag are defined as in FORMULA I-1;

R², at each occurrence, is independently selected from hydrogen, halogen, cyano, nitro, azido, amino, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₃-C₈ cycloalkyl, optionally substituted C₁-C₈ alkoxy, optionally substituted aryl, or optionally substituted heteroaryl; and

m is selected from 0, 1, 2, 3, 4, and 5.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

A, B, Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

Y¹, Y², and Y³ are independently selected from NR³, CR⁴, O, and S;

X¹, X², X³, X⁴, X⁵, and X⁶, are independently selected from CR⁵ and N;

R³, at each occurrence, is independently selected from null, hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₃-C₈ cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl.

R⁴ and R⁵, at each occurrence, are independently selected from the group consisting of null, hydrogen, halogen, cyano, nitro, azido, amino, OR⁶, SR⁶, NR⁶R⁷, OCOR⁶, OCO₂R⁶, OCON(R⁶)R⁷, COR⁶, CO₂R⁶, CON(R⁶)R⁷, SOR⁶, SO₂R⁶, SO₂N(R⁶)R⁷, NR⁸CO₂R⁶, NR⁸COR⁶, NR⁸C(O)N(R⁶)R⁷, NR⁸SOR⁶, NR⁸SO₂R⁶, and NR⁸SO₂N(R⁶)R⁷, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted 3-10 membered heterocyclylC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclylC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein

R⁶, R⁷, and R⁸ are independently selected from the group consisting of null, hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxy, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₁alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclylC₁-C₈alkyl, optionally substituted 3-10 membered heterocyclylC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or R⁶ and R⁷, R⁶ and R⁸ together with the atom to which they are connected form a 3-20 membered heterocyclyl ring;

In one embodiment, Ar² is selected the group consisting of:

In one embodiment, Ar² is selected from optionally substituted monocyclic aryl or heteroaryl groups comprising:

In one embodiment, Ar² is selected from optionally substituted bicyclic heteroaryl groups comprising:

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE I-9, I-10, I-11, I-12, I-13 and I-14:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

A, B, Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

R³, R⁴, and R⁵ are defined as in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8;

n is 0, 1 or 2; and

p is 0, 1, 2, 3 or 4.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE I-15, I-16, I-17, I-18, I-19 and I-20:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

B, Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

R³, R⁴, and R⁵ are defined as in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8;

n and p are defined as in FORMULAE I-9, I-10, I-11, I-12, I-13 and I-14.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE I-21, I-22, I-23, I-24, I-25 and I-26:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

B, Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

R³, R⁴, and R⁵ are defined as in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8;

n and p are defined as in FORMULAE I-9, I-10, I-11, I-12, I-13 and I-14; and

R⁹ is selected from hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₃-C₈ cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE I-27, I-28, I-29, I-30, I-31 and I-32:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

R³, R⁴, and R⁵ are defined as in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8;

n and p are defined as in FORMULAE I-9, I-10, I-11, I-12, I-13 and I-14.

R⁹ is defined as in FORMULA I-19.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE I-33, I-34, I-35, I-36, I-37 and I-38:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

R³, R⁴, and R⁵ are defined as in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8;

R⁹ is defined as in FORMULA I-19;

R²′ is defined as R² in FORMULA I-2; and

R⁵′ is defined as R⁵ in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8.

In one embodiment, R², R²′, R⁵ and R⁵′ are independently selected from hydrogen, halogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl.

In one embodiment, R², R²′, R⁵ and R⁵′ are independently selected from H, CH₃, F, Cl, Br, and Br.

In one embodiment, R² is Br or I.

In one embodiment, R² is I.

In one embodiment, R²′ is F.

In one embodiment, R⁵ and R⁵′ are independently selected from F or CH₃.

In one embodiment, R³ is selected from H, CH₃, isopropyl, and cyclopropyl.

In one embodiment, R³ is CH₃.

In one embodiment, R⁹ is selected from optionally substituted aryl, or optionally substituted heteroaryl.

In one embodiment, R⁹ is optionally substituted phenyl.

In one embodiment, R⁹ is

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE II:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

Linker and Degradation Tag are defined as in FORMULA I-1;

R², and m are defined as in FORMULA I-2;

R³, and R⁵ are defined as in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8;

R⁹ is defined as in FORMULA I-19;

R²′ is defined as R² in FORMULA I-2; and

R³′ is defined as R³ in FORMULAE I-3, I-4, I-5, I-6, I-7 and I-8.

In one embodiment, R², R²′, and R⁵ are independently selected from hydrogen, halogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl.

In one embodiment, R², R²′, and R⁵ are independently selected from H, CH₃, F, Cl, Br, and Br.

In one embodiment, R² is Br or I.

In one embodiment, R² is I.

In one embodiment, R²′ is F.

In one embodiment, R⁵ and R⁵′ are independently selected from F or CH₃.

In one embodiment, R³ and R³′ are independently selected from hydrogen, optionally substituted C₁-C₈ alkyl, or optionally substituted C₃-C₈ cycloalkyl;

In one embodiment, R³ and R³′ are independently selected from H, CH₃, isopropyl, and cyclopropyl.

In one embodiment, R³ is CH₃.

In one embodiment, R³′ is cyclopropyl.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE III:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

Linker and Degradation Tag are defined as in FORMULA I-1.

In one embodiment, a heterobifunctional compound disclosed herein comprises a moiety of FORMULAE IV:

or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, tautomer, or analog thereof,

wherein

Linker and Degradation Tag are defined as in FORMULA I-1.

In some embodiments, heterobifunctional compound disclosed herein comprises FORMULAE I-1, I-2, I-3, I-9, I-15, I-21, I-27, or I-33.

In some embodiments, the Degradation Tag is a moiety of FORMULAE 6A, 6B, or 6C, wherein R_E¹ is selected from isopropyl and tert-butyl.

In some embodiments, the Degradation Tag is a moiety of FORMULAE 6A-1, 6B-1, 6C-1, 6A-2, 6B-2, or 6C-2:

wherein R_E², R_E²′, R_E³, R_E⁴, R_E⁴′, R_E⁵, and R_E⁶ are defined as in FORMULAE 6A, 6B, or 6C.

In some embodiments, R_E² is H or Me.

In some embodiments, R_E²′ is null or CH₂.

In some embodiments, the Degradation Tag is a moiety of FORMULAE 6A-3, 6B-3, 6C-3, 6A-4, 6B-4, or 6C-4:

wherein R_E¹, R_E³, R_E⁴, R_E⁴′, R_E⁵, and R_E⁶ are defined as in FORMULAE 6A, 6B, or 6C.

In some embodiments, R_E³ is H.

In some embodiments, the Degradation Tag is a moiety of FORMULAE 6A-5, 6B-5, and 6C-5:

wherein

R_E¹, R_E², R_E²′, R_E⁴, R_E⁴′, R_E⁵, and R_E⁶ are defined as in FORMULAE 6A, 6B, or 6C. In some embodiments, R_E⁵ is H or F. In some embodiments, the Degradation Tag is a moiety of FORMULAE, 6A-6, 6B-6, 6C-6, 6A-7, 6B-7, and 6C-7:

wherein

R_E¹, R_E², R_E²′, R_E³, R_E⁴, R_E⁴′, and R_E⁶ are defined as in FORMULAE 6A, 6B, or 6C.

In some embodiments, R_E⁶ is selected from hydrogen, halogen, cyano, optionally substituted aryl, and optionally substituted heteroaryl,

In some embodiments, R_E⁶ is selected from the group consisting of halogen, cyano, optionally substituted thiazole, optionally substituted oxazole, optionally substituted imidazole, optionally substituted pyrazole, optionally substituted oxadiazole, optionally substituted triazole, and optionally substituted isoxazole.

In some embodiments, R_E⁶ is methyl thiazole.

In some embodiments, the Degradation Tag is a moiety of FORMULAE 6A-8, 6B-8, or 6C-8:

wherein

R_E¹, R_E², R_E²′, R_E³, R_E⁴, R_E⁴′, and R_E⁵ are defined as in FORMULAE 6A, 6B, and 6C.

In some embodiments, R_E⁴ is selected from —N(R_E¹⁰)R_E¹¹, —N(R_E¹⁰)C(O)R_E¹¹,

; and/or R_E⁴′ is selected from —N(R_E¹⁰)—, N(R_E¹⁰)C(O)R_E¹¹′—,

wherein

* indicates the connection to the Linker moiety of the heterobifunctional compound;

R_E¹⁰ is selected from null, hydrogen, optionally substituted C₁-C₈alkyl, optionally substituted C₁-C₈cycloalkyl, optionally substituted C₁-C₈alkyl-CO, optionally substituted C₃-C₈cycloalkyl-CO, optionally substituted C₃-C₈cycloalkyl-C₁-C₈alkyl-CO, optionally substituted 3-10 membered heterocyclyl-CO, optionally substituted 3-10 membered heterocyclyl-C₁-C₈alkyl-CO, optionally substituted aryl-CO, optionally substituted aryl-C₁-C₈alkyl-CO, optionally substituted heteroaryl-CO, optionally substituted heteroaryl-C₁-C₈alkyl-CO, optionally substituted aryl, and optionally substituted heteroaryl;

R_Eis selected from null, hydrogen, optionally substituted C₁-C₈alkyl, and optionally substituted C₃-C₈cycloalkyl, and optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C₃-C₈ carbocyclclyl, and optionally substituted C₃-C₈ heterocyclclyl;

R_E¹¹′, at each occurrence, is a divalent group independently selected from null, O, optionally substituted C₁-C₈alkylene, optionally substituted C₃-C₈ cycloalkylene, optionally substituted C₃-C₈ heterocycloalkylene, optionally substituted C₃-C₈ carbocyclclyl, and optionally substituted C₃-C₈ heterocyclclyl;

R_E¹², at each occurrence, is independently selected from hydrogen, halogen, cyano, optionally substituted C₁-C₈alkyl, optionally substituted C₃-C₈cycloalkyl, optionally substituted 3-8 membered heterocycloalkyl, optionally substituted C₁-C₈alkoxy, and optionally substituted C₃-C₈cycloalkoxy; and

n_E is 0, 1, 2, 3, or 4.

In some embodiments, the substituent(s) for R_E¹¹ and R_E¹¹′ are independently optionally substituted groups selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, halogen, and CN.

In some embodiments, R_E⁴ is selected from NH₂, NHC(O)Me,

In some embodiments, R_E⁴′ is selected from NH, C(O)NH, CH₂C(O)NH,

In some embodiments, the Degradation Tag is a moiety of FORMULAE 6A-9, 6A-10, 6A-11, 6A-12, 6A-13, 6B-9, 6B-10, 6B-11, 6B-12, 6B-13, 6B-14, 6B-15, 6C-9, 6C-10, 6C-11, 6C-12, 6C-13, 6C-14, or 6C-15:

wherein R_E¹, R_E², R_E²′, R_E³, R_E⁵, and R_E⁶ are defined as in FORMULAE 6A, 6B, or 6C.

In some embodiments, the Degradation Tag is a moiety of any of FORMULAE 7A to 7BJ:

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, wherein R_E² at each occurrence, is independently selected from the group consisting of absent, hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkenyl, optionally substituted C₁-C₆ alkynyl, optionally substituted C₁-C₆ alkoxy, optionally substituted C₁-C₆ alkylamino, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein V_E¹, V_E², V_E³, V_E⁴ and V_E⁵, at each occurrence, are each independently selected from the group consisting of C, CR_E², S, N, and NR_E²; or V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴, or V_E⁴ and V_E⁵ are combined to optionally form C₆ aryl ring or a 5, 6 or 7 membered heteroaryl ring.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is a group consisting of FORMULA A_E1, and wherein V_E¹, V_E², V_E³, and V_E⁴ are each independently selected from the group consisting of C, CR_E², S, N, and NR_E².

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is a group consisting of FORMULA A_E2, and wherein V_E¹, V_E², V_E³, V_E⁴ and V_E⁵, at each occurrence, are each independently selected from the group consisting of C, CR_E², S, N, and NR_E².

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is a group consisting of FORMULA A_E3, and wherein V_E¹, V_E², V_E³, V_E⁴ and V_E⁵ are each independently selected from the group consisting of C, CR_E², S, N, and NR_E²; or V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴, or V_E⁴ and V_E⁵ are combined together to optionally form C₆ aryl ring or a 5, 6 or 7 membered heteroaryl ring.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is a group consisting of FORMULA A_E4, and wherein is a single bond and W_E¹, W_E², W_E³ and W_E⁴ are each independently selected from the group consisting of —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is a group consisting of FORMULA A_E5, and wherein V_E¹, V_E², and V_E³ are each independently selected from the group consisting of CR_E², S, N, with the proviso that at least one of V_E¹, V_E², and V_E³ is S, N or NR_E²; or V_E¹ and V_E², V_E² and V_E³ are combined together to optionally form 5 membered heteroaryl ring.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein R_E¹ is selected from hydrogen, halogen, cyano, nitro, optionally substituted C₁-C₆ alkyl, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl; preferably, R_E¹ is selected from hydrogen, halogen, cyano, nitro, and C₁-C₈ alkyl; more preferably, R_E¹ is selected from H, CH₃, or F.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein R_E² is selected from hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkoxyl, optionally substituted C₁-C₆ alkylamino, optionally substituted 3 to 8 membered carbocyclyl, and optionally substituted 3 to 8 membered heterocyclyl; preferably, R_E² is selected from hydrogen, halogen, cyano, nitro, and C₁-C₆ alkyl, optionally substituted C₁-C₆ alkoxyl, optionally substituted 3 to 8 membered carbocyclyl, and optionally substituted 3 to 8 membered heterocyclyl; more preferably, R_E² is selected from H, F, OMe, O-iPr, or O-cPr.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein R_E³ and R_E⁴ are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C₁-C₆ alkyl, optionally substituted 3 to 8 membered carbocyclyl, and optionally substituted 3 to 8 membered heterocyclyl; or R_E³ and R_E⁴ together with the atom(s) to which they are connected form a 3-8 membered carbocyclyl, or 3-8 membered heterocyclyl.

In another embodiment, R_E^r, at each occurrence, is selected from Group R_E, and

Group R_E consists of optionally substituted following cyclic groups

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein in the group of Z_E, at most one R_E^Z is R_E^r.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein n_E=0, 1, 2 or 3.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Z_E is a divalent group selected from the group consisting of —R_E^w—, —(R_E^w)₂—, —(R_E^w)₃—, —R_E^r—, —R_E^w—R_E^r—R_E^w—, —R_E^r—R_E^w— and —R_E^r—(R_E^w)₂—.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein R_E⁵ and R_E⁶ at each occurrence are independently selected from a bond, hydrogen, halogen, oxo, hydroxyl, amino, cyano, nitro, optionally substituted C₁-C₆ alkyl, optionally substituted 3 to 8 membered carbocyclyl, and optionally substituted 3 to 8 membered heterocyclyl; or R_E⁵ and R_E⁶ together with the atom(s) to which they are connected form a 3-8 membered cycloalkyl or heterocyclyl ring.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein R_E^Z is selected from —CO—, —CR_E⁵R_E⁶—, —NR_E⁵—, —O—, optionally substituted C₁-C₁₀ alkylene, optionally substituted C₁-C₁₀ alkenylene, optionally substituted C₁-C₁₀ alkynylene, optionally substituted 3-8 membered carbocyclyl, optionally substituted 3-8 membered heterocyclyl.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Z_E is selected from a bond, CH₂, CH═CH, C≡C, NH, and O.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is of FORMULA A_E4 and L_E is not null.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5, and wherein Ring A_E is of FORMULA A_E4 and L_E is selected from the group consisting of —NH—, —N(C₁-C₄ alkyl)-, —CO—, —NH—CO—, —N(C₁-C₄ alkyl)-CO—, —CO—NH—, and —CO—N(C₁-C₄ alkyl)-.

In another embodiment, the Degradation Tag is a moiety selected from the group consisting of FORMULA 5-1, 5-2, 5-3, 5-4, 5-5 and 5-6, and the Degradation Tag is connected to the Linker moiety of the heterobifunctional compound via a divalent group of Z_E;

wherein

Z_E, R_E¹. L_E, , V_E¹, V_E², V_E³, V_E⁴, V_E⁵, W_E¹, W_E², W_E³ and W_E⁴ are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety selected from the group consisting of FORMULAE 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H, 5I, 5J, 5K, 5L and 5M:

wherein,

V_E⁶, V_E⁷, V_E⁸, and V_E⁹ are each independently selected from a bond, C, CR_E¹² and N; or V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴, or V_E⁴ and V_E⁵ are combined together to optionally form C₆ aryl ring or a 5, 6 or 7 membered heteroaryl ring;

R_E¹², at each occurrence, is independently selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkenyl, optionally substituted C₁-C₆ alkynyl, optionally substituted C₁-C₆ alkoxy, optionally substituted C₁-C₆ alkylamino, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl;

W_E⁶ and W_E⁷ are each independently selected from —CR_E²═ and —N═;

W_E¹, W_E², W_E³, W_E⁴, V_E¹, V_E², V_E³, V_E⁴, V_E⁵, R_E¹, R_E³, and Z_E are defined as in FORMULA 5.

In another embodiment, W_E¹ is selected from —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—.

In another embodiment, Ring A_E is a divalent group of FORMULA A_E1 or A_E5; and Ring A_E is attached to L_E via W_E².

In another embodiment, Ring A_E is a divalent group of FORMULA A_E1 or A_E5, wherein W_E¹and W_E³ are each independently selected from the group consisting of CO, O, CR_E³R_E⁴, NR_E³; and W_E² is N.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-1 or 5-6, and the Degradation Tag is connected to the Linker moiety of the heterobifunctional compound via a divalent group of Z_E; wherein

W_E¹ and W_E³ are each independently selected from the group consisting of —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—;

W_E² is N, and connected to

Z_E, R_E¹. R_E³. R_E⁴L_E, , V_E¹, V_E², V_E³, V_E⁴, and V_E⁵, are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULAE 5A or 5M; wherein W_E¹ is independently selected from the group consisting of —CO—, —O—, —CR_E³R_E⁴—,  NR_E³—; and V_E¹, V_E², V_E³, V_E⁴, R_E¹, R_E³, R_E⁴ and Z_E are defined as in FORMULA 5.

In another embodiment, R_E³ and R_E⁴, at each occurrence, are independently selected from the group consisting of absent, hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-1, or FORMULA 5-3,

wherein

V_E¹, V_E², V_E³, and V_E⁴ are each independently selected from a bond, C, CR_E², and N; or V_E¹ and V_E², V_E² and V_E³, or V_E³ and V_E⁴ are combined together to optionally form 6 memberedaryl ring or 5, 6 or 7 membered heteroaryl ring;

indicates a single bond or a double bond; wherein (i) when there is a single bond between W_E¹ and W_E² (i.e. the between W_E¹ and W_E² indicates single bond), W_E¹, W_E² and W_E³ are each independently selected from the group consisting of —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—; or (ii) when there is a double bond between W_E¹ and W_E² (i.e. the between W_E¹ and W_E² indicates a double bond), W_E¹ and W_E² are each independently selected from the group consisting of —N═, —C≡ and —CR_E³═; W_E³ is selected from the group consisting of —CR_E³R_E⁴—, —O—, —N═, —C(O)NR_E³—, —CR_E³═CR_E⁴—, and —CR_E³═N—;

Z_E, R_E², R_E³, R_E⁴ and R_E¹ are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-1 or 5-3, and wherein V_E¹, V_E², V_E³, and V_E⁴ are each independently selected from C, N, and CR_E².

In another embodiment, the Degradation Tag FORMULA 5-1 is moiety of FORMULA 5A, 5B, 5E, 5F or 5G

wherein W_E⁶ and W_E⁷ are each independently selected from —CR_E²═ and —N═; and V_E¹, V_E², V_E³, V_E⁴, W_E¹, W_E³, Z_E, R_E³ and R_E¹ are defined as in FORMULA 5-1.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5A, 5B, 5E, 5F or 5G, and wherein V_E¹, V_E², V_E³, and V_E⁴ are each independently selected from a bond, C, CR_E² and N (preferably, C, CR_E² and N).

In another embodiment, the Degradation Tag is a moiety of FORMULA 5A, 5B, 5E, 5F or 5G, and wherein W_E¹ and W_E³ are each independently selected from —CO—, —O—, —CR_E³R_E⁴— —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—; preferably, W_E¹ and W_E³ are each independently selected from —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—.

In another embodiment, the Degradation Tag FORMULA 5-3 is moiety of FORMULA 5C

wherein W_E³ is N or CR_E³; and V_E¹, V_E², V_E³, V_E⁴, Z_E, and R_E¹ are defined as in FORMULA 5-3. In another embodiment, the Degradation Tag is a moiety of FORMULA 5C, wherein V_E¹, V_E², V_E³, and V_E⁴ are each independently selected from a bond, CR_E² and N.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-2,

V_E¹, V_E², V_E³, V_E⁴ and V_E⁵ are each independently selected from a bond, C, CR_E², and N; or V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴, or V_E⁴ and V_E⁵ are combined together to optionally form C₆ aryl ring or 5, 6, or 7 heteroaryl ring;

indicates a single bond or a double bond; (i) when there is a single bond between W_E¹ and W_E² (i.e. the between W_E¹ and W_E² indicates single bond), W_E¹ and W_E⁴ are each independently selected from —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—, and W_E² and W_E³ are each independently selected from —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—; or (ii) when there is a double bond between W_E¹ and W_E² (i.e. the between W_E¹ and W_E² indicates a double bond), W_E¹ and W_E² are each independently selected from —N═, C and —CR_E²═; W_E³ is selected from —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—; and W_E⁴ is selected from —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—;

Z_E, R_E², R_E³, R_E⁴ and R_E¹ are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-2, wherein V_E¹, V_E², V_E³, V_E⁴ and V_E⁵ are each independently selected from a bond, C, CR_E², and N.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-2, wherein indicates a single bond.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-2, wherein indicates a single bond, W_E¹ and W_E⁴ are each independently selected from —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—, and W_E² and W_E³ are each independently selected from —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—.

In another embodiment, the Degradation Tag FORMULA 5-2 is moiety of FORMULA 5D.

wherein V_E¹, V_E², V_E³, V_E⁴, V_E⁵, W_E¹, Z_E, and R_E¹ are defined as in FORMULA 5-2.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5D, wherein W_E¹ is selected from —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—; preferably, W_E¹ is selected from —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5D, wherein V_E¹, V_E², V_E³, V_E⁴, and V_E⁵ are each independently selected from a bond, C, CR_E² and N; or V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴, or V_E⁴ and V_E⁵ are combined together to optionally form a C₆ aryl ring or 5, 6 or 7 heteroaryl ring; preferably, V_E¹, V_E², V_E³, V_E⁴, and V_E⁵ are each independently selected from a bond, C, CR_E² and N.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4,

wherein V_E¹, V_E², V_E³, V_E⁴, V_E⁵. L_E, Z_E, and R_E¹ are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein L_E is not null.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein L_E is selected from the group consisting of —NH—, —N(C₁-C₄ alkyl)-, —CO—, —NH—CO—, —N(C₁-C₄ alkyl)-CO—, —CO—NH—, and —CO—N(C₁-C₄ alkyl)-.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein

V_E¹, V_E², V_E³, V_E⁴ and V_E⁵, at each occurrence, are each independently selected from the group consisting of C, CR_E² and N; or

V_E¹ and V_E², V_E² and V_E³, V_E³ and V_E⁴; or V_E⁴ and V_E⁵ are combined together to optionally form a ring of

wherein V_E⁶, V_E⁷, V_E⁸, and V_E⁹ are each independently selected from the group consisting of C, CR_E¹² and N;

R_E¹², at each occurrence, is independently selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkenyl, optionally substituted C₁-C₆ alkynyl, optionally substituted C₁-C₆ alkoxy, optionally substituted C₁-C₆ alkylamino, optionally substituted 3-8 membered carbocyclyl, and optionally substituted 3-8 membered heterocyclyl.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein V_E⁶, V_E⁷, V_E⁸, and V_E⁹ are each independently selected from the group consisting of CR_E¹² and N.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein R_E¹², at each occurrence, is independently selected from the group consisting of hydrogen, halogen, cyano, nitro, hydroxy, amino, optionally substituted C₁-C₆ alkyl.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein

is selected from the group consisting of

wherein

V_E¹, V_E², V_E³, V_E⁴ and V_E⁵ are each independently selected from the group consisting of C, CR_E² and N; and V_E⁶, V_E⁷, V_E⁸, and V_E⁹ are each independently selected from the group consisting of CR_E¹² and N.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-4, and wherein Z_E is null, —CH₂—, —O—, or —NH—.

In another embodiment, the Degradation Tag FORMULA 5-4 is moiety of FORMULA 5H, or 5I;

wherein V_E¹, V_E², V_E³, V_E⁴, V_E⁵, V_E⁶, V_E⁷, V_E⁸, and V_E⁹ are each independently selected from a bond, C, CR_E² and N; and Z_E and R_E¹ are defined as in FORMULA 5-4.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-5,

wherein , W_E¹, W_E², W_E³, W_E⁴, Z_E and R_E¹ are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-5, and wherein W_E¹, W_E², W_E³ and W_E⁴ are each independently selected from the group consisting of —C≡, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-5, and wherein W_E¹, W_E², W_E³ and W_E⁴ are each independently selected from the group consisting of —C≡, —CH═, —CO—, —O—, —N—, —CH₂—, and —NH—.

In another embodiment, the Degradation Tag FORMULA 5-5 is moiety of FORMULA 5J, 5K or 5L

wherein W_E¹, W_E², W_E³, W_E⁴, Z_E, R_E³ and R_E¹ are defined as in FORMULA 5-5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-6,

wherein

V_E¹, V_E², and V_E³ are each independently selected from C, CR_E², S, N, and NR_E²; or V_E¹ and V_E², or V_E² and V_E³ are combined together to optionally form 5 membered heteroaryl ring;

indicates a single bond or a double bond; wherein (i) when there is a single bond between W_E¹ and W_E² (i.e. the between W_E¹ and W_E² indicates single bond), W_E¹, W_E² and W_E³ are each independently selected from the group consisting of —N═, —CR_E³═, —CO—, —O—, —CR_E³R_E⁴—, —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—; or (ii) when there is a double bond between W_E¹ and W_E² (i.e. the between W_E¹ and W_E² indicates a double bond), W_E¹ and W_E² are each independently selected from the group consisting of —N—, —C≡ and —CR_E³═; W_E³ is selected from the group consisting of —O—, —N═, —NR_E³—, —C(O)NR_E³—, —CR_E³R_E⁴—, —CR_E³═CR_E⁴—, and —CR_E³═N—;

Z_E, R_E², R_E³, R_E⁴ and R_E¹ are defined as in FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-6, and wherein V_E¹, V_E², V_E³, and V_E⁴ are each independently selected from C, CR_E², S, N, and NR_E².

In another embodiment, the Degradation Tag FORMULA 5-6 is moiety of FORMULA 5M:

wherein V_E¹, V_E², V_E³, W_E¹, Z_E and R_E¹ are defined as in FORMULA 5-6.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5M, and wherein V_E¹, V_E², and V_E³ are each independently selected from C, CR_E², S, N, and NR_E² (preferably, one of V_E¹, V_E², and V_E³ is S).

In another embodiment, the Degradation Tag is a moiety of FORMULA 5M, and wherein W_E¹ is selected from —CO—, —O—, —CR_E³R_E⁴— —NR_E³—, —CR_E³═CR_E⁴—, —N═CR_E³—, and —N═N—; preferably, W_E¹ is selected from —CO—, —O—, —CR_E³R_E⁴—, and —NR_E³—.

In another embodiment, the Degradation Tag is a moiety of FORMULAE 8A to:

In another embodiment, the Degradation Tag is a moiety of FORMULA 4A:

wherein

V_E¹, V_E², V_E³, V_E⁴, and V_E⁵, are independently selected from CR_E⁴ and N; and

R_E¹, R_E², R_E³, and R_E⁴ are independently selected from hydrogen, halogen, cyano, nitro, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, and optionally substituted C₂-C₈ alkynyl; optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkoxy, optionally substituted C₁-C₈alkylamino, optionally substituted C₃-C₁₀ carbocyclyl, and optionally substituted 3-10 membered heterocyclyl.

In another embodiment, the Degradation Tag is a moiety of FORMULA 4B:

wherein

R_E¹, R_E², and R_E³ are independently selected from hydrogen, halogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₃-C₇ cycloalkyl, optionally substituted 3-7 membered heterocyclyl, optionally substituted C₂-C₈ alkenyl, and optionally substituted C₂-C₈ alkynyl;

R_E⁴ and R_E⁵ are independently selected from hydrogen, COR_E⁶, CO₂R_E⁶, CONR_E⁶R_E⁷, SOR_E⁶, SO₂R_E⁶, SO₂NR_E⁶R_E⁷, optionally substituted C₁-C₈ alkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted aryl-C₁-C₈alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein

R_E⁶ and R_E⁷ are independently selected from hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted 3-8 membered cycloalkyl, optionally substituted 3-8 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or R_E⁶ and R_E⁷ together with the atom(s) to which they are connected form a 3-8 membered cycloalkyl or heterocyclyl ring.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6A, 6B, and 6C.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6A.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6B.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6C.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6A-1 to 6A-13.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6B-1 to 6A-15.

In another embodiment, the Degradation Tag is a moiety of FORMULA 6C-1 to 6C-15.

In another embodiment, the Degradation Tag is a moiety of FORMULA 7A to 7BJ.

In another embodiment, the Degradation Tag is a moiety of FORMULA 7F, 7P, 7AC, 7AQ, and 7BE.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-1 to 5-6.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5-1.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5A to 5M.

In another embodiment, the Degradation Tag is a moiety of FORMULA 5A.

In another embodiment, the Degradation Tag is a moiety of FORMULA 8A to 8HE.

In another embodiment, the Degradation Tag is a moiety of FORMULA 8A to 8AD.

In another embodiment, the Degradation Tag is a moiety of FORMULA 8DJ to 8FW.

In another embodiment, the Degradation Tag is a moiety of FORMULA 8A and 8G.

In some embodiments, the Linker comprises acyclic or cyclic saturated or unsaturated carbon, ethylene glycol, amide, amino, ether, urea, carbamate, aromatic, heteroaromatic, heterocyclic or carbonyl groups.

In certain embodiments, the length of the Linker is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or more atoms.

In another embodiment, A_L and B_L, at each occurrence, are independently selected from the group consisting of null, R_L^d-R_L^e, R_L^dCOR_L^e, R_L^dC(O)OR_L^e, R_L^dC(O)N(R_L¹)R_L^e, R_L^dOR_L^e, R_L^dSR_L^e, R_L^dN(R_L¹)R_L^e, R_L^dN(R_L¹)COR_L^e, R_L^dN(R_L¹)CON(R_L²)R_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, and R_L^dN(R_L¹)SO₂N(R_L²)R_L^e, wherein R_L^d and R_L^e, at each occurrence, are independently selected from the group consisting of null, optionally substituted C₁, C₂ or C₃ alkylene, R_L^r, R_L^r—(C₁, C₂ or C₃ alkylene), (C₁, C₂ or C₃ alkylene)-R_L^r, and (C₁, C₂ or C₃ alkylene)-R_L^r—(C₁, C₂ or C₃ alkylene).

In another embodiment, A_L and B_L, at each occurrence, are independently selected from the group consisting of null, R_L^d-R_L^e, R_L^dCOR_L^e, R_L^dC(O)OR_L^e, R_L^dC(O)N(R_L¹)R_L^e, R_L^dOR_L^e, R_L^dSR_L^e, R_L^dN(R_L¹)R_L^e, R_L^dN(R_L¹)COR_L^e, R_L^dN(R_L¹)CON(R_L²)R_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, and R_L^dN(R_L¹)SO₂N(R_L²)R_L^e, wherein R_L^d and R_L^e, at each occurrence, are independently selected from the group consisting of null, R_L^r, and optionally substituted C₁, C₂ or C₃ alkylene.

In another embodiment, W_L¹ and W_L², at each occurrence, are independently selected from null, O, S, NR_L¹, R_L^r, optionally substituted C₁-C₃ alkylene, with the proviso that at least one of W_L¹ and W_L² is not null.

In another embodiment, none of W_L¹-W_L², A_L-W_L¹ and W_L²-B_L is a moiety of —O—O—.

In another embodiment, W_L², at each occurrence, is independently null, O, or NR_L¹; and W_L¹, at each occurrence, is independently selected from R_L^r, and optionally substituted C₁, C₂ or C₃ alkylene.

In another embodiment, W_L¹, at each occurrence, is independently null, O, or NR_L¹; and W_L², at each occurrence, is independently selected from R_L^r, and optionally substituted C₁, C₂ or C₃ alkylene.

In another embodiment, A_L is the attachment to the MEK Ligand;

A_L is selected from the group consisting of R_L^d-R_L^e, R_L^dC(O)R_L^e, R_L^dC(O)NHR_L^e, R_L^dNHC(O)R_L^e, R_L^dNHC(O)NHR_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, and R_L^dN(R_L¹)SO₂N(R_L²)R_L^e;

B_L is selected from the group consisting of null, R_L^dC(O)NHR_L^e, R_L^dC(O)R_L^e, R_L^dNHC(O)R_L^e, and R_L^dNHR_L^e, R_L^dOR_L^e, and R_L^d-R_L^e;

R_L^d and R_L^e, at each occurrence, are independently selected from the group consisting of null, optionally substituted C₁, C₂ or C₃ alkylene, R_L^r, R_L^r-(C₁, C₂ or C₃ alkylene), (C₁, C₂ or C₃ alkylene)-R_L^r, and (C₁, C₂ or C₃ alkylene)-R_L^r-(C₁, C₂ or C₃ alkylene);

W_L², at each occurrence, is independently selected from null, O, or NR_L¹, and W_L¹, at each occurrence, is independently selected from R_L^r, and optionally substituted C₁, C₂ or C₃ alkylene.

In another embodiment, A_L is the attachment to the MEK Ligand;

A_L is selected from the group consisting of R_L^d-R_L^e, R_L^dC(O)R_L^e, R_L^dC(O)NHR_L^e, R_L^dNHC(O)R_L^e, R_L^dNHC(O)NHR_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, and R_L^dN(R_L¹)SO₂N(R_L²)R_L^e;

B_L is selected from the group consisting of null, R_L^dC(O)NHR_L^e, R_L^dC(O)R_L^e, R_L^dNHC(O)R_L^e, R_L^dNHR_L^e, R_L^dOR_L^e, and R_L^d-R_L^e;

R_L^d and R_L^e, at each occurrence, are independently selected from the group consisting of null, R_L^r, optionally substituted C₁, C₂ or C₃ alkylene;

W_L² is O, or NR_L¹; and W_L¹, at each occurrence, is optionally independently selected from R_L^r, optionally substituted C₁, C₂ or C₃ alkylene;

m_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

In another refinement, the length of the Linker is 3 to 30 chain atoms.

In another refinement, the length of the Linker is 6 to 25 chain atoms.

In another embodiment, R_L^r, at each occurrence, is selected from FORMULAE C1, C2, C3, C4, and C5

wherein

A_L¹, B_L¹, C_L¹ and D_L¹, at each occurrence, are independently selected from the group consisting of null, O, CO, SO, SO₂, NR_L^b, CR_L^bR_L^c;

X_L′, Y_L′, A_L², B_L², C_L², D_L² and E_L², at each occurrence, are independently selected from N, CR_L^b;

A_L³, B_L³, C_L³, D_L³, and E_L³, at each occurrence, are independently selected from N, O, S, NR_L^b, CR_L^b;

R_L^b and R_L^c, at each occurrence, are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxy, optionally substituted C₁-C₈ alkoxyalkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈ alkylamino, and optionally substituted C₁-C₈alkylaminoC₁-C₈ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₃-C₁₀ cycloalkoxy, optionally substituted C₃-C₁₀ carbocyclylamino, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl; and

m_L¹, n_L¹, o_L¹ and p_L¹ are independently selected from 0, 1, 2, 3, 4 and 5.

In another embodiment, R_L^r, at each occurrence, is selected from Group R_L^r1 and Group R_L^r2, and

Group R_L^r1 consists of optionally substituted following cyclic groups

Group R_L^r2 consists of optionally substituted following cyclic groups

In one embodiment, the Linker moiety is of FORMULA 9A:

wherein

R_L¹, R_L², R_L³ and R_L⁴, at each occurrence, are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxy, optionally substituted C₁-C₈ alkoxyalkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈ alkylamino, and optionally substituted C₁-C₈ alkylaminoC₁-C₈ alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₃-C₁₀ cycloalkoxy, optionally substituted C₃-C₁₀ carbocyclylamino, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or

R_L¹ and R_L², R_L³ and R_L⁴ together with the atom(s) to which they are connected form a 3-20 membered cycloalkyl or 3-20 membered heterocyclyl ring;

A_L, W_L and B_L, at each occurrence, are bivalent moieties independently selected from null, R_L^d-R_L^e, R_L^dCOR_L^e, R_L^dC(O)OR_L^e, R_L^dC(O)N(R_L⁵)R_L^e, R_L^dC(S)N(R_L⁵)R_L^e, R_L^dOR_L^e, R_L^dSR_L^e, R_L^dSOR_L^e, R_L^dSO₂R_L^e, R_L^dSO₂N(R_L⁵)R_L^e, R_L^dN(R_L⁵)R_L^e, R_L^dN(R_L⁵)COR_L^e, R_L^dN(R_L⁵)CON(R_L⁶)R_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, R_L^dN(R_L¹)SO₂N(R_L²)R_L^e, R_L^dN(R_L⁵)C(S)R_L^e, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₃-C₁₃ carbocyclyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein

R_L^d and R_L^e, at each occurrence, are independently selected from null, optionally substituted (C₁-C₈ alkyl)-R_L^r, optionally substituted R_L^r-(C₁-C₈ alkylene), optionally substituted (C₁-C₈ alkylene)-R_L^r-(C₁-C₈ alkylene), or a moiety comprising of optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈alkylaminoC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₃-C₁₃ carbocyclyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^r is defined as in FORMULA9;

R_L⁵ and R_L⁶, at each occurrence, are independently selected from hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxyalkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^d and R_L^e, R_L^≡and R_L⁶, R_L^d and R_L⁵, R_L^d and R_L⁶, R_L^e and R_L⁵, R_L^e and R_L⁶ together with the atom(s) to which they are connected form a 3-20 membered cycloalkyl or 3-20 membered heterocyclyl ring;

m_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;

n_L, at each occurrence, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; and

o_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

In another embodiment, the Linker moiety is of FORMULA 9B:

wherein

R_L¹ and R_L², at each occurrence, are independently selected from hydrogen, halogen, hydroxyl, amino, cyano, nitro, and optionally substituted C₁-C₈ alkyl, optionally substituted C₁-C₈ alkoxy, optionally substituted C₁-C₈ alkoxy C₁-C₈ alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈ alkylamino, C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₃-C₁₀ cycloalkoxy, optionally substituted C₃-C₁₀ carbocyclylamino, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, or

R_L¹ and R_L² together with the atom(s) to which they are connected form a 3-20 membered cycloalkyl or 3-20 membered heterocyclyl ring;

A_L and B_L, at each occurrence, are independently selected from null, or bivalent moiety selected from R_L^d-R_L^e, R_L^dCOR_L^e, R_L^dCO₂R_L^e, R_L^dC(O)N(R_L³)R_L^e, R_L^dC(S)N(R_L³)R_L^e, R_L^dOR_L^e, R_L^dSR_L^e, R_L^dSOR_L^e, R_L^dSO₂R_L^e, R_L^dSO₂N(R_L³)R_L^e, R_L^dN(R_L³)R_L^e, R_L^dN(R_L³)COR_L^e, R_L^dN(R_L³)CON(R_L⁴)R_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, R_L^dN(R_L¹)SO₂N(R_L²)R_L^e, R_L^dN(R_L³)C(S)R_L^e, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₃-C₁₃ carbocyclyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein

R_L^d and R_L^e, at each occurrence, are independently selected from null, optionally substituted (C₁-C₈ alkylene)-R_L^r, optionally substituted R_L^r-(C₁-C₈ alkylene), optionally substituted (C₁-C₈ alkylene)-alkylene), or a moiety comprising of optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₁-C₈ alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈alkylaminoC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₃-C₁₃ carbocyclyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^r is defined as in FORMULA 9;

R_L³ and R_L⁴, at each occurrence, are independently selected from hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxyalkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^d and R_L^e, R_L³ and R_L⁴, R_L^d and R_L³, R_L^d and R_L⁴, R_L^eand R_L³, R_L^e and R_L⁴ together with the atom(s) to which they are connected form a 3-20 membered cycloalkyl or 3-20 membered heterocyclyl ring;

each m_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; and

n_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

In another embodiment, the Linker moiety is of FORMULA 9C:

wherein

X_L, at each occurrence, is selected from O and NR_L⁷;

R_L¹, R_L², R_L³, R_L⁴, R_L⁵, and R_L⁶, at each occurrence, are independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, cyano, nitro, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxy, optionally substituted C₁-C₈ alkoxy C₁-C₈ alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈ alkylamino, optionally substituted C₁-C₈ alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted C₃-C₁₀ cycloalkoxy, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

A_L and B_L, at each occurrence, are independently selected from null, or bivalent moiety selected from R_L^d-R_L^e, R_L^dCOR_L^e, R_L^dCO₂R_L^e, R_L^dC(O)N(R_L⁸)R_L^e, R_L^dC(S)N(R_L⁸)R_L^e, R_L^dOR_L^e, R_L^dSR_L^e, R_L^dSOR_L^e, R_L^dSO₂R_L^e, R_L^dSO₂N(R_L⁸)R_L^e, R_L^dN(R_L⁸)R_L^e, R_L^dN(R_L⁸)COR_L^e, R_L^dN(R_L⁸)CON(R_L⁹)R_L^e, R_L^dN(R_L¹)SON(R_L²)R_L^e, R_L^dN(R_L¹)SO₂N(R_L²)R_L^e, R_L^dN(R_L⁸)C(S)R_L^e, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted 4-13 membered fused cycloalkyl, optionally substituted 5-13 membered fused heterocyclyl, optionally substituted 5-13 membered bridged cycloalkyl, optionally substituted 5-13 membered bridged heterocyclyl, optionally substituted 5-13 membered spiro cycloalkyl, optionally substituted 5-13 membered spiro heterocyclyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl, wherein

R_L^d and R_L^e, at each occurrence, are independently selected from null, optionally substituted (C₁-C₈ alkylene)-R_L^r, optionally substituted R_L^r-(C₁-C₈ alkylene), optionally substituted (C₁-C₈ alkylene)-R_L^r-(C₁-C₈ alkylene), or a moiety comprising of optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkoxyC₁-C₈alkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ alkylene, optionally substituted C₂-C₈ alkenylene, optionally substituted C₂-C₈ alkynylene, optionally substituted C₁-C₈ hydroxyalkylene, optionally substituted C₁-C₈alkoxyC₁-C₈alkylene, optionally substituted C₁-C₈alkylaminoC₁-C₈alkylene, optionally substituted C₁-C₈ haloalkylene, optionally substituted C₃-C₁₃ carbocyclyl, optionally substituted 3-13 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^r is defined as in FORMULA 9;

R_L⁷, R_L⁸ and R_L⁹, at each occurrence, are independently selected from hydrogen, optionally substituted C₁-C₈ alkyl, optionally substituted C₂-C₈ alkenyl, optionally substituted C₂-C₈ alkynyl, optionally substituted C₁-C₈ alkoxyalkyl, optionally substituted C₁-C₈ haloalkyl, optionally substituted C₁-C₈ hydroxyalkyl, optionally substituted C₁-C₈alkylaminoC₁-C₈alkyl, optionally substituted C₃-C₁₀ carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

R_L^d and R_L^e, R_L⁸ and R_L⁹, R_L^d and R_L⁸, R_L^d and R_L⁹, R_L^e and R_L⁸, R_L^e and R_L⁹ together with the atom(s) to which they are connected form a 3-20 membered cycloalkyl or 3-20 membered heterocyclyl ring;

m_L, at each occurrence, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;

n_L, at each occurrence, is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15;

o_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; and

p_L is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.

In another refinement, the length of the Linker is 3 to 30 chain atoms.

In another refinement, the length of the Linker is 6 to 25 chain atoms.

Without wishing to be bound by any particular theory, it is contemplated herein that, in some embodiments, attaching VHL-1 or pomalidomide to either portion of the molecule can recruit the VHL E3 ligase or cereblon E3 ligase to MEK.

The heterobifunctional compounds disclosed herein can selectively affect MEK-mediated disease cells compared to WT (wild type) cells (i.e., an heterobifunctional compound able to kill or inhibit the growth of an MEK-mediated disease cell while also having a relatively low ability to lyse or inhibit the growth of a WT cell), e.g., possess a GI₅₀ for one or more MEK-mediated disease cells more than 1.5-fold lower, more than 2-fold lower, more than 2.5-fold lower, more than 3-fold lower, more than 4-fold lower, more than 5-fold lower, more than 6-fold lower, more than 7-fold lower, more than 8-fold lower, more than 9-fold lower, more than 10-fold lower, more than 15-fold lower, or more than 20-fold lower than its GI₅₀ for one or more WT cells, e.g., WT cells of the same species and tissue type as the MEK-mediated disease cells.

In some aspects, provided herein is a method for identifying a heterobifunctional compound which mediates degradation or reduction of MEK, the method comprising: providing a heterobifunctional test compound comprising an MEK Ligand conjugated to a Degradation Tag through a Linker; contacting the heterobifunctional test compound with a cell comprising a ubiquitin ligase and MEK; determining whether MEK level is decreased in the cell; and identifying the heterobifunctional test compound as a heterobifunctional compound which mediates degradation or reduction of MEK. In certain embodiments, the cell is a cancer cell. In certain embodiments, the cancer cell is a MEK-mediated cancer cell.

Synthesis and Testing of Heterobifunctional Compounds

The binding affinity of novel synthesized heterobifunctional compounds can be assessed using standard biophysical assays known in the art (e.g., isothermal titration calorimetry (ITC), surface plasmon resonance (SPR)). Cellular assays can then be used to assess the heterobifunctional compound's ability to induce MEK degradation and inhibit cancer cell proliferation. Besides evaluating a heterobifunctional compound's induced changes in the protein levels of MEK, MEK mutants, MEK deletions, or MEK fusion proteins, protein-protein interaction or kinase enzymatic activity can also be assessed. Assays suitable for use in any or all of these steps are known in the art, and include, e.g., western blotting, quantitative mass spectrometry (MS) analysis, flow cytometry, enzymatic activity assay, ITC, SPR, cell growth inhibition, xenograft, orthotopic, and patient-derived xenograft models. Suitable cell lines for use in any or all of these steps are known in the art and include FIT-29 and SK-MEL-28 cells. Suitable mouse models for use in any or all of these steps are known in the art and include subcutaneous xenograft models, orthotopic models, patient-derived xenograft models, and patient-derived orthotopic models.

By way of non-limiting example, detailed synthesis protocols are described in the Examples for specific exemplary heterobifunctional compounds.

Pharmaceutically acceptable isotopic variations of the compounds disclosed herein are contemplated and can be synthesized using conventional methods known in the art or methods corresponding to those described in the Examples (substituting appropriate reagents with appropriate isotopic variations of those reagents). Specifically, an isotopic variation is a compound in which at least one atom is replaced by an atom having the same atomic number, but an atomic mass different from the atomic mass usually found in nature. Useful isotopes are known in the art and include, for example, isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine. Exemplary isotopes thus include, e.g., ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, ¹⁷O, ¹⁸O, ³²F, ³⁵S, ¹⁸F, and ³⁶Cl.

Isotopic variations (e.g., isotopic variations containing ²H) can provide therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements. In addition, certain isotopic variations (particularly those containing a radioactive isotope) can be used in drug or substrate tissue distribution studies. The radioactive isotopes tritium (³H) and carbon-14 (¹⁴C) are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

Pharmaceutically acceptable solvates of the compounds disclosed herein are contemplated. A solvate can be generated, e.g., by substituting a solvent used to crystallize a compound disclosed herein with an isotopic variation (e.g., D₂O in place of H₂O, d₆-acetone in place of acetone, or d₆-DMSO in place of DMSO).

Pharmaceutically acceptable fluorinated variations of the compounds disclosed herein are contemplated and can be synthesized using conventional methods known in the art or methods corresponding to those described in the Examples (substituting appropriate reagents with appropriate fluorinated variations of those reagents). Specifically, a fluorinated variation is a compound in which at least one hydrogen atom is replaced by a fluoro atom. Fluorinated variations can provide therapeutic advantages resulting from greater metabolic stability, e.g., increased in vivo half-life or reduced dosage requirements.

Pharmaceutically acceptable prodrugs of the compounds disclosed herein are contemplated and can be synthesized using conventional methods known in the art or methods corresponding to those described in the Examples (e.g., converting hydroxyl groups or carboxylic acid groups to ester groups). As used herein, a “prodrug” refers to a compound that can be converted via some chemical or physiological process (e.g., enzymatic processes and metabolic hydrolysis) to a therapeutic agent. Thus, the term “prodrug” also refers to a precursor of a biologically active compound that is pharmaceutically acceptable. A prodrug may be inactive when administered to a subject, i.e. an ester, but is converted in vivo to an active compound, for example, by hydrolysis to the free carboxylic acid or free hydroxyl. The prodrug compound often offers advantages of solubility, tissue compatibility or delayed release in an organism. The term “prodrug” is also meant to include any covalently bonded carriers, which release the active compound in vivo when such prodrug is administered to a subject. Prodrugs of an active compound may be prepared by modifying functional groups present in the active compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent active compound. Prodrugs include compounds wherein a hydroxy, amino or mercapto group is bonded to any group that, when the prodrug of the active compound is administered to a subject, cleaves to form a free hydroxy, free amino or free mercapto group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of an alcohol or acetamide, formamide and benzamide derivatives of an amine functional group in the active compound and the like.

Definition of Terms

As used herein, the terms “comprising” and “including” are used in their open, non-limiting sense.

As used herein, the term “heterobifunctional compound(s)” and “bivalent compound(s)” can be used interchangeably.

As used herein, the terms “Tyrosine Kinase 2 ligand” and “MEK ligand”, or “MEK targeting moiety” are to be construed to encompass any molecules ranging from small molecules to large proteins that associate with or bind to MEK proteins. The MEK ligand is capable of binding to a MEK protein comprising MEK, a MEK mutant, a MEK deletion, or a MEK fusion protein. The MEK ligand can be, for example but not limited to, a small molecule compound (i.e., a molecule of molecular weight less than about 1.5 kilodaltons (kDa)), a peptide or polypeptide, nucleic acid or oligonucleotide, carbohydrate such as oligosaccharides, or an antibody or fragment thereof.

“Alkyl” refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation. An alkyl may comprise one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen carbon atoms. In certain embodiments, an alkyl comprises one to fifteen carbon atoms (e.g., C₁-C₁₅ alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C₁-C₁₃ alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., C₁-C₈ alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C₅-C₁₅ alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C₅-C₈ alkyl). The alkyl is attached to the rest of the molecule by a single bond, for example, methyl (Me), ethyl (Et), n-propyl (nPr), 1-methylethyl (iso-propyl, iPr), n-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), pentyl, 3-methylhexyl, 2-methylhexyl, and the like.

“Alkenyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond. An alkenyl may comprise two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen carbon atoms. In certain embodiments, an alkenyl comprises two to twelve carbon atoms (e.g., C₂-C₁₂ alkenyl). In certain embodiments, an alkenyl comprises two to eight carbon atoms (e.g., C₂-C₈ alkenyl). In certain embodiments, an alkenyl comprises two to six carbon atoms (e.g., C₂-C₆ alkenyl). In other embodiments, an alkenyl comprises two to four carbon atoms (e.g., C₂-C₄ alkenyl). The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.

The term “allyl,” as used herein, means a —CH₂CH═CH₂ group.

As used herein, the term “alkynyl” refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond. An alkynyl may comprise two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen carbon atoms. In certain embodiments, an alkynyl comprises two to twelve carbon atoms (e.g., C₂-C₁₂ alkynyl). In certain embodiments, an alkynyl comprises two to eight carbon atoms (e.g., C₂-C₈ alkynyl). In other embodiments, an alkynyl has two to six carbon atoms (e.g., C₂-C₆ alkynyl). In other embodiments, an alkynyl has two to four carbon atoms (e.g., C₂-C₄ alkynyl). The alkynyl is attached to the rest of the molecule by a single bond. Examples of such groups include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, 2-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, and the like.

The term “alkoxy”, as used herein, means an alkyl group as defined herein witch is attached to the rest of the molecule via an oxygen atom. Examples of such groups include, but are not limited to, methoxy, ethoxy, n-propyloxy, iso-propyloxy, n-butoxy, iso-butoxy, tert-butoxy, pentyloxy, hexyloxy, and the like.

The term “aryl”, as used herein, “refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon atoms. An aryl may comprise from six to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) π-electron system in accordance with the Hückel theory. In certain embodiments, an aryl comprises six to fourteen carbon atoms (C₆-C₁₄ aryl or 6-14 membered aryl). In certain embodiments, an aryl comprises six to ten carbon atoms (C₆-C₁₀ aryl or 6-10 membered aryl). Examples of such groups include, but are not limited to, phenyl, fluorenyl and naphthyl. The terms “Ph” and “phenyl,” as used herein, mean a —C₆H₅ group.

The term “heteroaryl”, refers to a radical derived from a 3- to 18-membered aromatic ring radical (i.e. 3-18 membered heteroaryl) that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) π-electron system in accordance with the Hückel theory. In certain embodiments, a heteroaryl refers to a radical derived from a 3- to 10-membered aromatic ring radical (3-10 membered heteroaryl). In certain embodiments, a heteroaryl refers to a radical derived from 5- to 7-membered aromatic ring (5-7 membered heteroaryl). Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of such groups include, but not limited to, pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, furopyridinyl, and the like. In certain embodiments, a heteroaryl is attached to the rest of the molecule via a ring carbon atom. In certain embodiments, an heteroaryl is attached to the rest of the molecule via a nitrogen atom (N-attached) or a carbon atom (C-attached). For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached).

The term “heterocyclyl”, as used herein, means a non-aromatic, monocyclic, bicyclic, tricyclic, or tetracyclic radical having a total of from 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 atoms in its ring system, and containing from 3 to 12 (such as 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12)carbon atoms and from 1 to 4(such as 1, 2. 3 or 4) heteroatoms each independently selected from O, S and N, and with the proviso that the ring of said group does not contain two adjacent O atoms or two adjacent S atoms. A heterocyclyl group may include fused, bridged or spirocyclic ring systems. In certain embodiments, a hetercyclyl group comprises 3 to 10 ring atoms (3-10 membered heterocyclyl). In certain embodiments, a hetercyclyl group comprises 3 to 8 ring atoms (3-8 membered heterocyclyl). In certain embodiments, a hetercyclyl group comprises 3 to 10 ring atoms (3-10 membered heterocyclyl). In certain embodiments, a hetercyclyl group comprises 3 to 8 ring atoms (3-8 membered heterocyclyl). A heterocyclyl group may contain an oxo substituent at any available atom that will result in a stable compound. For example, such a group may contain an oxo atom at an available carbon or nitrogen atom. Such a group may contain more than one oxo substituent if chemically feasible. In addition, it is to be understood that when such a heterocyclyl group contains a sulfur atom, said sulfur atom may be oxidized with one or two oxygen atoms to afford either a sulfoxide or sulfone. An example of a 4 membered heterocyclyl group is azetidinyl (derived from azetidine). An example of a 5 membered cycloheteroalkyl group is pyrrolidinyl. An example of a 6 membered cycloheteroalkyl group is piperidinyl. An example of a 9 membered cycloheteroalkyl group is indolinyl. An example of a 10 membered cycloheteroalkyl group is 4H-quinolizinyl. Further examples of such heterocyclyl groups include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl, quinolizinyl, 3-oxopiperazinyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, and 1-oxo-2,8,diazaspiro[4.5]dec-8-yl. A heteroaryl group may be attached to the rest of molecular via a carbon atom (C-attached) or a nitrogen atom (N-attached). For instance, a group derived from piperazine may be piperazin-l-yl (N-attached) or piperazin-2-yl (C-attached).

The term “cycloalkyl” or “carbocyclyl” means a saturated, monocyclic, bicyclic, tricyclic, or tetracyclic radical having a total of from 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 carbon atoms in its ring system. A cycloalkyl may be fused, bridged or spirocyclic. In certain embodiments, a cycloalkyl comprises 3 to 8 carbon ring atoms (3-8 membered or C₃-C₈carbocyclyl). In certain embodiments, a cycloalkyl comprises 3 to 10 carbon ring atoms (C₃-C₁₀ cycloalkyl). Examples of such groups include, but are not limited to, cyclopropyl(cPr), cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptyl, adamantyl, and the like.

The term “spirocyclic” as used herein has its conventional meaning, that is, any ring system containing two or more rings wherein two of the rings have one ring carbon in common. Each ring of the spirocyclic ring system, as herein defined, independently comprises 3 to 20 ring atoms. Preferably, they have 3 to 10 ring atoms. Non-limiting examples of a spirocyclic system include spiro[3.3]heptane, spiro[3.4]octane, and spiro[4.5]decane.

The term cyano” refers to a —C≡N group.

An “aldehyde” group refers to a —C(O)H group.

An “alkoxy” group refers to both an —O-alkyl, as defined herein.

An “alkoxycarbonyl” refers to a —C(O)-alkoxy, as defined herein.

An “alkylaminoalkyl” group refers to an -alkyl-NR-alkyl group, as defined herein.

An “alkylsulfonyl” group refer to a —SO₂alkyl, as defined herein.

An “amino” group refers to an optionally substituted —NH₂.

An “aminoalkyl” group refers to an -alkyl-amino group (such as —CH₂(NH₂)), as defined herein.

An “alkylamino” group refers to an -amino-alkyl group (such as —NH(CH₃)), as defined herein.

An “cycloalkylamino” group refers to an -amino-cycloalkyl group (such as

as defined herein.

An “aminocarbonyl” refers to a —C(O)-amino, as defined herein.

An “arylalkyl” group refers to -alkylaryl, where alkyl and aryl are defined herein.

An “aryloxy” group refers to both an —O-aryl and an —O-heteroaryl group, as defined herein.

An “aryloxycarbonyl” refers to —C(O)-aryloxy, as defined herein.

An “arylsulfonyl” group refers to a —SO₂aryl, as defined herein.

A “carbonyl” group refers to a —C(O)-group, as defined herein.

A “carboxylic acid” group refers to a —C(O)OH group.

A “cycloalkoxy” refers to a —O-cycloalkyl group, as defined herein.

A “halo” or “halogen” group refers to fluorine, chlorine, bromine or iodine.

A “haloalkyl” group refers to an alkyl group substituted with one or more halogen atoms.

A “hydroxy” group refers to an —OH group.

A “nitro” group refers to a —NO₂ group.

An “oxo” group refers to the ═O substituent.

A “trihalomethyl” group refers to a methyl substituted with three halogen atoms.

The term “alkylene” is a bidentate radical obtained by removing a hydrogen atom from a alkyl group as defined above. Examples of such groups include, but are not limited to, —CH₂—, —CH₂CH₂—, etc. The term “cycloalkylene” or “carbocyclylene” is a bidentate radical obtained by removing a hydrogen atom from a cycloalkyl ring as defined above. Examples of such groups include, but are not limited to, cyclopropylene, cyclobutylene, cyclopentylene, cyclopentenylene, cyclohexylene, cycloheptylene, and the like. Similarly, the terms “ alkenylene”, “alkynylene”, “alkoxyalkylene”, “haloalkylene”, “hydroxyalkylene”, “ aminoalkylene”, “alkylaminoalkylene”, and “heterocyclylene” are bidentate radicals obtained by removing a hydrogen atom from an alkenyl radical, an alkynyl radical, an alkoxyalkyl radical, a haloalkyl radical, an hydroxyalkylene“, ” aminoalkyl radical, and an alkylaminoalkyl radical, respectively.

The term “length” when refers to a moiety means the smallest number of carbon and/or hetero atoms from one end to the other end of the moiety. When it refers to the Linker, it means the smallest number of atoms from the end connects to the MEK ligand and the end connects to the Degradation Tag. It applies to both situations where the Linker is linear or branched, and where the Linker comprises a ring system.

The term “substituted”, unless otherwise stated, means that the specified group or moiety bears one or more substituents independently selected from C₁-C₄ alkyl, aryl, heteroaryl, aryl-C₁-C₄ alkyl-, heteroaryl-C₁-C₄ alkyl-, C₁-C₄ haloalkyl, —OC₁-C₄ alkyl, —OC₁-C₄ alkylphenyl, —C₁-C₄ alkyl-OH, —OC₁-C₄ haloalkyl, halo, —OH, —NH₂, —C₁-C₄ alkyl-NH₂, —N(C₁-C₄ alkyl)(C₁-C₄ alkyl), —NH(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)(C₁-C₄ alkylphenyl), —NH(C₁-C₄ alkylphenyl), cyano, nitro, oxo, —CO₂H, —C(O)OC₁-C₄ alkyl, —CON(C₁-C₄ alkyl)(C₁-C₄ alkyl), —CONH(C₁-C₄ alkyl), —CONH₂, —NHC(O)(C₁-C₄ alkyl), —NHC(O)(phenyl), —N(C₁-C₄ alkyl)C(O)(C₁-C₄ alkyl), —N(C₁-C₄ alkyl)C(O)(phenyl), —C(O)C₁-C₄ alkyl, —C(O)C₁-C₄ alkylphenyl, —C(O)C₁-C₄ haloalkyl, —OC(O)C₁-C₄ alkyl, —SO₂(C₁-C₄ alkyl), —SO₂(phenyl), —SO₂(C₁-C₄ haloalkyl), —SO₂NH₂, —SO₂NH(C₁-C₄ alkyl), —SO₂NH(phenyl), —NHSO₂(C₁-C₄ alkyl), —NHSO₂(phenyl), and —NHSO₂(C₁-C₄ haloalkyl).

The term “null” means the absence of an atom or moiety, and there is a bond between adjacent atoms in the structure.

The term “optionally substituted” means that the specified group may be either unsubstituted or substituted by one or more substituents as defined herein. It is to be understood that in the compounds of the present invention when a group is said to be “unsubstituted,” or is “substituted” with fewer groups than would fill the valencies of all the atoms in the compound, the remaining valencies on such a group are filled by hydrogen. For example, if a C₆ aryl group, also called “phenyl” herein, is substituted with one additional substituent, one of ordinary skill in the art would understand that such a group has 4 open positions left on carbon atoms of the C₆ aryl ring (6 initial positions, minus one at which the remainder of the compound of the present invention is attached to and an additional substituent, remaining 4 positions open). In such cases, the remaining 4 carbon atoms are each bound to one hydrogen atom to fill their valencies. Similarly, if a C₆ aryl group in the present compounds is said to be “disubstituted,” one of ordinary skill in the art would understand it to mean that the C₆ aryl has 3 carbon atoms remaining that are unsubstituted. Those three unsubstituted carbon atoms are each bound to one hydrogen atom to fill their valencies. Unless otherwise specified, an optionally substituted radical may be a radical unsubstituted or substituted with one or more substituents selected from halogen, CN, NO₂, OR^m, SR^m, NRⁿR^o, COR^m, CO₂R^m, CONRⁿR^o, SOR^m, SO₂R^m, SO₂NRⁿR^o, NRⁿCOR^o, NR^mC(O)NRⁿR^o,NRⁿSOR^o, NRⁿSO₂R^o, C₁-C₈ alkyl, C₁-C₈alkoxyC₁-C₈alkyl, C₁-C₈ haloalkyl, C₁-C₈ hydroxyalkyl, C₁-C₈alkylaminoC₁-C₈ alkyl, C₃-C₇ cycloalkyl, 3-7 membered heterocyclyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, aryl, and heteroaryl, wherein R^m, Rⁿ, and R^o are independently selected from null, hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₇ cycloalkyl, 3-7 membered heterocyclyl, aryl, and heteroaryl, or Rⁿand R^o together with the atom to which they are connected form a 3-8 membered cycloalkyl or heterocyclyl ring.

As used herein, the same symbol in different FORMULA means different definition, for example, the definition of R1 in FORMULA 1 is as defined with respect to FORMULA 1 and the definition of R1 in FORMULA 6 is as defined with respect to FORMULA 6.

As used herein, each unit in the Linker moiety (e.g., —(W_L¹-W_L²)—,

can be the same as or different from each other. In certain embodiments, each unit in the Linker moiety is the same as each other.

As used herein, when m (or n or o or p) is defined by a range, for example, “m is 0 to 15” or “m=0-3” mean that m is an integer from 0 to 15 (i.e. m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15) or m is an integer from 0 to 3(i.e. m is 0, 1, 2, or 3) or is any integer in the defined range.

“Pharmaceutically acceptable salt” includes both acid and base addition salts. A pharmaceutically acceptable salt of any one of the heterobifunctional compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.

“Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like. Also included are salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc. and include, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like. Also contemplated are salts of amino acids, such as arginates, gluconates, and galacturonates (see, for example, Berge S. M. et al., “Pharmaceutical Salts,” Journal of Pharmaceutical Science, 66:1-19 (1997), which is hereby incorporated by reference in its entirety). Acid addition salts of basic compounds may be prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.

“Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Pharmaceutically acceptable base addition salts may be formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like. See Berge et al., supra.

Pharmaceutical Compositions

In some aspects, the compositions and methods described herein include the manufacture and use of pharmaceutical compositions and medicaments that include one or more heterobifunctional compounds as disclosed herein. Also included are the pharmaceutical compositions themselves.

In some aspects, the compositions disclosed herein can include other compounds, drugs, or agents used for the treatment of cancer. For example, in some instances, pharmaceutical compositions disclosed herein can be combined with one or more (e.g., one, two, three, four, five, or less than ten) compounds. Such additional compounds can include, e.g., conventional chemotherapeutic agents or any other cancer treatment known in the art. When co-administered, heterobifunctional compounds disclosed herein can operate in conjunction with conventional chemotherapeutic agents or any other cancer treatment known in the art to produce mechanistically additive or synergistic therapeutic effects.

In some aspects, the pH of the compositions disclosed herein can be adjusted with pharmaceutically acceptable acids, bases, or buffers to enhance the stability of the heterobifunctional compound or its delivery form.

Pharmaceutical compositions typically include a pharmaceutically acceptable excipient, adjuvant, or vehicle. As used herein, the phrase “pharmaceutically acceptable” refers to molecular entities and compositions that are generally believed to be physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human. A pharmaceutically acceptable excipient, adjuvant, or vehicle is a substance that can be administered to a patient, together with a compound of the invention, and which does not compromise the pharmacological activity thereof and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the compound. Exemplary conventional nontoxic pharmaceutically acceptable excipients, adjuvants, and vehicles include, but not limited to, saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.

In particular, pharmaceutically acceptable excipients, adjuvants, and vehicles that can be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat. Cyclodextrins such as α-, β-, and γ-cyclodextrin, may also be advantageously used to enhance delivery of compounds of the formulae described herein.

Depending on the dosage form selected to deliver the heterobifunctional compounds disclosed herein, different pharmaceutically acceptable excipients, adjuvants, and vehicles may be used. In the case of tablets for oral use, pharmaceutically acceptable excipients, adjuvants, and vehicles may be used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried corn starch. When aqueous suspensions or emulsions are administered orally, the active ingredient may be suspended or dissolved in an oily phase is combined with emulsifying or suspending agents. If desired, certain sweetening, flavoring, or coloring agents can be added.

As used herein, the heterobifunctional compounds disclosed herein are defined to include pharmaceutically acceptable derivatives or prodrugs thereof. A “pharmaceutically acceptable derivative” means any pharmaceutically acceptable salt, solvate, or prodrug, e.g., carbamate, ester, phosphate ester, salt of an ester, or other derivative of a compound or agent disclosed herein, which upon administration to a recipient is capable of providing (directly or indirectly) a compound described herein, or an active metabolite or residue thereof. Particularly favored derivatives and prodrugs are those that increase the bioavailability of the compounds disclosed herein when such compounds are administered to a subject (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species. Preferred prodrugs include derivatives where a group that enhances aqueous solubility or active transport through the gut membrane is appended to the structure of formulae described herein. Such derivatives are recognizable to those skilled in the art without undue experimentation. Nevertheless, reference is made to the teaching of Burger's Medicinal Chemistry and Drug Discovery, 5^th Edition, Vol. 1: Principles and Practice, which is incorporated herein by reference to the extent of teaching such derivatives.

The heterobifunctional compounds disclosed herein include pure enantiomers, mixtures of enantiomers, pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates, mixtures of diastereoisomeric racemates and the meso-form and pharmaceutically acceptable salts, solvent complexes, morphological forms, or deuterated derivatives thereof.

In some aspects, the pharmaceutical compositions disclosed herein can include an effective amount of one or more heterobifunctional compounds. The terms “effective amount” and “effective to treat,” as used herein, refer to an amount or a concentration of one or more compounds or a pharmaceutical composition described herein utilized for a period of time (including acute or chronic administration and periodic or continuous administration) that is effective within the context of its administration for causing an intended effect or physiological outcome (e.g., treatment or prevention of cell growth, cell proliferation, or cancer). In some aspects, pharmaceutical compositions can further include one or more additional compounds, drugs, or agents used for the treatment of cancer (e.g., conventional chemotherapeutic agents) in amounts effective for causing an intended effect or physiological outcome (e.g., treatment or prevention of cell growth, cell proliferation, or cancer).

In some aspects, the pharmaceutical compositions disclosed herein can be formulated for sale in the United States, import into the United States, or export from the United States.

Administration of Pharmaceutical Compositions

The pharmaceutical compositions disclosed herein can be formulated or adapted for administration to a subject via any route, e.g., any route approved by the Food and Drug Administration (FDA). Exemplary methods are described in the FDA Data Standards Manual (DSM) (available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs). In particular, the pharmaceutical compositions can be formulated for and administered via oral, parenteral, or transdermal delivery. The term “parenteral” as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraperitoneal, intra-articular, intra-arterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques.

For example, the pharmaceutical compositions disclosed herein can be administered, e.g., topically, rectally, nasally (e.g., by inhalation spray or nebulizer), buccally, vaginally, subdermally (e.g., by injection or via an implanted reservoir), or ophthalmically.

For example, pharmaceutical compositions of this invention can be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, emulsions and aqueous suspensions, dispersions and solutions.

For example, the pharmaceutical compositions of this invention can be administered in the form of suppositories for rectal administration. These compositions can be prepared by mixing a compound of this invention with a suitable non-irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore will melt in the rectum to release the active components. Such materials include, but are not limited to, cocoa butter, beeswax, and polyethylene glycols.

For example, the pharmaceutical compositions of this invention can be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and can be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, or other solubilizing or dispersing agents known in the art.

For example, the pharmaceutical compositions of this invention can be administered by injection (e.g., as a solution or powder). Such compositions can be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, e.g., as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are mannitol, water, Ringers solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, e.g., olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions can also contain a long-chain alcohol diluent or dispersant, or carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms such as emulsions and or suspensions. Other commonly used surfactants such as Tweens, Spans, or other similar emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms can also be used for the purposes of formulation.

In some aspects, an effective dose of a pharmaceutical composition of this invention can include, but is not limited to, e.g., about 0.00001, 0.0001, 0.001, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.15, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2500, 5000, or 10000 mg/kg/day, or according to the requirements of the particular pharmaceutical composition.

When the pharmaceutical compositions disclosed herein include a combination of the heterobifunctional compounds described herein and one or more additional compounds (e.g., one or more additional compounds, drugs, or agents used for the treatment of cancer or any other condition or disease, including conditions or diseases known to be associated with or caused by cancer, inflammation, and/or autoimmune diseases), both the heterobifunctional compounds and the additional compounds may be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.

The additional agents can be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents can be part of a single dosage form, mixed together with the compounds of this invention in a single composition.

In some aspects, the pharmaceutical compositions disclosed herein can be included in a container, pack, or dispenser together with instructions for administration.

Methods of Treatment

The methods disclosed herein contemplate administration of an effective amount of a compound or composition to achieve the desired or stated effect. Typically, the compounds or compositions of the invention will be administered from about 1 to about 6 times per day or, alternately or in addition, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that can be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). Alternatively, such preparations can contain from about 20% to about 80% active compound.

In some aspects, provided herein are a heterobifunctional compound described herein for preventing or treating a disease or condition.

In some aspects, provided herein are a heterobifunctional compound described herein for treating or preventing one or more diseases or conditions disclosed herein in a subject in need thereof.

In certain embodiments, the disease or condition is a MEK-mediated disease or condition. In certain embodiments, the disease or condition is resulted from MEK expression, mutation, deletion, or fusion. In certain embodiments, the diseases or conditions are cancer, hyperproliferative disorder, inflammation, auto-immune disease, dermatological disorders, viral infections, dry eye disorders, bone remodeling disorders, organ transplant associated immunological complications, relapsed cancer, and immunological diseases. In one embodiment, the MEK-mediated cancer is selected from the group consisting of brain cancer, stomach cancer, squamous cell cancer, gastrointestinal tract cancer, liver cancer, biliary passage cancer, breast cancer, ovary cancer, cervix cancer, prostate cancer, testis cancer, penile cancer, genitourinary tract cancer, esophagus cancer, larynx cancer, skin cancer, lung cancer, pancreas cancer, thyroid cancer, gland cancer, bladder cancer, kidney cancer, muscle cancer, bone cancer, head cancer, neck cancer, renal cancer, colorectal cancer, gynecological cancer, cancers of the hematopoietic system, myeloproliferative neoplasms, essential thrombocythemia, polycythemia vera, primary myelofibrosis, chronic neutrophilic leukemia, acute lymphoblastic leukemia, Hodgkin's lymphoma, chronic myelomonocytic leukemia, systemic mast cell disease, hyper eosinophilic syndrome, cutaneous T-cell lymphoma, B-cell lymphoma, and myeloma. In one embodiment, the MEK-mediated non-cancerous hyperproliferative disorder is selected from benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)). In one embodiment, the MEK-mediated disorder is selected from benign hyperplasia of the skin (e.g., psoriasis), restenosis, or prostate (e.g., benign prostatic hypertrophy (BPH)). In one embodiment, the MEK-mediated disorder is selected from pancreatitis or kidney disease (including proliferative glomemlonephritis and diabetes-induced renal disease). In one embodiment, the MEK-mediated disorder is pain. In one embodiment, the MEK-mediated inflammatory disorders are selected from the group consisting of ankylosing spondylitis, Crohn's disease, inflammatory bowel disease, ulcerative colitis, and ischemia reperfusion injuries. In one embodiment, the MEK-mediated auto-immune diseases are selected from the group consisting of multiple sclerosis, scleroderma, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, psoriasis, myasthenia gravis, type I diabetes, diabetic retinopathy, systemic lupus erythematosus, IgA nephropathy, autoimmune thyroid disorders, alopecia areata, and bullous pemphigoid. In one embodiment, the MEK-mediated dermatological disorders are selected from the group consisting of atopic dermatitis, pruritus, alopecia areata, psoriasis, skin rash, skin irritation, skin sensitization, chronic mucocutaneous candidiasis, dermatomyositis, erythema multiforme, palmoplantar pustulosis, vitiligo, polyarteritis nodosa, and STING-associated vasculopathy. In one embodiment, the MEK-mediated diseases are selected from retinopathy of prematurity, age-related macular degeneration, and hemangionia. In some aspects, provided herein are use of a heterobifunctional compound in manufacture of a medicament for preventing or treating one or more diseases or conditions disclosed herein.

In some aspects, the methods disclosed include the administration of a therapeutically effective amount of one or more of the compounds or compositions described herein to a subject (e.g., a mammalian subject, e.g., a human subject) who is in need of, or who has been determined to be in need of, such treatment. In some aspects, the methods disclosed include selecting a subject and administering to the subject an effective amount of one or more of the compounds or compositions described herein, and optionally repeating administration as required for the prevention or treatment of cancer.

In some aspects, subject selection can include obtaining a sample from a subject (e.g., a candidate subject) and testing the sample for an indication that the subject is suitable for selection. In some aspects, the subject can be confirmed or identified, e.g. by a health care professional, as having had, having an elevated risk to have, or having a condition or disease. In some aspects, suitable subjects include, for example, subjects who have or had a condition or disease but that resolved the disease or an aspect thereof, present reduced symptoms of disease (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease), or that survive for extended periods of time with the condition or disease (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease), e.g., in an asymptomatic state (e.g., relative to other subjects (e.g., the majority of subjects) with the same condition or disease). In some aspects, exhibition of a positive immune response towards a condition or disease can be made from patient records, family history, or detecting an indication of a positive immune response. In some aspects, multiple parties can be included in subject selection. For example, a first party can obtain a sample from a candidate subject and a second party can test the sample. In some aspects, subjects can be selected or referred by a medical practitioner (e.g., a general practitioner). In some aspects, subject selection can include obtaining a sample from a selected subject and storing the sample or using the in the methods disclosed herein. Samples can include, e.g., cells or populations of cells.

In some aspects, methods of treatment can include a single administration, multiple administrations, and repeating administration of one or more compounds disclosed herein as required for the prevention or treatment of the disease or condition disclosed herein (e.g., an MEK-mediated disease). In some aspects, methods of treatment can include assessing a level of disease in the subject prior to treatment, during treatment, or after treatment. In some aspects, treatment can continue until a decrease in the level of disease in the subject is detected.

The term “subject,” as used herein, refers to any animal. In some instances, the subject is a mammal. In some instances, the term “subject,” as used herein, refers to a human (e.g., a man, a woman, or a child).

The terms “administer,” “administering,” or “administration,” as used herein, refer to implanting, ingesting, injecting, inhaling, or otherwise absorbing a compound or composition, regardless of form. For example, the methods disclosed herein include administration of an effective amount of a compound or composition to achieve the desired or stated effect.

The terms “treat”, “treating,” or “treatment,” as used herein, refer to partially or completely alleviating, inhibiting, ameliorating, or relieving the disease or condition from which the subject is suffering. This means any manner in which one or more of the symptoms of a disease or disorder (e.g., cancer) are ameliorated or otherwise beneficially altered. As used herein, amelioration of the symptoms of a particular disorder (e.g., cancer) refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with treatment by the heterobifunctional compounds, compositions and methods of the present invention. In some embodiments, treatment can promote or result in, for example, a decrease in the number of tumor cells (e.g., in a subject) relative to the number of tumor cells prior to treatment; a decrease in the viability (e.g., the average/mean viability) of tumor cells (e.g., in a subject) relative to the viability of tumor cells prior to treatment; a decrease in the rate of growth of tumor cells; a decrease in the rate of local or distant tumor metastasis; or reductions in one or more symptoms associated with one or more tumors in a subject relative to the subject's symptoms prior to treatment.

The terms “prevent,” “preventing,” and “prevention,” as used herein, shall refer to a decrease in the occurrence of a disease or decrease in the risk of acquiring a disease or its associated symptoms in a subject. The prevention may be complete, e.g., the total absence of disease or pathological cells in a subject. The prevention may also be partial, such that the occurrence of the disease or pathological cells in a subject is less than, occurs later than, or develops more slowly than that which would have occurred without the present invention. In certain embodiments, the subject has an elevated risk of developing one or more MEK-mediated diseases. Exemplary MEK-mediated diseases that can be treated with heterobifunctional compounds include, for example, cancer (e.g. cancers of brain, stomach, gastrointestinal tracts, liver, biliary passage, breast, ovary, cervix, prostate, testis, penile, genitourinary tract, esophagus, larynx, skin, lung, pancreas, thyroid, glands, bladder, kidney, muscle, bone, and cancers of the hematopoietic system, such as myeloproliferative neoplasms, including essential thrombocythemia, polycythemia vera, primary myelofibrosis, chronic neutrophilic leukemia, acute lymphoblastic leukemia, Hodgkin's lymphoma, chronic myelomonocytic leukemia, systemic mast cell disease, hypereosinophilic syndrome, cutaneous T-cell lymphoma, B-cell lymphoma, myeloma, and other hematologic malignancies, particularly cancers that involve inflammation, mutations or other aberrations that activate the MEK pathway); inflammation (e.g. ankylosing spondylitis, Crohn's disease, inflammatory bowel disease, ulcerative colitis, and ischemia reperfusion injuries, which are conditions related to inflammatory ischemic events such as stroke or cardiac arrest); auto-immune diseases (e.g. multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, psoriasis, myasthenia gravis, type I diabetes, systemic lupus erythematosus, IgA nephropathy, autoimmune thyroid disorders, alopecia areata, and bullous pemphigoid); dermatological disorders (e.g. atopic dermatitis, pruritus, alopecia areata, psoriasis, skin rash, skin irritation, skin sensitization, chronic mucocutaneous candidiasis, dermatomyositis, erythema multiforme, palmoplantar pustulosis, vitiligo, polyarteritis nodosa, and STING-associated vasculopathy); viral infections (e.g. viral infections and consequent complications, such as infections of Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV), Human T-lymphotropic Virus (HTLV1), Epstein Barr Virus (EBV), Varicella-Zoster Virus (VZV) and Human Papilloma Virus (HPV)); dry eye disorder, also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS); bone remodeling disorders (e.g. osteoporosis and osteoarthritis); organ transplant associated immunological complications(e.g. graft-versus-host diseases).

Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the patient's disposition to the disease, condition or symptoms, and the judgment of the treating physician.

An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a therapeutic compound (i.e., an effective dosage) depends on the therapeutic compounds selected. Moreover, treatment of a subject with a therapeutically effective amount of the compounds or compositions described herein can include a single treatment or a series of treatments. For example, effective amounts can be administered at least once. The compositions can be administered from one or more times per day to one or more times per week; including once every other day. The skilled artisan will appreciate that certain factors can influence the dosage and timing required to effectively treat a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health or age of the subject, and other diseases present.

Following administration, the subject can be evaluated to detect, assess, or determine their level of disease. In some instances, treatment can continue until a change (e.g., reduction) in the level of disease in the subject is detected. Upon improvement of a patient's condition (e.g., a change (e.g., decrease) in the level of disease in the subject), a maintenance dose of a compound, or composition disclosed herein can be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, can be reduced, e.g., as a function of the symptoms, to a level at which the improved condition is retained. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

The present disclosure is also described and demonstrated by way of the following examples. However, the use of these and other examples anywhere in the specification is illustrative only and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to any particular preferred embodiment or aspect described herein. Indeed, many modifications and variations may be apparent to those skilled in the art upon reading this specification, and such variations can be made without departing from the invention in spirit or in scope. The invention is therefore to be limited only by the terms of the appended claims along with the full scope of equivalents to which those claims are entitled.

EXAMPLES

Example 1

3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(3-oxopropoxy)benzamide (Z5)

Step 1. Synthesis of 2-(2-(1,3-dioxolan-2-yl)ethoxy)isoindoline-1,3-dione (Z2).

To a solution of compound Z1 (1 g, 5.5 mmol) in DMF (5 mL) were added 2-hydroxyisoindoline-1,3-dione (0.9 g, 5.5 mmol) and DBU (1.6 mL, 11.0 mmol). The reaction mixture was heated to 50° C. for 4 h. The reaction was monitored by UPLC. Upon completion, the reaction mixture was purified by reverse column chromatography to give compound Z2 (1.2 g, 4.5 mmol, 82% yield) as yellow solid. ¹H NMR (600 MHz, Methanol-d₄) δ8.36-7.40 (m, 4H), 5.10 (t, J=4.7 Hz, 1H), 4.31 (t, J=6.6 Hz, 2H), 3.98-3.93 (m, 2H), 3.87-3.82 (m, 2H), 2.09 (td, J=6.6, 4.6 Hz, 2H). UPLC >95%, t_R=1.12 min. MS (ESI) [M+H]⁺=264.1638.

Step 2. Synthesis of O-(2-(1,3-dioxolan-2-yl)ethyl)hydroxylamine (Z3).

A solution of compound Z2 (1.2 g, 4.5 mmol) and hydrazine monohydrate (0.66 mL, 13.5 mmol) in MeOH (4 mL) and DCM (2 mL) was stirred at room temperature for 2 h. The reaction was monitored by UPLC. Upon completion, the solvent was evaporated, water (20 mL) was added to the residue, and then extracted with DCM (20 mL×3). The combined organic layers were washed with 5% NaHCO₃ solution and brine, then dried over anhydrous Na₂SO₄, filtered, and concentrated to obtain compound Z3 (0.53 g, 4.0 mmol, 89% yield) as colorless liquid without further purification.

Step 3. Synthesis of N-(2-(1,3-dioxolan-2-yl)ethoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino) benzamide (Z4).

To a solution of compound Z3 (0.53 g, 4.0 mmol) and 3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (1.6 g, 4.0 mmol) in DMSO (5 mL) were added HOAt (0.8 g, 6.0 mmol), EDCI (1.2 g, 6.0 mmol), and 4-methylmorpholine (1.3 mL, 12.0 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was monitored by UPLC. Upon completion, the reaction mixture was purified by reverse column chromatography to give compound Z4 (1.5 g, 3.0 mmol, 75% yield) as white solid. ¹H NMR (600 MHz, Methanol-d₄) δ7.45 (dd, J=10.6, 1.9 Hz, 1H), 7.38 (t, J=7.0 Hz, 1H), 7.35 (dt, J=8.5, 1.5 Hz, 1H), 7.03 (td, J=9.2, 7.0 Hz, 1H), 6.60 (td, J=8.7, 4.2 Hz, 1H), 4.97 (t, J=4.9 Hz, 1H), 3.96 (t, J=6.7 Hz, 2H), 3.95-3.90 (m, 2H), 3.86-3.78 (m, 2H), 1.97 (td, J=6.7, 4.7 Hz, 2H). UPLC >95%, t_R=1.95 min. MS (ESI) -[M+H]⁺=507.0261.

Step 4. Synthesis of 3,4-Difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-(3-oxopropoxy)benzamide (Z5).

To a solution of compound Z4 (0.5 g, 1.0 mmol) in THF (3 mL) was added 3M HCl (5 mL). The reaction mixture was stirred at room temperature for 6 h. The reaction was monitored by UPLC. Upon completion, the reaction mixture was cooled to 0° C., neutralized with saturated NaHCO₃ to pH 7˜8, and then extracted with EtOAc (30 mL×3) to obtain compound Z5 (0.37 g, 0.8 mmol, 80% yield) as colorless liquid without further purification.

Example 2

(2S,4R)-1-((S)-2-((6-Aminohexyl)amino)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (Z7)

To a solution of compound Z6 (0.5 g, 1.2 mmol) and 7-((tert-butoxycarbonyl)amino)heptanoic acid (0.3 g, 1.2 mmol) in DMSO (5 mL) were added HOAt (0.2 g, 1.8 mmol), EDCI (0.4 g, 1.8 mmol), and 4-methylmorpholine (0.4 mL, 3.6 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was monitored by UPLC. Upon completion, the reaction mixture was purified by reverse column chromatography to give the desired intermediate (0.7 g, 1.1 mmol, 92% yield) as a white solid. This intermediate (0.7 g, 1.1 mmol) then was dissolved in DCM (2 mL), and trifluoroacetic acid (2 mL) was added. The reaction mixture was stirred at room temperature for 2 h. The reaction was monitored by UPLC. Once completion, the solvent was evaporated, and the residue was purified by reverse column chromatography to obtain compound Z7 (0.6 g, 1.0 mmol, 91% yield) as a white solid. 1H NMR (600 MHz, methanol-d4) δ9.80 (s, 1H), 7.56 (dd, J=8.2, 4.1 Hz, 2H), 7.51 (d, J=7.9 Hz, 2H), 4.65-4.60 (m, 1H), 4.58-4.56 (m, 1H), 4.55-4.52 (m, 1H), 4.52-4.49 (m, 1H), 4.41 (d, J=15.7 Hz, 1H), 3.91 (d, J=11.0 Hz, 1H), 3.81 (dd, J=11.0, 3.9 Hz, 1H), 2.92 (t, J=7.7 Hz, 2H), 2.59 (s, 3H), 2.35-2.27 (m, 2H), 2.27-2.22 (m, 1H), 2.12-2.04 (m, 1H), 1.70-1.60 (m, 4H), 1.51-1.34 (m, 4H), 1.04 (s, 9H).

Example 3

(2S,4R)-1-((S)-16-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,14-dioxo-3-oxa-2,7,15-triazaheptadecan-17-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-001)

To a solution of compound Z7 (0.1 g, 0.2 mmol) and compound Z5 (0.1 g, 0.2 mmol) in DCM (2 mL) and MeOH (1 mL) was added NaBH₃CN (19 mg, 0.3 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was monitored by UPLC. Upon completion, the reaction mixture was purified by preparative HPLC to give CPD-001 (0.1 g, 0.1 mmol, 50% yield) as a white solid. ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (d, J=6.0 Hz, 1H), 7.51-7.45 (m, 3H), 7.44-7.39 (m, 3H), 7.38 (d, J=8.8 Hz, 1H), 7.07 (q, J=8.9 Hz, 1H), 6.63 (td, J=8.6, 4.0 Hz, 1H), 4.67-4.63 (m, 1H), 4.58-4.55 (m 1H), 4.53 (d, J=10.4 Hz, 1H), 4.51-4.49 (m, 1H), 4.36 (d, J=15.4 Hz, 1H), 4,05 (t, J=5.1 Hz, 2H), 3.90 (d, J=11.0 Hz, 1H), 3,81 (dd, J=10.9, 4.0 Hz, 1H), 3.23 (t, J=5.9 Hz, 2H), 3.10-2.99 (m, 2H), 2.48 (s, 3H), 2.31 (dt, J=14.9, 7.6 Hz, 1H), 2.28-2.25 (m, 1H), 2.25-2.19 (m, 1H), 2.08 (ddd, J=13.3, 9.1, 4.4 Hz, 1H), 2.05-1.99 (m, 2H), 1.73 (p, J=7.8 Hz, 2H), 1.61 (dt, J=13.7, 6.9 Hz, 2H), 1.42 (p, J=7.1 Hz, 2H), 1.37 (q, J=7.2 Hz, 2H), 1.03 (s, 9H).

Example 4

(2S,4R)-1-((S)-14-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,12-dioxo-3,10-dioxa-2,7,13-triazapentadecan-15-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-002)

CPD-002 was synthesized following the same procedures as CPD-001 as described in Example 3 (0.1 g, yield: 49%). ¹H NMR (600 MHz, Methanol-d₄) δ8.98 (s, 1H), 7.50-7.44 (m, 3H), 7.42 (d, J=8.3 Hz, 2H), 7.40-7.35 (m, 2H), 7.06 (q, J=8.8 Hz, 1H), 6.62 (td, J=8.8, 4.0 Hz, 1H), 4.67 (s, 1H), 4.59-4.55 (m, 1H), 4.54 (d, J=3.3 Hz, 1H), 4.51 (d, J=10.2 Hz, 1H), 4.35 (d, J=15.4 Hz, 1H), 4.12 (s, 1H), 4.09 (s, 1H), 4.07-4.03 (m, 3H), 3.91-3.84 (m, 3H), 3.80 (dd, J=11.0, 3.7 Hz, 1H), 3.36-3.34 (m, 1H), 3.28 (p, J=1.7 Hz, 1H), 2.48 (s, 3H), 2.24 (dd, J=13.1, 7.7 Hz, 1H), 2.12-2.02 (m, 4H), 1.01 (s, 9H).

Example 5

(2S,4R)-1-((S)-15-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,13-dioxo-3,10-dioxa-2,7,14-triazahexadecan-16-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-003)

CPD-003 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.06 g, yield: 42%). ¹H NMR (600 MHz, Methanol-d₄) δ9.73 (s, 1H), 7.50 (t, J=6.7 Hz, 2H), 7.46 (d, J=8.2 Hz, 2H). 7.43 (dd, J=10.6, 2.01 Hz, 1H), 7.39 (t, J=7.2 Hz, 1H), 7.34 (d, J=8.1 Hz, 1H), 7.01 (d, J=7.7 Hz, 1H), 6.68-6.54 (m, 1H), 4.63-4.55 (m, 2H), 4.50 (d, J=14.8 Hz, 2H), 4.43 (d, J=15.6 Hz, 1H), 4.04 (t, J=5.4 Hz, 2H), 3.98-3.89 (m, 2H), 3.85-3.68 (m, 6H), 2.57 (s, 6H), 2.26 (t, J=10.6 Hz, 1H), 2.07 (q, J=6.3, 5.3 Hz, 4H), 1.01 (s, 9H).

Example 6

(2S,4R)-1-((S)-18-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,16-dioxo-3,10,13-trioxa-2,7,17-triazanonadecan-19-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-004)

CPD-004 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 42%). ¹H NMR (600 MHz, Methanol-d₄) δ9.28 (s, 1H), 7.51-7.47 (m, 3H), 7.45 (d, J=8.1 Hz, 2H), 7.41 (t, J=6.9 Hz, 1H), 7.38-7.35 (m, 1H), 7.05 (q, J=8.6 Hz, 1H), 6.63 (td, J=8.6, 4.1 Hz, 1H), 4.64 (s, 1H), 4.58-4.53 (m, 1H), 4.52-4.49 (m, 2H), 4.40 (d, J=15.6 Hz, 1H), 4.07 (t, J=5.2 Hz, 2H), 3.96-3.88 (m, 1H), 3.83-3.76 (m, 3H), 3.74-3.63 (m, 3H), 3.58 (t, J=4.5 Hz, 2H), 3.56-3.52 (m, 2H), 3.30-3.23 (m, 3H), 2.57-2.52 (m, 1H), 2.52 (s, 3H), 2.50-2.43 (m, 1H), 2.24 (dd, J=13.2, 7.6 Hz, 1H), 2.14-2.00 (m, 3H), 1.02 (s, 9H).

Example 7

(2S,4R)-1-((S)-11-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,9-dioxo-3-oxa-2,7,10-triazadodecan-12-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-005)

CPD-005 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 42%). ¹H NMR (600 MHz, Methanol-d₄) δ9.30 (d, J=4.2 Hz, 1H), 7.53-7.47 (m, 3H), 7.47-7.44 (m, 2H), 7.40-7.36 (m, 2H), 7.01 (td, J=9.1, 6.9 Hz, 1H), 6.68 (td, J=8.7, 3.8 Hz, 1H), 4.58-4.55 (m, 2H), 4.53 (d, J=8.4 Hz, 2H), 4.51-4.48 (dt, J=4.5, 2.5 Hz, 1H), 4.37 (d, J=15.6 Hz, 1H), 4.08 (dt, J=9.8, 5.0 Hz, 1H), 4.03 (dq, J=9.9, 5.3 Hz, 1H), 3.98 (d, J=15.8 Hz, 1H), 3.87 (d, J=15.8 Hz, 1H), 3.81 (d, J=11.0 Hz, 1H), 3.76 (dd, J=10.9, 3.8 Hz, 1H), 2.52 (s, 3H), 2.25-2.20 (m, 1H), 2.11-2.03 (m, 4H), 1.03 (s, 9H).

Example 8

(2S,4R)-1-((S)-12-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,10-dioxo-3-oxa-2,7,11-triazatridecan-13-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-006)

CPD-006 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 41%). ¹H NMR (600 MHz, Methanol-d₄) δ8.96 (s, 1H), 7.51-7.45 (m, 3H), 7.44-7.40 (m, 3H), 7.38 (dt, J=8.3, 1.4 Hz, 1H), 7.05 (td, J=9.1, 6.9 Hz, 1H), 6.66 (td, J=8.7, 3.9 Hz, 1H), 4.59-4.53 (m, 3H), 4.50-4.47 (m, 1H), 4.34 (d, J=15.5 Hz, 1H), 4.03 (t, J=5.2 Hz, 2H), 3.90 (d, J=10.9 Hz, 1H), 3.75 (dd, J=10.9, 3.9 Hz, 1H), 3.35-3.32 (m, 2H), 3.27-3.22 (m, 2H), 2.78 (t, J=6.6 Hz, 2H), 2.47 (s, 3H), 2.25-2.20 (m, 1H), 2.08 (ddd, J=13.4, 9.3, 4.3 Hz, 1H), 2.05-1.99 (m, 2H), 1.02 (s, 9H).

Example 9

(2S,4R)-1-((S)-14-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,12-dioxo-3-oxa-2,7,13-triazapentadecan-15-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-007)

CPD-007 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 40%). ¹H NMR (600 MHz, Methanol-d₄) δ8.88 (s, 1H), 7.49 (dd, J=10.7, 1.9 Hz, 1H), 7.46 (d, J=8.2 Hz, 2H), 7.43-7.39 (m, 2H), 7.39-7.33 (m, 2H), 7.07 (td, J=9.2, 7.1 Hz, 1H), 6.64 (td, J=8.7, 3.9 Hz, 1H), 4.61 (s, 1H), 4.55 (dq, J=14.0, 6.7 Hz, 2H), 4.50 (dd, J=4.2, 2.2 Hz, 1H), 4.35 (d, J=15.5 Hz, 1H), 4.07-3.99 (m, 2H), 3.89 (dt, J=11.1, 1.7 Hz, 1H), 3.80 (dd, J=10.9, 3.9 Hz, 1H), 3.66-3.62 (m, 1H), 3.59 (dd, J=12.6, 3.9 Hz, 1H), 3.22 (t, J=5.9 Hz, 2H), 3.05 (t, J=7.3 Hz, 2H), 2.47 (s, 2H), 2.34 (tt, J=15.0, 7.6 Hz, 2H), 2.24-2.19 (m, 1H), 2.09 (ddd, J=13.3, 9.2, 4.5 Hz, 1H), 2.04-1.98 (m, 2H), 1.81-1.65 (m, 4H), 1.03 (s, 9H).

Example 10

(2S,4R)-1-((S)-13-(tert-Butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,11-dioxo-3-oxa-2,7,12-triazatetradecan-14-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-008)

CPD-008 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.03 g, yield: 39%). ¹H NMR (600 MHz, Methanol-d₄) δ8.98 (s, 1H), 7.50-7.45 (m, 3H), 7.44-7.38 (m, 3H), 7.37 (dt, J=8.5, 1.3 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.8, 3.9 Hz, 1H), 4.58 (d, J=6.8 Hz, 1H), 4.56 (dd, J=3.0, 1.4 Hz, 1H), 4.53 (d, J=9.7 Hz, 1H), 4.51-4.49 (m, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.03 (dp, J=11.8, 4.2 Hz, 2H), 3.91 (d, J=10.9 Hz, 1H), 3.79 (dd, J=10.9, 3.9 Hz, 1H), 3.22 (t, J=5.9 Hz, 2H), 3.08 (td, J=7.5, 1.8 Hz, 2H), 2.48 (s, 3H), 2.48-2.44 (m, 2H), 2.22 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.08 (ddd, J=13.3, 9.3, 4.4 Hz, 1H), 2.04-197 (m, 4H), 1.03 (s, 9H).

Example 11

(2S,4R)-1-((S)-15-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,13-dioxo-3-oxa-2,7,14-triazahexadecan-16-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-009)

CPD-009 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.03 g, yield: 38%). ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.51-7.45 (m, 3H), 7.42 (d, J=7.8 Hz, 3H), 7.37 (d, J=9.1 Hz, 1H), 7.07 (q, J=8.6 Hz, 1H), 6.63 (td, J=8.7, 4.0 Hz, 1H), 4.64 (s, 1H), 4.61-4.52 (m, 2H), 4.50 (s, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.04 (t, J=5.2 Hz, 2H), 3.91 (d, J=11.0 Hz, 1H), 3.81 (dd, J=11.0, 3.9 Hz, 1H), 3.23 (t, J=5.9 Hz, 2H), 3.04 (t, J=7.9 Hz, 2H), 2.48 (s, 3H), 2.35-2.26 (m, 2H), 2.22 (dd, J=13.2, 7.8 Hz, 1H), 2.09 (ddd, J=13.3, 9.1, 4.4 Hz, 1H), 2.02 (dd, J=11.0, 5.3 Hz, 2H), 1.74 (p, J=7.8 Hz, 2H), 1.65 (p, J=7.2 Hz, 2H), 1.42 (p, J=7.8 Hz, 2H), 1.03 (s, 9H).

Example 12

(2S,4R)-1-((S)-18-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,16-dioxo-3-oxa-2,7,17-triazanonadecan-19-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-010)

CPD-010 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.03 g, yield: 35%). ¹H NMR (600 MHz, Methanol-d₄) δ8.97 (s, 1H), 7.51-7.45 (m, 3H), 7.45-7.39 (m, 3H), 7.37 (dt, J=8.5, 1.3 Hz, 1H), 7.07 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 4.64 (s, 1H), 4.60-4.55 (m, 1H), 4.54-4.52 (m, 1H), 4.50 (dq, J=4.1, 2.1 Hz, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.07 (dd, J=5.8, 4.5 Hz, 2H), 3.90 (dt, J=11.2, 1.7 Hz, 1H), 3.81 (dd, J=10.9, 3.9 Hz, 1H), 3.23 (t, J=5.8 Hz, 2H), 3.10-2.90 (m, 2H), 2.48 (s, 3H), 2.33-2.26 (m, 1H), 2.25-2.18 (m, 2H), 2.08 (ddd, J=13.3, 9.1, 4.51 Hz, 1H), 2.02 (dt, J=10.2, 5.1 Hz, 2H), 1.72 (p, J=7.8 Hz, 2H), 1.59 (q, J=7.2 Hz, 2H), 1.42-1.36 (d, J=7.9 Hz, 2H), 1.35-1.29 (m, 6H), 1.03 (s, 9H).

Example 13

(2S,4R)-1-((S)-17-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,15-dioxo-3-oxa-2,7,16-triazaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-011)

CPD-011 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.03 g, yield: 39%). ¹H NMR (600 MHz, Methanol-d₄) δ8.92 (s, 1H), 7.52-7.45 (m, 3H), 7.44-7.39 (m, 3H), 7.38 (dt, J=8.6, 1.3 Hz, 1H), 7.07 (td, J=9.2, 7.0 Hz, 1H), 6.63 (td, J=8.7, 4.3 Hz, 1H), 4.67-4.62 (m, 1H), 4.60-4.55 (m, 1H), 4.54 (d, 12.9 Hz, 1H), 4.51-4.48 (m, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.06 (t, J=5.1 Hz, 2H), 3.90 (d, 11.0 Hz, 1H), 3.81 (dd, J=11.0, 3.9 Hz, 1H), 3.23 (t, J=5.9 Hz, 2H), 3.09-2.97 (m, 2H), 2.48 (s, 3H), 2.32-2.27 (m, 1H), 2.26-2.20 (m, 2H), 2.08 (ddd, J=13.3, 9.2, 4.5 Hz, 1H), 2.02 (dt, J=10.1, 5.0 Hz, 2H), 1.72 (p, J=7.7 Hz, 2H), 1.61 (dp, J=14.5, 7.1 Hz, 2H), 1.43-1.38 (m, 2H), 1.38-1.28 (m, 4H), 1.03 (s, 9H).

Example 14

(2S,4R)-1-((S)-17-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,15-dioxo-3,10,13-trioxa-2,7,16-triazaoctadecan-18-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-012)

CPD-012 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.03 g, yield: 46%). ¹H NMR (600 MHz, Methanol-d₄) δ8.95 (s, 1H), 7.50-7.45 (m, 2H), 7.45-7.41 (m, 3H), 7.40-7.35 (m, 2H), 7.16-6.99 (m, 1H), 6.63 (td, J=8.8, 4.0 Hz, 1H), 4.77-4.70 (m, 1H), 4.59-4.53 (m, 1H), 4.50 (d, J=6.0 Hz, 1H), 4.48-4.38 (m, 2H), 4.08-4.00 (m, 3H), 3.96 (d, J=15.8 Hz, 1H), 3.88 (d, J=11.2 Hz, 1H), 3.81 (dt, J=9.8, 3.8 Hz, 3H), 3.67-3.61 (m, 4H), 3.30-3.23 (m, 3H), 2.47 (s, 3H), 2.33-2.21 (m, 1H), 2.14-2.06 (m, 2H), 2.04 (d, J=14.1 Hz, 2H), 1.03 (s, 9H).

Example 15

(2S,4R)-1-((S)-19-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,17-dioxo-3-oxa-2,7,18-triazaicosan-20-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-013)

CPD-013 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.09 g, yield: 46%). ¹H NMR (600 MHz, Methanol-d₄) δ8.96 (s, 1H), 7.50-7.44 (m, 3H), 7.44-7.39 (m, 3H), 7.38 (dt, 8.5, 1.3 Hz, 1H), 7.07 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 4.63 (s, 1H), 4.59-4.55 (m, 1H), 4.54 (d, J=12.1 Hz, 1H), 4.50 (dd, J=4.3, 2.2 Hz, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.11-4.02 (m, 2H), 3.90 (d, J=11.0 Hz, 1H), 3.80 (dd, J=11.0, 3.9 Hz, 1H), 3.24 (t, J=5.9 Hz, 2H), 3.08-2.99 (m, 2H), 2.48 (s, 3H), 2.29 (ddd, J=15.2, 8.4, 7.0 Hz, 1H), 2.26-2.19 (m, 2H), 2.08 (ddd, J=13.3, 9.1, 4.5 Hz, 1H), 2.02 (dt, J=10.3, 5.1 Hz, 2H), 1.71 (p, J=7.7 Hz, 2H), 1.65-1.53 (m, 2H), 1.42-1.36 (m, 2H), 1.34-1.25 (m, 8H), 1.03 (s, 9H).

Example 16

(2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-014)

CPD-014 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 40%). ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (s, 1H), 7.50-7.44 (m, 3H), 7.44-7.39 (m, 3H), 7.38 (dt, J=8.5, 1.3 Hz, 1H), 7.07 (td, J=9.2, 6.9 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 4.64 (s, 1H), 4.59-4.55 (m, 1H), 4.54 (d, J 12.6 Hz, 1H), 4.51-4.49 (m, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.13-4.03 (m, 2H), 3.90 (d, J=11.0 Hz, 1H), 3.81 (dd, J=11.0, 3.9 Hz, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.10-2.97 (m, 2H), 2.48 (s, 3H), 2.32-2.26 (m, 1H), 2.26-2.19 (m, 2H), 2.08 (ddd, J=13.4, 9.2, 4.5 Hz, 1H), 2.05-1.99 (m, 2H), 1.71 (p, J=7.7 Hz, 2H), 1.59 (tq, J=14.3, 6.9 Hz, 2H), 1.44-1.35 (m, 2H), 1.32-1.29 (m, 6H), 1.29-1.26 (m, 4H), 1.03 (s, 9H).

Example 17

(2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro—Example 17: 2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3,10,13,16-tetraoxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-015)

CPD-015 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.06 g, yield: 47%). ¹H NMR (600 MHz, Methanol-d₄) δ8.99 (s, 1H), 7.49-7.45 (m, 3H), 7.42 (d, J=8.2 Hz, 2H), 7.41-7.38 (m, 1H), 7.37 (dt, J=8.4, 1.3 Hz, 1H), 7.05 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.8, 4.2 Hz, 1H), 4.68 (s, 1H), 4.56 (dd, J=7.9, 1.7 Hz, 1H), 4.53 (d, J=11.4 Hz, 1H), 4.51-4.48 (m, 1H), 4.39 (d, J=15.5 Hz, 1H), 4.14-4.00 (m, 4H), 3.88 (d, J=11.1 Hz, 1H), 3.81 (dd, J=10.9, 3.8 Hz, 1H), 3.77 (dd, J=5.7, 4.3 Hz, 2H), 3.71-3.65 (m, 2H), 3.63-3.58 (m, 4H), 3.58-3.55 (m, 2H), 3.30-3.23 (m, 4H), 2.48 (s, 3H), 2.24 (ddt, J=13.2, 7.5, 1.8 Hz, 1H), 2.08 (ddd, J=13.4, 9.5, 4.3 Hz, 1H), 2.05-2.00 (m, 2H), 1.04 (s, 9H).

Example 18

(2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,19-dioxo-3,10,13,16-tetraoxa-2,7,20-triazadocosan-22-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-016)

CPD-016 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 51%). ¹H NMR (600 MHz, Methanol-d₄) δ9.02 (s, 1H), 7.51-7.44 (m, 3H), 7.43-7.39 (m, 3H), 7.38 (dt, J=8.5, 1.3 Hz, 1H), 7.18-6.99 (m, 1H), 6.64 (td, J=8.7, 4.2 Hz, 1H), 4.64 (s, 1H), 4.59-4.55 (m,1H), 4.53 (d, J=15.4 Hz, 1H), 4.49 (d, J=3.3 Hz, 1H), 4.37 (d, J=15.5 Hz, 1H), 4.15-4.02 (m, 2H), 3.89 (d, J=11.0 Hz, 1H), 3.80 (dd, J=11.0, 3.9 Hz, 1H), 3.78-3.75 (m, 2H), 3.74-3.66 (m, 2H), 3.60-3.57 (dd, J=5.8, 2.2 Hz, 3H), 3.56-3.53 (m, 5H), 3.30-3.25 (m, 4H), 2.61-2.52 (m, 1H), 2.51-2.39 (m, 4H), 2.27-2.19 (m, 1H), 2.09 (dt, J=8.3, 4.3 Hz, 1H), 2.05 (td, J=6.7, 4.5 Hz, 2H), 1.03 (s, 9H).

Example 19

(2S,4R)-1-((S)-24-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,22-dioxo-3,10,13,16,19-pentaoxa-2,7,23-triazapentacosan-25-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (CPD-017)

CPD-017 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 52%). ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.50-7.44 (m, 3H), 7.43-7.39 (m, 3H), 7.38 (dt, J=8.5, 1.3 Hz, 1H), 7.06 (td, J=9.1, 6.8 Hz, 1H), 6.64 (td, J=8.7, 4.0 Hz, 1H), 4.68-4.63 (m, 1H), 4.58-4.54 (m, 1H), 4.54-4.51 (m, 1H), 4.51-4.48 (m, 1H), 4.39-4.33 (m, 1H), 4.11-4.03 (m, 2H), 3.93-3.86 (m, 1H), 3.83-3.76 (m, 3H), 3.75-3.67 (m, 2H), 3.63-3.58 (m, 6H), 3.57 (dq, J=5.7, 3.2, 2.6 Hz, 6H), 3.30-3.25 (m, 4H), 2.57 (ddd, J=15.2, 7.2, 5.2 Hz, 1H), 2.50-2.41 (m, 4H), 2.26 2.19 (m, 1H), 2.09 (dt, J=8.4, 4.2 Hz, 1H), 2.07-2.02 (m, 2H), 1.03 (s, 9H).

Example 20

(2S,4R)-1-((S)-27-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,25-dioxo-3,10,13,16,19,22-hexaoxa-2,7,26-triazaoctacosan-28-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyppyrrolidine-2-carboxamide (CPD-018)

CPD-018 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 52%). ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (s, 1H), 7.50-7.44 (m, 3H), 7.43-7.39 (m, 3H), 7.39-7.36 (m, 1H), 7.06 (q, J=8.7 Hz, 1H), 6.65 (td, J=8.7, 4.2 Hz, 1H), 4.64 (s, 1H), 4.59-4.55 (m, 1H), 4.53 (d, J=10.7 Hz, 1H), 4.51-4.48 (m, 1H), 4.36 (d, J=15.5 Hz, 1H), 4.06 (t, J=5.1 Hz, 2H), 3.99-3.92 (m, 1H), 3.89 (d, J=11.0 Hz, 1H), 3.84-3.76 (m, 3H), 3.75-3.68 (m, 2H), 3.65-3.58 (m, 10H), 3.57-3.54 (m, 6H), 3.29-3.24 (m, 2H), 2.61-2.54 (m, 1H), 2.51-2.43 (m, 4H), 2.22 (dd, J=13.2, 7.8 Hz, 1H), 2.09 (dt, J=8.4, 4.3 Hz, 1H), 2.07-2.01 (m, 2H), 1.39-1.27 (m, 1H), 1.03 (s, 9H).

Example 21

N-(3-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-019)

CPD-019 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 52%). ¹H NMR (600 MHz, Methanol-d₄) δ7.46 (dd, J=8.6, 7.1 Hz, 1H), 7.38 (dd, J=10.7, 2.0 Hz, 1H), 7.35 (dd, J=7.7, 2.3 Hz, 1H), 7.26 (dt, J=8.3, 1.3 Hz, 1H), 6.96 (d, J=7.0 Hz, 1H), 6.95-6.88 (m, 2H), 6.57 (td, J=8.8, 4.7 Hz, 1H), 4.98-4.93 (m, 1H), 4.15-4.07 (m, 2H), 3.93-3.83 (m, 2H), 3.77 (ddd, J=6.0, 4.5, 1.9 Hz, 2H), 3.45 (dd, J=5.7, 4.2 Hz, 2H), 3.34 (t, J=5.2 Hz, 4H), 2.82 (ddd, J=17.5, 13.8, 5.3 Hz, 1H), 2.71 (ddd, J=17.5, 4.5, 2.7 Hz, 1H), 2.60 (qd, J=13.1, 4.5 Hz, 1H), 2.09-2.03 (m, 2H), 2.00 (ddd, J=13.1, 5.3, 3.0 Hz, 1H).

Example 22

N-(3-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-020)

CPD-020 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 48%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (dd, J=8.6, 7.1 Hz, 1H), 7.44 (dd, J=10.7, 1.9 Hz, 1H), 7.39-7.31 (m, 2H), 7.09-6.97 (m, 3H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 5.03 (dd, J=12.8, 5.5 Hz, 1H), 4.04 (t, J=5.0 Hz, 2H), 3.81 (t, J=5.0 Hz, 2H), 3.67 (t, J=5.1 Hz, 2H), 3.66-3.58 (m, 4H), 3.45 (dd, J=5.8, 4.5 Hz, 2H), 3.27 (t, J=6.0 Hz, 2H), 3.24 (t, J=5.1 Hz, 2H), 2.83 (ddd, J=17.5, 13.9, 5.3 Hz, 1H), 2.76-2.56 (m, 2H), 2.12-2.04 (m, 1H), 2.01 (dt, J=10.5, 5.2 Hz, 2H).

Example 23

N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9-trioxa-12-azapentadecan-15-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-021)

CPD-021 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 44%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (dd, J=8.5, 7.0 Hz, 1H), 7.46 (dd, J=10.6, 1.9 Hz, 1H), 7.40-7.31 (m, 2H), 7.04 (dt, J=15.9, 8.7 Hz, 3H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 5.04 (dd, J=12.8, 5.5 Hz, 1H), 4.03 (t, J=5.1 Hz, 2H), 3.78-3.74 (m, 2H), 3.70 (t, J=5.2 Hz, 2H), 3.65-3.60 (m, 4H), 3.60 (s, 4H), 3.48 (t, J=5.1 Hz, 2H), 3.26 (t, J=6.0 Hz, 2H), 3.24 (t, J=5.0 Hz. 2H), 2.84 (ddd, J=17.6, 14.0, 5.3 Hz, 1H), 2.73 (ddd, J=17.5, 4.3, 2.6 Hz, 1H), 2.71-2.65 (m, 1H), 2.17-2.05 (m, 1H), 2.04-1.97 (m, 2H).

Example 24

N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxa-15-azaoctadecan-18-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-022)

CPD-022 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 40%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (dd, J=8.6, 7.1 Hz, 1H), 7.47 (dd, J=10.7, 1.9 Hz, 1H), 7.43-7.31 (m, 2H), 7.10-6.98 (m, 3H), 6.64 (td, J=8.7, 4.1 Hz, 1H), 5.04 (dd, J=12.7, 5.6 Hz, 1H), 4.04 (t, J=5.2 Hz, 2H), 3.80-3.74 (m, 2H), 3.71 (t, J=5.2 Hz, 2H), 3.67-3.62 (m, 4H), 3.60 (dt, J=3.8, 2.6 Hz, 2H), 3.59-3.54 (m, 6H), 3.49 (t, J=5.2 Hz, 2H), 3.28 (t, J=6.0 Hz, 2H), 3.25 (t, J=5.0 Hz, 2H), 2.85 (ddd, J=17.6, 14.0, 5.3 Hz, 1H), 2.76-2.72 (m, 1H), 2.69 (td, J=13.3, 4.5 Hz, 1H), 2.09 (ddt, J=13.1, 5.5, 2.8 Hz, 1H), 2.02 (dt, J=10.5, 5.2 Hz, 2H).

Example 25

N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12,15-pentaoxa-18-azahenicosan-21-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-023)

CPD-023 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 38%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (dd, J=8.5, 7.1 Hz, 1H), 7.47 (dd, 10.7, 1.9 Hz, 1H), 7.40 (ddd, J=9.0, 5.3, 1.7 Hz, 1H), 7.37 (ddd, J=8.5, 2.0, 1.0 Hz, 1H), 7.11-6.99 (m, 3H), 6.64 (td, J=8.7, 4.2 Hz, 1H), 5.04 (dd, J=12.8, 5.5 Hz, 1H), 4.05 (t, J=5.2 Hz, 2H), 3.79-3.75 (m, 2H), 3.71 (t, J=5.2 Hz, 2H), 3.65 (s, 4H), 3.64-3.61 (m, 2H), 3.60-3.58 (m, 2H), 3.58-3.56 (m, 4H), 3.54 (dd, J=6.0, 2.7 Hz, 3H), 3.48 (t, J=5.2 Hz, 2H), 3.29 (t, J=6.1 Hz, 2H), 3.26 (t, J=5.1 Hz, 2H), 2.85 (ddd, J=17.6, 14.0, 5.3 Hz, 1H), 2.75 (dd, J=4.4, 2.6 Hz, 1H), 2.74-2.70 (m, 1H), 2.70-2.66 (m, 1H), 2.15-2.07 (m, 1H), 2.06-1.99 (m, 2H).

Example 26

N-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethypamino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-024)

CPD-024 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.05 g, yield: 37%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (dd, J=8.6, 7.1 Hz, 1H), 7.37-7.34 (m, 1H), 7.32 (dd, J=10.7, 1.9 Hz, 1H), 7.29 (dt, J=8.6, 1.2 Hz, 1H), 7.09 (d, J=8.5 Hz, 1H), 7.06-7.00 (m, 2H), 6.58 (td, J=8.7, 4.6 Hz, 1H), 4.95-4.91 (m, 1H), 4.19-4.02 (m, 2H), 3.77 (td, J=5.7, 2.3 Hz, 2H), 3.37 (t, 5.8 Hz, 2H), 3.33 (t, J=5.9 Hz, 2H), 2.79 (ddd, J=17.5, 13.9, 5.4 Hz, 1H), 2.67 (ddd, J=17.5, 4.6, 2.6 Hz, 1H), 2.52 (qd, J=13.1, 4.5 Hz, 1H), 2.11-2.00 (m, 2H) 1.94 (dtd, J=13.1, 5.3, 2.5 Hz, 1H).

Example 27

N-(3-((3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-025)

CPD-025 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.04 g, yield: 33%). ¹H NMR (600 MHz, Methanol-d₄) δ7.50 (dd, J=8.6, 7.1 Hz, 1H), 7.40-7.37 (m, 1H), 7.35 (dd, J=10.8, 1.9 Hz, 1H), 7.27 (dt, J=8.5, 1.3 Hz, 1H), 7.06 (dd, J=9.3, 7.0 Hz, 1H), 7.03 (d, J=2.4 Hz, 1H), 7.02 (d, J=3.9 Hz, 1H), 6.56 (td, J=8.7, 4.3 Hz, 1H), 5.01 (dd, J=12.8, 5.5 Hz, 1H), 4.08 (dd, J=5.7, 4.4 Hz, 2H), 3.49 (t, J=6.5 Hz, 2H), 3.27 (t, J=5.7 Hz, 2H), 3.21 (t, J=7.2 Hz, 2H), 2.84 (ddd, J=17.5, 13.9, 5.3 Hz, 1H), 2.73 (ddd, J=17.4, 4.4, 2.6 Hz, 1H), 2.66 (qd, J=13.1, 4.5 Hz, 1H), 2.13-2.07 (m, 2H), 2.06-1.99 (m, 3H).

Example 28

N-(3-((4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-026)

CPD-026 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.04 g, yield: 33%). ¹H NMR (600 MHz, Methanol-d₄) δ7.52 (dd, J=8.6, 7.1 Hz, 1H), 7.40 (dd, J=10.7, 1.9 Hz, 1H), 7.38-7.35 (m, 1H), 7.27 (dt, J=8.5, 1.3 Hz, 1H), 7.09-7.03 (m, 1H), 7.02 (d, J=7.1 Hz, 1H), 6.99 (d, J=8.5 Hz, 1H), 6.60 (td, J=8.7, 4.6 Hz, 1H), 5.01-4.93 (m, 1H), 4.17-4.01 (m, 2H), 3.35 (td, J=6.6, 1.6 Hz, 2H), 3.25 (t, J=5.8 Hz, 2H), 3.13 (t, J=7.4 Hz, 2H), 2.82 (ddd, J=17.5, 13.9, 5.3 Hz, 1H), 2.72 (ddd, J=17.5, 4.5, 2.6 Hz, 1H), 2.63 (qd, J=13.1, 4.5 Hz, 1H), 2.08-1.97 (m, 3H), 1.89 (p, J=7.3 Hz, 2H), 1.83-1.75 (m, 2H).

Example 29

N-(3-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)pentyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-027)

CPD-027 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 33%). ¹H NMR (600 MHz, Methanol-d₄) δ7.51 (dd, J=8.6, 7.1 Hz, 1H), 7.42 (dd, J=10.7, 1.9 Hz, 1H), 7.40-7.37 (m, 1H), 7.31 (dt, J=8.4, 1.3 Hz, 1H), 7.07-7.00 (m, 2H), 6.98 (d, J=8.6 Hz, 1H), 6.60 (td, J=8.8, 4.6 Hz, 1H), 5.00 (dd, J=12.7, 5.5 Hz, 1H), 4.08 (t, J=5.3 Hz, 2H), 3.32-3.28 (m, 2H), 3.25 (t, J=5.7 Hz, 2H), 3.09 (t, J=7.6 Hz, 2H), 2.84 (ddd, J=17.4, 13.8, 5.3 Hz, 1H), 2.78-2.71 (m, 1H), 2.70-2.62 (m, 1H), 2.09-1.95 (m, 3H), 1.82 (p, J=7.8 Hz, 2H), 1.71 (p, J=7.0 Hz, 2H), 1.56 (tt, J=10.0, 6.3 Hz, 2H).

Example 30

N-(3-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-028)

CPD-028 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 30%). ¹H NMR (600 MHz, Methanol-d₄) δ7.52 (dd, J=8.6, 7.0 Hz, 1H), 7.43 (dd, J=10.6, 1.9 Hz, 1H), 7.39 (ddd, J=8.9, 5.3, 1.7 Hz, 1H), 7.34 (dt, J=8.4, 1.3 Hz, 1H), 7.05 (dd, J=9.3, 7.1 Hz, 1H), 7.03 (d, J=7.0 Hz, 1H), 7.00 (d, J=8.5 Hz, 1H), 6.61 (td, J=8.7, 4.4 Hz, 5.03 (dd, J=12.7, 5.4 Hz, 1H), 4.08 (t, J=5.1 Hz, 2H), 3.30-3.28 (m, 2H), 3.24 (t, J=5.8 Hz, 2H), 3.10-3.02 (m, 2H), 2.88-2.80 (m, 1H), 2.73 (ddd, J=16.2, 4.0, 2.1 Hz, 1H), 2.67 (td, J=13.3, 4.4 Hz, 1H), 2.10-2.05 (m, 1H) 2.05-2.00 (m, 2H), 1.76 (q, J=7.4 Hz, 2H), 1.64 (q, J=6.9 Hz, 2H), 1.47 (t, J=3.7 Hz, 4H).

Example 31

N-(3-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-029)

CPD-029 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 30%). ¹H NMR (600 MHz, Methanol-d₄) δ7.52 (dd, J=8.6, 7.0 Hz, 1H), 7.44 (dd, J=10.7, 1.9 Hz, 1H), 7.39 (ddd, J=8.7, 5.3, 1.7 Hz, 1H), 7.35 (dt, J=8.6, 1.4 Hz, 1H), 7.07-7.01 (m, 2H), 7.00 (d, J=8.5 Hz, 1H), 6.62 (td, J=8.7, 4.41 Hz, 1H), 5.03 (dd, J=12.8, 5.4 Hz, 1H), 4.20-3.95 (m, 2H), 3.29 (t, J=7.1 Hz, 2H), 3.23 (t, J=5.8 Hz, 2H), 3.07-3.02 (m, 2H), 2.85 (ddd, J=17.5, 14.0, 5.4 Hz, 1H), 2.76-2.71 (m, 1H), 2.71-2.66 (m, 1H), 2.12-2.06 (m, 1H), 2.03 (td, J=6.0, 4.4 Hz, 2H), 1.74 (p, J=7.6 Hz, 2H), 1.65 (p, J=6.9 Hz, 2H), 1.51-1.35 (m, 6H).

Example 32

N-(3-((8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-030)

CPD-030 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 38%). ¹H NMR (600 MHz, Methanol-d₄) δ7.53 (dd, J=8.6, 7.1 Hz, 1H), 7.45 (dd, J=10.6, 1.9 Hz, 1H), 7.40 (dd, J=8.6, 5.5 Hz, 1H), 7.36 (dt, J=8.4, 1.3 Hz, 1H), 7.05 (dd, J=9.2, 7.1 Hz, 1H), 7.03 (d, J=7.1 Hz, 1H), 7.01 (d, J=8.5 Hz, 1H), 6.63 (td, J=8.7, 4.4 Hz, 1H), 5.04 (dd, J=12.8, 5.5 Hz, 1H), 4.08 (dd, J=5.8, 4.5 Hz, 2H), 3.30-3.28 (m, 2H), 3.23 (t, J=5.8 Hz, 2H), 3.08-3.00 (m, 2H), 2.85 (ddd, J=17.5, 13.9, 5.3 Hz, 1H), 2.78-2.60 (m, 2H), 2.09 (dtd, J=10.2, 5.7, 2.5 Hz, 1H), 2.05-1.99 (m, 2H), 1.72 (p, J=7.6 Hz, 2H), 1.64 (p, J=7.0 Hz, 2H), 1.41 (d, J=5.4 Hz, 4H), 1.38-1.33 (m, 4H).

Example 33

(2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-031)

CPD-031 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 38%). ¹H NMR (800 MHz, Methanol-d₄) δ8.97 (s, 1H), 7.43 (dq, J=17.7, 10.2 Hz, 6H), 7.37 (d, J=8.6 Hz, 1H), 7.06 (q, J=8.5 Hz, 1H), 6.64 (td, J=8.8, 4.0 Hz, 1H), 5.00 (q, J=6.9 Hz, 1H), 4.62 (s, 1H), 4.57 (t, J=8.3 Hz, 1H), 4.43 (d, J=5.2 Hz, 1H), 4.08 (t, J=5.2 Hz, 2H), 3.88 (d, J=11.1 Hz, 1H), 3.75 (dd, J=11.1, 3.9 Hz, 1H), 3.23 (q, J=9.5, 7.7 Hz, 2H), 3.04 (q, J=7.1, 6.3 Hz, 2H), 2.49 (s, 3H), 2.29 (dt, J=15.0, 7.7 Hz, 1H), 2.22 (ddd, J=27.3, 13.7, 8.1 Hz, 2H), 2.03 (p, J=5.5 Hz, 2H), 1.95 (ddd, J=13.3, 9.1, 4.5 Hz, 1H), 1.72 (p, J=7.9 Hz, 2H), 1.63-1.55 (m, 2H), 1.51 (d, J=7.0 Hz, 3H), 1.38 (q, J=7.6 Hz, 2H), 1.33-1.25 (m, 10H), 1.04 (s, 9H).

Example 34

(2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,19-dioxo-3-oxa-2,7,20-triazadocosan-22-oyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (CPD-032)

CPD-032 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 34%). ¹H NMR (600 MHz, Methanol-d₄) δ9.05 (s, 1H), 7.50-7.47 (m, 2H), 7.44 (td, J=6.9, 6.2, 1.8 Hz, 3H), 7.41-7.39 (m, 1H), 7.39-7.36 (m, 1H), 7.10-7.03 (m, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 4.63 (s, 1H), 4.59-4.52 (m, 2H), 4.50 (dtt, J=3.8, 2.6, 1.3 Hz, 1H), 4.36 (d, J=15.7 Hz, 1H), 4.08 (t, J=5.1 Hz, 2H), 3.90 (d, J=11.3 Hz, 1H), 3.81 (dd, J=10.9, 4.0 Hz, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.07-3.01 (m, 2H), 2.49 (s, 3H), 2.30 (dt, J=14.0, 7.9 Hz, 1H), 2.26-2.19 (m, 2H), 2.08 (ddd, J=13.3, 9.1, 4.5 Hz, 1H), 2.03 (dd, J=6.3, 4.4 Hz, 2H), 1.72 (p, J=7.7 Hz, 2H), 1.64-1.54 (m, 2H), 1.38 (q, J=7.4 Hz, 2H), 1.29 (d, J=18.3 Hz, 12H), 1.03 (s, 9H).

Example 35

(2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,19-dioxo-3-oxa-2,7,20-triazadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-033)

CPD-033 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 34%). ¹H NMR (600 MHz, Methanol-d₄) δ9.12 (d, J=1.7 Hz, 1H), 7.49-7.42 (m, 5H), 7.39 (dd, J=16.6, 8.0 Hz. 2H), 7.07 (q, J=8.5, 8.0 Hz, 1H), 6.70-6.57 (m, 1H), 4.64-4.60 (m, 1H), 4.59-4.54 (m, 1H), 4.45-4.41 (m, 1H), 4.15-4.03 (m, 2H), 3.88 (d, J=10.9 Hz, 1H), 3.79-3.72 (m, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.04 (t, J=7.8 Hz, 2H), 2.55-2.46 (m, 3H), 2.30 (dt, J=15.6, 8.0 Hz, 1H), 2.26-2.17 (m, 2H), 2.06-2.00 (m, 3H), 1.98-1.90 (m, 1H), 1.75-1.68 (m, 2H), 1.65-1.54 (m, 2H), 1.51 (dd, J=7.1, 1.7 Hz, 3H), 1.42-1.36 (m, 2H), 1.35-1.24 (m, 12H), 1.04 (s, 9H).

Example 36

(2R,4S)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-034)

CPD-034 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 34%). ¹H NMR (800 MHz, Methanol-d₄) δ8.98 (s, 1H), 7.52 (d, J=7.9 Hz, 2H), 7.46-7.42 (m, 3H), 7.41 (dd, J=8.8, 5.1 Hz, 1H), 7.35 (d, J=8.6 Hz, 1H), 7.05 (q, J=8.6 Hz, 1H), 6.62 (td, J=8.7, 4.1 Hz, 1H), 5.02 (q, J=7.9, 7.1 Hz, 1H), 4.55 (t, J=7.4 Hz, 1H), 4.49 (s, 1H), 4.45 (p, J=4.5 Hz, 1H), 4.08 (t, J=5.1 Hz, 2H), 3.94 (dd, J=10.8, 4.9 Hz, 1H), 3.69 (dd, J=10.9, 3.5 Hz, 1H), 3.23 (t, J=5.8 Hz, 2H), 3.02 (t, J=7.8 Hz, 2H), 2.49 (s, 3H), 2.28 (dt, J=15.1, 7.9 Hz, 1H), 2.23-2.16 (m, 2H), 2.10 (dt, J=12.5, 5.8 Hz, 1H), 2.02 (dd, J=11.0, 5.6 Hz, 2H), 1.70 (p, J=7.8 Hz, 2H), 1.59-1.51 (m, 2H), 1.45 (d, J=7.0 Hz, 3H), 1.36 (p, J=7.5 Hz, 2H), 1.30-1.26 (m, 4H), 1.25-1.21 (m, 6H), 1.05 (s, 9H).

Example 37

(2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,18-dioxo-3-oxa-2,8,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-035)

CPD-035 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 34%). ¹H NMR (600 MHz, Methanol-d₄) δ9.03 (s, 1H), 7.52-7.42 (m, 5H), 7.41-7.33 (m, 2H), 7.06 (q, J=8.7 Hz, 1H), 6.61 (td, J=8.8, 4.3 Hz, 1H), 5.00 (q, J=6.8 Hz, 1H), 4.63 (s, 1H), 4.57 (t, J=8.3 Hz, 1H), 4.43 (s, 1H), 3.93 (t, J=5.5 Hz, 2H), 3.87 (d, J=11.0 Hz, 1H), 3.75 (dd, J=11.0, 3.9 Hz, 1H), 3.10 (t, J=7.4 Hz, 2H), 3.05-2.95 (m, 2H), 2.50 (s, 3H), 2.30 (dt, J=15.0, 7.7 Hz, 1H), 2.25 (dd, J=8.1, 6.3 Hz, 1H), 2.22-2.17 (m, 1H), 1.95 (ddd, J=13.3, 9.0, 4.6 Hz, 1H), 1.88 (p, J=7.0 Hz, 2H), 1.76 (q, J=6.1 Hz, 2H), 1.68 (p, J=7.6 Hz, 2H), 1.63-1.55 (m, 2H), 1.51 (d, J=7.0 Hz, 3H), 1.42-1.28 (m, 10H), 1.04 (s, 9H).

Example 38

(2S,4R)-1-((S)-19-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,17-dioxo-3-oxa-2,7,18-triazaicosan-20-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-036)

CPD-036 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 32%). ¹H NMR (600 MHz, Methanol-d₄) δ9.03 (s, 1H), 7.48-7.44 (m, 3H), 7.43 (d, J=8.2 Hz, 2H), 7.40-7.36 (m, 2H), 7.07 (td, J=9.2, 6.9 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 5.03-4.98 (m, 1H), 4.62 (s, 1H), 4.59-4.53 (m, 1H), 4.43 (td, J=4.2, 2.0 Hz, 1H), 4.14-4.04 (m, 2H), 3.87 (d, J=11.0 Hz, 1H), 3.75 (dd, J=11.0, 4.0 Hz, 1H), 3.24 (t, J=5.9 Hz, 2H), 3.12-2.98 (m, 2H), 2.49 (s, 3H), 2.33-2.27 (m, 1H), 2.24 (dd, J=8.2, 6.3 Hz, 1H), 2.22-2.17 (m, 1H), 2.03 (dt, J=10.3, 5.0 Hz, 2H), 1.95 (ddd, J=13.3, 9.0, 4.5 Hz, 1H), 1.72 (p, J=7.8 Hz, 2H), 1.65-1.55 (m, 2H), 1.51 (d, J=7.0 Hz, 3H), 1.42-1.37 (m, 2H), 1.35-1.26 (m, 8H), 1.03 (s, 9H).

Example 39

(2S,4R)-1-((S)-22-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,20-dioxo-3-oxa-2,8,21-triazatricosan-23-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-038)

CPD-038 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 35%). ¹H NMR (600 MHz, Methanol-d₄) δ9.00 (s, 1H), 7.47-7.41 (m, 5H), 7.39 (td, J=6.4, 3.0 Hz, 1H), 7.37-7.34 (m, 1H), 7.05 (td, J=9.1, 6.9 Hz, 1H), 6.61 (td, J=8.7, 4.3 Hz, 1H), 5.00 (q, J=7.0 Hz, 1H), 4.62 (s, 1H), 4.57 (dd, J=9.1, 7.5 Hz, 1H), 4.44 (dp, J=4.3, 2.0 Hz, 1H), 3.93 (t, J=5.6 Hz, 2H), 3.88 (dt, J=11.3, 1.8 Hz, 1H), 3.75 (dd, J=11.0, 4.0 Hz, 1H), 3.10 (t, J=7.3 Hz, 2H), 3.02-2.95 (m, 2H), 2.49 (s, 3H), 2.33-2.27 (m, 1H), 2.26-2.23 (m, 1H), 2.23-2.17 (m, 1H), 1.96 (ddd, J=13.3, 9.0, 4.5 Hz, 1H), 1.88 (p, J=7.1 Hz, 2 H), 1.75 (h, J=5.5, 5.0 Hz, 2H), 1.68 (p, J=7.9 Hz, 2H), 1.63-1.56 (m, 2H), 1.51 (d, J=7.0 Hz, 3H), 1.41-1.25 (m, 14H), 1.04 (s, 9H).

Example 40

(2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,19-dioxo-3-oxa-2,8,20-triazadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-039)

CPD-039 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 34%). ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.50-7.41 (m, 5H), 7.37 (dd, J=8.5, 6.6 Hz, 2H), 7.06 (q, J=8.8 Hz, 1H), 6.62 (td, J=8.7, 4.2 Hz, 1H), 5.02-4.98 (m, 1H), 4.65-4.61 (m, 1H), 4.58-4.55 (m, 1H), 4.45-4.42 (m, 1H), 3.93 (t, J=5.6 Hz, 2H), 3.87 (d, J=11.1 Hz, 1H), 3.75 (dd, J=11.0, 4.0 Hz, 1H), 3.10 (t, J=7.3 Hz, 2H), 3.04-2.95 (m, 2H), 2.48 (s, 3H), 2.30 (dt, J=15.0, 7.6 Hz, 1H), 2.26-2.23 (m, 1H), 2.22-2.17 (m, 1H), 1.95 (ddd, J=13.4, 9.1, 4.6 Hz, 1H), 1.88 (t, J=7.1 Hz, 2H), 1.76 (q, J=6.1 Hz, 2H), 1.68 (p, J=7.6 Hz, 2H), 1.63-1.56 (m, 2H), 1.51 (d, J=7.0 Hz, 3H), 1.39-1.35 (m, 2H), 1.34-1.27 (m, 10H), 1.04 (s, 9H).

Example 41

N-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-040).

CPD-040 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.50 (d, J=8.3 Hz, 1H), 7.37-7.33 (m, 2H), 7.32-7.29 (m, 1H), 7.06 (q, J=8.8 Hz, 1H), 6.98 (d, J=2.2 Hz, 1H), 6.86 (dd, J=8.4, 2.3 Hz, 1H), 6.57 (td, J=8.7, 4.1 Hz, 1H), 5.06-4.98 (m, 1H), 4.05 (t, J=5.1 Hz, 2H), 3.67 (t, J=6.2 Hz, 2H), 3.35-3.32 (m, 3H), 2.84 (ddd, J=17.3, 13.8, 5.4 Hz, 1H), 2.73 (ddd, J=17.5, 4.5, 2.6 Hz, 1H), 2.66 (qd, J=13.1, 4.4 Hz, 1H), 2.05 (q, J=5.5, 5.0 Hz, 4H).

Example 42

N-(3-((3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)propyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-041)

CPD-041 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.50 (d, J=8.3 Hz, 1H), 7.36 (dd, J=10.7, 1.9 Hz, 1H), 7.31 (d, J=6.6 Hz, 1H), 7.30 (dt, J=8.5, 1.2 Hz, 1H), 7.04 (td, J=9.2, 7.0 Hz, 1H), 6.94 (d, J=2.2 Hz, 1H), 6.81 (dd, J=8.4, 2.2 Hz, 1H), 6.58 (td, J=8.7, 4.2 Hz, 1H), 5.02 (dd, J=12.8, 5.5 Hz, 1H), 4.13-4.02 (m, 2H), 3.36 (t, J=6.9 Hz, 2H), 3.27 (t, J=5.7 Hz, 2H), 3.22 (t, J=7.3 Hz, 2H), 2.85 (ddd, J=17.4, 13.9, 5.4 Hz, 1H), 2.73 (ddd, J=17.4, 4.5, 2.6 Hz, 1H), 2.66 (qd, J=13.1, 4.5 Hz, 1H), 2.13-2.07 (m, 2H), 2.07-2.02 (m, 3H).

Example 43

N-(3-((4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)butyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-042)

CPD-042 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Acetone-d₆) δ9.88 (s, 1H), 9.34 (s, 1H), 8.80 (s, 1H), 7.65-7.57 (m, 1H), 7.54 (d, J=8.4 Hz, 1H), 7.47 (dd, J=10.7, 2.0 Hz, 1H), 7.40 (dd, J=8.5, 1.9 Hz, 1H), 7.08 (td, J=9.3, 7.1 Hz, 1H), 6.98 (d, J=2.1 Hz, 1H), 6.90 (dd, J=8.4, 2.2 Hz, 1H), 6.76 (td, J=8.8, 5.2 Hz, 1H), 5.04 (dd, J=12.6, 5.4 Hz, 1H), 4.19 (t, J=5.2 Hz, 2H), 3.40 (s, 3H), 3.32 (t, J=6.8 Hz, 3H), 3.00-2.90 (m, 1H), 2.85-2.67 (m, 2H), 2.20-2.11 (m, 3H), 2.04-1.98 (m, 2H), 1.84 (p, J=7.0 Hz, 2H).

Example 44

N-(3-((5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)pentyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-043)

CPD-043 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 35%). ¹H NMR (600 MHz, Methanol-d₄) δ7.53 (d, J=8.4 Hz, 1H), 7.41 (dd, J=10.7, 1.9 Hz, IFI), 7.39-7.36 (m, 1H), 7.35-7.31 (m, 1H), 7.05 (q, J=8.7 Hz, 1H), 6.93 (d, J=2.1 Hz, 1H), 6.81 (dd, J=8.4, 2.2 Hz, 1H), 6.61 (td, J=8.7, 4.2 Hz, 1H), 5.03 (dd, J=12.6, 5.4 Hz, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.24 (t, J=5.8 Hz, 2H), 3.20 (t, J=7.0 Hz, 2H), 3.10-3.03 (m, 2H), 2.91-2.81 (m, 1H), 2.78-2.71 (m, 1H), 2.68 (td, J=13.3, 4.4 Hz, 1H), 2.12-2.06 (m, 1H), 2.05-1.99 (m, 2H), 1.81 (p, J=7.9 Hz, 2H), 1.70 (p, J=7.1 Hz, 2H), 1.54 (p, J=7.7, 7.3 Hz, 2H).

Example 45

N-(3-((6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)hexyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-044)

CPD-044 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.53 (d, J=8.4 Hz, 1H), 7.43 (dd, J=10.6, 1.9 Hz, 1H), 7.39 (t, J=7.1 Hz, 1H), 7.35 (dd, J=8.5, 1.5 Hz, 1H), 7.05 (q, J=8.7 Hz, 1H), 6.94 (d, J=2.3 Hz, 1H), 6.81 (dd, J=8.4, 2.2 Hz, 1H), 6.62 (td, J=8.7, 4.3 Hz, 1H), 5.08-4.99 (m, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.24 (t, J=5.8 Hz, 2H), 3.19 (t, 7.1 Hz, 2H), 3.09-3.02 (m, 2H), 2.86 (ddd, J=22.7, 12.4, 5.4 Hz, 1H), 2.78-2.71 (m, 1H), 2.68 (td, J=13.3, 4.5 Hz, 1H), 2.13-2.05 (m, 1H), 2.06-1.99 (m, 2H), 1.80-1.73 (m, 2H), 1.65 (t, J=7.0 Hz, 2H), 1.55-1.42 (m, 4H).

Example 46

N-(3-((7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)heptyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-045)

CPD-045 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 32%). ¹H NMR (600 MHz, Methanol-d₄) δ7.53 (d, J=8.3 Hz, 1H), 7.43 (dd, J=10.6, 1.9 Hz, 1H), 7.41-7.38 (m, 1H), 7.35 (dt, J=8.4, 1.3 Hz, 1H), 7.05 (td, J=9.2, 7.0 Hz, 6.93 (d, J=2.2 Hz, 1H), 6.80 (dd, J=8.4, 2.1 Hz, 1H), 6.62 (td, J=8.7, 4.3 Hz, 1H), 5.03 (dd, J=12.8, 5.5 Hz, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.23 (t, J=5.8 Hz, 2H), 3.18 (t, J=7.1 Hz, 2H), 3.08-3.02 (m, 2H), 2.85 (ddd, J=17.7, 14.0, 5.3 Hz, 1H), 2.77-2.71 (m, 1H), 2.68 (td, J=13.3, 4.4 Hz, 1H), 2.08 (dtd, J=14.9, 5.2, 4.3, 2.5 Hz, 1H), 2.03 (dt, J=6.5, 3.1 Hz, 2H), 1.74 (q, J=7.7 Hz, 2H), 1.64 (q, J=7.1 Hz, 2H), 1.47-1.35 (m, 6H).

Example 47

N-(3-((8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)octyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-046)

CPD-046 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (d, J=8.4 Hz, 1H), 7.45 (dd, J=10.6, 1.9 Hz, 1H), 7.40 (d, J=7.4 Hz, 1H), 7.36 (d, J=8.7 Hz, 1H), 7.09-7.02 (m, 1H), 6.94 (d, J=2.2 Hz, 1H), 6.81 (dd, J=8.4, 2.2 Hz, 1H), 6.63 (q, J=4.5 Hz, 1H), 5.03 (dd, J=12.7, 5.6 Hz, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.23 (t, J=5.8 Hz, 2H), 3.19 (t, J=7.1 Hz, 1H), 3.04 (t, J=7.9 Hz, 2H), 2.90-2.81 (m, 1H), 2.78-2.71 (m, 1H), 2.72-2.65 (m, 1H), 2.12-2.06 (m, 1H), 2.06-2.00 (m, 2H), 1.73 (d, J=7.9 Hz, 2H), 1.68-1.61 (m, 2H), 1.46-1.40 (m, 4H), 1.39-1.33 (m, 4H).

Example 48

N-(3-((2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-047)

CPD-047 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.50-7.40 (m, 2H), 7.33 (dd, J=8.5, 1.6 Hz, 1H), 7.29 (t, J=7.2 Hz, 1H), 7.00 (q, J=8.6 Hz, 1H), 6.86 (d, J=2.2 Hz, 1H), 6.74 (dd, J=8.4, 2.2 Hz, 1H), 6.59 (td, J=8.7, 4.4 Hz, 1H), 5.03 (dd, J=12.7, 5.5 Hz, 1H), 4.06 (t, J=5.0 Hz, 2H), 3.87-3.77 (m, 2H), 3.70 (t, J=5.3 Hz, 2H), 3.33 (t, J=5.4 Hz, 2H), 3.32-3.30 (m, 4H), 2.85 (ddd, J=17.2, 13.8, 5.3 Hz, 1H), 2.77-2.72 (m, 1H), 2.68 (qd, J=13.1, 4.4 Hz, 1H), 2.11-2.07 (m, 1H), 2.05 (t, J=5.8 Hz, 2H).

Example 49

N-(3-((2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)ethoxy)ethoxy)ethyl)amino)propoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-048)

CPD-048 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.54 (d, J=8.4 Hz, 1H), 7.46 (dd, J=10.7, 1.9 Hz, 1H), 7.37 (t, J=8.8 Hz, 2H), 7.09-7.02 (m, 1H), 7.01 (d, J=2.2 Hz, 1H), 6.84 (dd, J=8.4, 2.2 Hz, 1H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 5.09-5.00 (m, 1H), 4.04 (t, J=5.2 Hz, 2H), 3.77 (t, J=5.0 Hz, 2H), 3.69-3.56 (m, 6H), 3.38 (t, J=5.4 Hz, 2H), 3.27 (t, J=6.0 Hz, 2H), 3.23 (t, J=5.0 Hz, 2H), 2.85 (ddd, J=18.6, 14.0, 5.4 Hz, 1H), 2.77-2.71 (m, 1H), 2.69 (dd, J=13.4, 4.3 Hz, 1H), 2.12-2.07 (m, 1H), 2.02 (dd, J=11.5, 5.9 Hz, 2H).

Example 50

N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9-trioxa-12-azapentadecan-15-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-049)

CPD-049 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.55 (d, J=8.4 Hz, 1H), 7.46 (dd, 10.7, 2.0 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 7.35 (dd, J=8.5, 1.6 Hz, 1H), 7.07-7.02 (m, 1H), 7.01 (d, J=2.1 Hz, 1H), 6.86 (dd, J=8.3, 2.2 Hz, 1H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 5.03 (dd, J=12.7, 5.5 Hz, 1H), 4.04 (t, J=5.2 Hz, 2H), 3.81-3.73 (m, 2H), 3.68 (t, J=5.3 Hz, 2H), 3.62 (qd, J=3.4, 1.6 Hz, 4H), 3.59 (s, 3.40 (t, J=5.3 Hz, 2H), 3.25 (dt, J=10.1, 5.5 Hz, 4H), 2.84 (ddd, J=17.1, 13.8, 5.3 Hz, 1H), 2.78-2.71 (m, 1H), 2.67 (td, J=13.2, 4.3 Hz, 1H), 2.12-2.04 (m, 1H), 2.04-1.99 (m, 2H).

Example 51

N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxa-15-azaoctadecan-18-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-050)

CPD-050 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ7.55 (d, J=8.3 Hz, 1H), 7.46 (dd, J=10.6, 1.9 Hz, 1H), 7.39 (d, J=8.2 Hz, 1H), 7.36 (dt, J=8.5, 1.3 Hz, 1H), 7.09-7.02 (m, 1H), 7.02 (d, J=2.1 Hz, 1H), 6.86 (dd, J=8.4, 2.2 Hz, 1H), 6.64 (td, J=8.7, 4.1 Hz, 1H), 5.03 (dd, J=12.8, 5.4 Hz, 1H), 4.04 (t, J=5.2 Hz, 2H), 3.81-3.73 (m, 2H), 3.69 (t, J=5.3 Hz, 2H), 3.66-3.62 (m, 4H), 3.61-3.59 (m, 2H), 3.58-3.55 (m, 6H), 3.40 (t, J=5.3 Hz, 2H), 3.26 (t, J=6.1 Hz, 2H), 3.24 (t, J=5.1 Hz, 2H), 2.84 (ddd, J=17.7, 14.0, 5.4 Hz, 1H), 2.76-2.70 (m, 1H), 2.70-2.64 (m, 1H), 2.11-2.05 (m, 1H), 2.02 (dt, J=10.5, 5.2 Hz, 2H).

Example 52

N-((1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxa-18-azahenicosan-21-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide (CPD-051)

CPD-051 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 36%). ¹H NMR (600 MHz, Methanol-d₄) δ7.44 (d, J=8.4 Hz, 1H), 7.35 (dd, J=10.6, 2.0 Hz, 1H), 7.30 (ddd, J=9.0, 5.3, 1.7 Hz, 1H), 7.27-7.24 (m, 1H), 6.94 (td, J=9.2, 6.9 Hz, 1H), 6.90 (d, J=2.2 Hz, 1H), 6.75 (dd, J=8.4, 2.2 Hz, 1H), 6.53 (td, J=8.7, 4.2 Hz, 1H), 4.92 (dd, J=12.7, 5.5 Hz, 1H), 3.95 (t, J=5.2 Hz, 2H), 3.72-3.62 (m, 2H), 3.58 (t, J=5.3 Hz, 2H), 3.53 (s, 4H), 3.52-3.50 (m, 2H), 3.50-3.48 (m, 2H), 3.47 (td, J=4.7, 4.0, 1.6 Hz, 3H), 3.44 (dt, J=4.9, 2.1 Hz, 4H), 3.28 (t, J=5.3 Hz, 2H), 3.21 (p, J=1.7 Hz, 1H), 3.18 (t, J=6.1 Hz, 2H), 3.15 (t, J=5.0 Hz, 2H), 2.74 (ddd, J=17.1, 13.7, 5.2 Hz, 1H), 2.67-2.61 (m, 1H), 2.57 (td, J=13.3, 4.4 Hz, 1H), 1.98 (dtd, J=10.5, 5.6, 4.8, 2.9 Hz, 1H), 1.93 (dt, J=10.7, 5.2 Hz, 2H).

Example 53

(2R,4S)-1-((S)-22-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,20-dioxo-3-oxa-2,8,21-triazatricosan-23-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-052)

CPD-052 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 46%). ¹H NMR (600 MHz, Methanol-d₄) δ9.01 (s, 1H), 7.52 (d, J=8.0 Hz, 2H), 7.47-7.42 (m, 3H), 7.40-7.37 (m, 1H), 7.35 (dd, J=8.6, 1.7 Hz, 1H), 7.13-6.98 (m, 1H), 6.61 (td, J=8.7, 4.3 Hz, 1H), 5.02 (q, J=7.0 Hz, 1H), 4.55 (dd, J=8.2, 6.5 Hz, 1H), 4.49 (s, 1H), 4.45 (q, J=4.6 Hz, 1H), 3.93 (q, J=5.2 Hz, 3H), 3.69 (dd, J=10.8, 3.5 Hz, 1H), 3.10 (t, J=7.3 Hz, 2H), 3.02-2.93 (m, 2H), 2.50 (s, 3H), 2.33-2.25 (m, 1H), 2.19 (dt, J=14.4, 7.9 Hz, 2H), 2.10 (dt, J=12.6, 5.8 Hz, 1H), 1.88 (p, J=7.2 Hz, 2H), 1.75 (p, J=6.5 Hz, 2H), 1.66 (p, J=7.7 Hz, 2H), 1.55 (dt, J=22.0, 7.1 Hz, 2H), 1.45 (d, J=7.1 Hz, 3H), 1.38-1.31 (m, 2H), 1.31-1.21 (m, 12H), 1.06 (s, 9H).

Example 54

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-13-(4-(4-methylthiazol-5-yl)phenyl)-1,11-dioxo-3-oxa-2,7,10-triazatridecan-13-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-054)

CPD-054 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 46%). ¹H NMR (600 MHz, Methanol-d₄) δ8.95 (s, 1H), 7.44-7.41 (m, 3H), 7.39-7.33 (m, 4H), 7.02 (td, J=9.2, 7.0 Hz, 1H), 6.63 (td, J=8.7, 3.5 Hz, 1H), 5.31 (dd, J=7.9, 6.6 Hz, 1H), 4.72 (dd, J=9.3, 1.2 Hz, 1H), 4.55 (dd, J=9.4, 7.6 Hz, 1H), 4.44 (tt, J=3.7, 1.6 Hz, 1H), 4.06-3.98 (m, 2H), 3.84 (dt, J=11.3, 1.7 Hz, 1H), 3.76 (dd, J=11.1, 3.8 Hz, 1H), 3.55-3.49 (m, 2H), 3.25 (t, J=5.8 Hz, 2H), 3.17 (q, J=5.5 Hz, 2H), 2.80 (dd, J=14.7, 8.0 Hz, 1H), 2.71 (dd, J=14.7, 6.7 Hz, 1H), 2.47 (s, 3H), 2.19 (ddt, J=13.2, 7.0, 1.9 Hz, 1H), 2.01 (qt, J=5.6, 2.9 Hz, 2H), 1.93 (ddd, J=13.4, 9.5, 4.4 Hz, 1H), 1.40-1.26 (m, 4H), 1.04 (s, 9H).

Example 55

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-14-(4-(4-methylthiazol-5-yl)phenyl)-1,12-dioxo-3-oxa-2,7,11-triazatetradecan-14-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-055)

CPD-055 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g. yield: 46%). ¹H NMR (600 MHz, Methanol-d₄) δ8.92 (s, 1H), 7.53-7.42 (m, 5H), 7.40-7.37 (m, 1H), 7.35 (dt, J=8.6, 1.4 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.61 (td, J=8.8, 3.9 Hz, 1H), 5.34 (t, J=7.4 Hz, 1H), 4.75-4.71 (m, 1H), 4.56 (dd, J=9.3, 7.6 Hz, 1H), 4.44 (tt, J=3.8, 1.6 Hz, 1H), 4.03 (t, J=5.3 Hz, 2H), 3.83 (dt, J=11.5, 1.7 Hz, 1H), 3.75 (dd, J=11.1, 3.8 Hz, 1H), 3.27 (t, J=6.5 Hz, 2H), 3.14 (t, J=6.1 Hz, 2H), 2.92 (dt, J=13.6, 7.1 Hz, 1H), 2.87 (ddt, J=9.5, 6.0, 3.4 Hz, 2H), 2.78 (dd, J=14.6, 7.8 Hz, 1H), 2.47 (s, 3H), 2.20 (ddt, J=13.2, 7.7, 2.0 Hz, 1H), 1.99 (tt, J=8.7, 4.4 Hz, 2H), 1.92 (ddd, J=13.4, 9.4, 4.4 Hz, 1H), 1.84 (pd, J=6.8, 3.7 Hz, 2H), 1.41-1.25 (m, 4H), 1.05 (s, 9H).

Example 56

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-15-(4-(4-methylthiazol-5-yl)phenyl)-1,13-dioxo-3-oxa-2,7,12-triazapentadecan-15-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-056)

CPD-056 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 36%). ¹H NMR (600 MHz, Methanol-d₄) δ8.97 (s, 1H), 7.46 (dd, J=10.5, 1.8 Hz, 5H), 7.40-7.37 (m, 1H), 7.37-7.34 (m, 1H), 7.05 (td, J=9.1, 7.0 Hz, 1H), 6.61 (td, J=8.7, 4.1 Hz, 1H), 5.32 (dd, J=7.9, 6.5 Hz, 1H), 4.77-4.69 (m, 1H), 4.58 (dd, J=9.3, 7.6 Hz, 1H), 4.44 (tt, J=3.9, 1.7 Hz, 1H), 4.08-3.99 (m, 2H), 3.83 (dt, J=11.4, 1.7 Hz, 1H), 3.76 (dd, J=11.1, 3.8 Hz, 1H), 3.20 (t, J=6.0 Hz, 2H), 3.15 (td, J=6.9, 5.3 Hz, 2H), 3.06-3.00 (m, 2H), 2.85 (dd, J=14.3, 6.6 Hz, 1H), 2.74 (dd, J=14.2, 8.0 Hz, 1H), 2.47 (s, 3H), 2.20 (ddt, J=13.0, 7.5, 1.8 Hz, 1H), 2.01 (tt, J=7.9, 3.9 Hz, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.70-1.63 (m, 2H), 1.52 (p, J=7.4 Hz, 2H), 1.40-1.26 (m, 4H), 1.05 (s, 9H).

Example 57

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-16-(4-(4-methylthiazol-5-yl)phenyl)-1,14-dioxo-3-oxa-2,7,13-triazahexadecan-16-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-057)

CPD-057 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 46%). ¹H NMR (600 MHz, Methanol-d₄) δ8.86 (d, J=5.6 Hz, 1H), 7.48-7.45 (m, 2H), 7.44 (d, J=4.1 Hz, 2H), 7.43-7.41 (m, 1H), 7.40-7.38 (m, 1H), 7.35 (ddd, J=8.5, 2.0, 1.0 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.60 (td, J=8.7, 4.1 Hz, 1H), 5.32 (dd, J=8.5, 6.0 Hz, 1H), 4.73 (dd, J=9.4, 1.2 Hz, 1H), 4.57 (dd, J=9.3, 7.6 Hz, 1H), 4.44 (dq, J=4.0, 2.1 Hz, 1H), 4.09-3.97 (m, 2H), 3.83 (dt, J=11.4, 1.7 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.18 (t, J=5.8 Hz, 2H), 3.11 (q, J=6.9 Hz, 1H), 3.06 (dd, J=13.5, 6.8 Hz, 1H), 2.99-2.93 (m, 2H), 2.85 (dd, J=14.2, 6.0 Hz, 1H), 2.75 (dd, J=14.2, 8.6 Hz, 1H), 2.45 (s, 3H), 2.19 (ddt, J=13.2, 7.5, 1.9 Hz, 1H), 2.04-1.98 (m, 2H), 1.95 (ddd, J=13.4, 9.4, 4.4 Hz, 1H), 1.73-1.62 (m, 2H), 1.45-1.38 (m, 2H), 1.38-1.24 (m, 6H), 1.05 (s, 9H).

Example 58

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-17-(4-(4-methylthiazol-5-yl)phenyl)-1,15-dioxo-3-oxa-2,7,14-triazaheptadecan-17-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-058)

CPD-058 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 39%). ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (s, 1H), 7.48-7.43 (m, 5H), 7.42-7.38 (m, 1H), 7.36 (ddd, J=8.5, 1.9, 1.0 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.62 (td, J=8.7, 4.1 Hz, 1H), 5.32 (dd, J=8.4, 6.0 Hz, 1H), 4.77-4.71 (m, 1H), 4.57 (dd, J=9.3, 7.7 Hz, 1H), 4.45 (tt, J=4.0, 1.7 Hz, 1H), 4.05 (t, J=5.1 Hz, 2H), 3.83 (dt, J=11.3, 1.7 Hz, 1H), 3.76 (dd, J=11.1, 3.8 Hz, 1H), 3.21 (t, J=5.8 Hz, 2H), 3.11 (dt, J=14.0, 7.1 Hz, 1H), 3.06 (dt, J=13.5, 7.0 Hz, 1H), 3.01-2.96 (m, 2H), 2.85 (dd, J=14.1, 6.1 Hz, 1H), 2.74 (dd, J=14.1, 8.4 Hz, 1H), 2.47 (s, 3H), 2.19 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.02 (dt, J=9.9, 5.0 Hz, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.72-1.63 (m, 2H), 1.42-1.27 (m, 8H), 1.26-1.18 (m, 2H), 1.05 (s, 9H).

Example 59

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-18-(4-(4-methylthiazol-5-yl)phenyl)-1,16-dioxo-3-oxa-2,7,15-triazaoctadecan-18-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-059)

CPD-059 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.02 g, yield: 38%). ¹H NMR (600 MHz, Methanol-d₄) δ8.90 (s, 1H), 7.48-7.42 (m, 5H), 7.42-7.38 (m, 1H), 7.36 (ddd, J=8.5, 1.9, 1.0 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.62 (td, J=8.7, 4.2 Hz, 1H), 5.31 (dd, J=8.6, 5.9 Hz, 1H), 4.74 (dd, J=9.4, 1.3 Hz, 1H), 4.58 (dd, J=9.3, 7.6 Hz, 1H), 4.45 (tt, J=4.0, 1.7 Hz, 1H), 4.13-4.01 (m, 2H), 3.83 (dt, J=11.4, 1.7 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.22 (t, J=5.8 Hz, 2H), 3.10 (dt, J=13.9, 7.1 Hz, 1H), 3.06-3.00 (m, 1H), 2.99-2.94 (m, 2H), 2.87-2.80 (m, 1H), 2.74 (dd, J=14.1, 8.5 Hz, 1H), 2.47 (d, J=2.5 Hz, 3H), 2.19 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.02 (dt, J=10.1, 4.9 Hz, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.69-1.62 (m, 2H), 1.40-1.20 (m, 10H), 1.16 (q, J=8.3 Hz, 2H), 1.06 (s, 9H).

Example 60

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-19-(4-(4-methylthiazol-5-yl)phenyl)-1,17-dioxo-3-oxa-2,7,16-triazanonadecan-19-yl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-060)

CPD-060 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 30%). ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.48-7.43 (m, 5H), 7.42-7.39 (m, 1H), 7.36 (dd, J=8.2, 1.8 Hz, 1H), 7.06 (q, J=8.6 Hz, 1H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 5.31 (dd, J=8.6, 5.8 Hz, 1H), 4.74 (dt, J=8.7, 1.2 Hz, 1H), 4.57 (dd, J=9.1, 7.7 Hz, 1H), 4.44 (s, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.83 (d, J=11.1 Hz, 1H), 3.76 (dd, J=11.1, 3.8 Hz, 1H), 3.23 (t, J=5.8 Hz, 2H), 3.10 (dt, J=13.8, 7.0 Hz, 1H), 3.02 (dt, J=16.7, 7.5 Hz, 3H), 2.84 (dd, J=14.1, 5.8 Hz, 1H), 2.73 (dd, J=14.1, 8.6 Hz, 1H), 2.48 (s, 3H), 2.19 (dd, J=13.1, 7.8 Hz, 1H), 2.08-2.00 (m, 2H), 1.95 (ddd, J=13.4, 9.3, 4.3 Hz, 1H), 1.66 (p, J=7.8 Hz, 2H), 1.38-1.26 (m, 8H), 1.25-1.17 (m, 4H), 1.16-1.11 (m, 2H), 1.06 (s, 9H).

Example 61

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-20-(4-(4-methylthiazol-5-yl)phenyl)-1,18-dioxo-3-oxa-2,7,17-triazaicosan-20-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-061)

CPD-061 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 30%). ¹H NMR (600 MHz, Methanol-d₄) δ8.90 (s, 1H), 7.47-7.42 (m, 5H), 7.41 (td, J=6.0, 2.8 Hz, 1H), 7.36 (ddd, J=8.5, 2.0, 1.0 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.63 (td, J=8.7, 4.3 Hz, 1H), 5.31 (dd, J=8.7, 5.7 Hz, 1H), 4.74 (dd, J=9.3, 1.2 Hz, 1H), 4.58 (dd, J=9.3, 7.5 Hz, 1H), 4.45 (tt, J=4.0, 1.7 Hz, 1H), 4.12-4.03 (m, 2H), 3.83 (dt, J=11.3, 1.7 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.10 (dt, J=13.8, 7.0 Hz, 1H), 3.05-2.97 (m, 3H), 2.84 (dd, J=14.0, 5.8 Hz, 1H), 2.73 (dd, J=14.0, 8.7 Hz, 1H), 2.48 (d, J=1.9 Hz, 3H), 2.20 (ddt, J=13.2, 7.7, 1.9 Hz, 1H), 2.08-2.01 (m, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.73-1.66 (m, 2H), 1.38-1.28 (m, 8H), 1.24-1.15 (m, 6H), 1.13-1.09 (m, 2H), 1.06 (s, 9H).

Example 62

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-21-(4-(4-methylthiazol-5-yl)phenyl)-1,19-dioxo-3-oxa-2,7,18-triazahenicosan-21-yl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-062)

CPD-062 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 30%). ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.48-7.43 (m, 5H), 7.42-7.39 (m, 1H), 7.36 (d, J=8.5 Hz, 1H), 7.06 (q, J=8.6 Hz, 1H), 6.63 (td, J=8.8, 4.3 Hz, 1H), 5.31 (dd, J=8.7, 5.7 Hz, 1H), 4.77-4.71 (m, 1H), 4.57 (dd, J=9.1, 7.7 Hz, 1H), 4.46-4.43 (m, 1H), 4.08 (t, J=5.1 Hz, 2H), 3.83 (d, J=11.2 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.10 (dt, J=13.8, 7.1 Hz, 1H), 3.06-2.98 (m, 3H), 2.84 (dd, J=14.0, 5.8 Hz, 1H), 2.73 (dd, J=14.0, 8.6 Hz, 1H), 2.48 (s, 3H), 2.27-2.13 (m, 1H), 2.10-2.01 (m, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.70 (p, J=7.8 Hz, 2H), 1.44-1.27 (m, 8H), 1.25-1.15 (m, 8H), 1.14-1.09 (m, 2H), 1.06 (s, 9H).

Example 63

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-22-(4-(4-methylthiazol-5-yl)phenyl)-1,20-dioxo-3-oxa-2,7,19-triazadocosan-22-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-063)

CPD-063 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 30%). ¹H NMR (600 MHz, Methanol-d₄) δ8.91 (s, 1H), 7.48-7.42 (m, 5H), 7.42-7.39 (m, 1H), 7.36 (ddd, J=8.4, 1.9, 1.0 Hz, 1H), 7.05 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 5.31 (dd, J=8.6, 5.8 Hz, 1H), 4.74 (dd, J=9.4, 1.3 Hz, 1H), 4.58 (dd, J=9.2, 7.5 Hz, 1H), 4.45 (dt, J=4.1, 2.1 Hz, 1H), 4.13-4.03 (m, 2H), 3.83 (dt, J=11.2, 1.7 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.10 (dt, J=13.7, 7.0 Hz, 1H), 3.06-2.98 (m, 3H), 2.84 (dd, J=14.0, 5.8 Hz, 1H), 2.74 (dd, J=14.0, 8.6 Hz, 1H), 2.48 (d, J=1.8 Hz, 3H), 2.20 (ddt, J=13.2, 7.7, 2.0 Hz, 1H), 2.06-2.01 (m, 2H), 1.96 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.74-1.68 (m, 2H), 1.43-1.23 (m, 10H), 1.21-1.14 (m, 8H), 1.11 (q, J=7.3, 6.3 Hz, 2H), 1.06 (s, 9H).

Example 64

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-16-(4-(4-methylthiazol-5-yl)phenyl)-1,14-dioxo-3,10-dioxa-2,7,13-triazahexadecan-16-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-064)

CPD-064 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 31%). ¹H NMR (600 MHz, Methanol-d₄) δ9.14 (s, 1H), 7.47-7.42 (m, 5H), 7.39 (ddd, J=8.9, 5.4, 1.7 Hz, 1H), 7.33 (ddd, J=8.4, 2.0, 1.0 Hz, 1H), 7.03 (td, J=9.2, 6.9 Hz, 1H), 6.58 (td, J=8.7, 4.1 Hz, 1H), 5.31 (dd, J=7.9, 6.6 Hz, 1H), 4.75-4.70 (m, 1H), 4.59-4.53 (m, 1H), 4.44 (tt, J=3.9, 1.7 Hz, 1H), 4.05 (ddt, J=8.8, 6.1, 2.9 Hz, 2H), 3.83 (d, J=11.4 Hz, 1H), 3.76 (dd, J=11.2, 3.9 Hz, 1H), 3.72 (ddd, J=9.0, 5.8, 4.5 Hz, 2H), 3.46 (t, J=5.8 Hz, 2H), 3.29-3.25 (m, 4H), 3.25-3.21 (m, 2H), 2.84 (dd, J=14.4, 6.6 Hz, 1H), 2.73 (dd, J=14.4, 7.9 Hz, 1H), 2.49 (s, 3H), 2.21 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.05 (dq, J=7.5, 5.5 Hz, 2H), 1.94 (ddd, J=13.5, 9.4, 4.4 Hz, 1H), 1.41-1.25 (m, 4H), 1.05 (s, 9H).

Example 65

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-23-(4-(4-methylthiazol-5-yl)phenyl)-1,21-dioxo-3-oxa-2,7,20-triazatricosan-23-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-065)

CPD-065 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.07 g, yield: 37%). ¹H NMR (600 MHz, Methanol-d₄) δ8.97 (s, 1H), 7.49-7.43 (m, 5H), 7.41 (ddd, J=8.8, 4.4, 1.6 Hz, 1H), 7.37 (ddd, J=8.4, 2.0, 1.0 Hz, 1H), 7.05 (td, J=9.3, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.4 Hz, 1H), 5.31 (dd, J=8.6, 5.8 Hz, 1H), 4.74 (dd, J=9.3, 1.3 Hz, 1H), 4.58 (dd, J=9.2, 7.5 Hz, 1H), 4.45 (tt, J=4.0, 1.7 Hz, 1H), 4.08 (dd, J=5.7, 4.5 Hz, 2H), 3.88-3.81 (m, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.10 (dt, J=13.8, 7.0 Hz, 1H), 3.06-2.98 (m, 3H), 2.84 (dd, J=14.0, 5.8 Hz, 1H), 2.74 (dd, J=14.0, 8.6 Hz, 1H), 2.49 (d, J=1.8 Hz, 3H), 2.20 (ddt, J=13.3, 7.7, 2.0 Hz, 1H), 2.03 (dt, J=10.2, 5.0 Hz, 2H), 1.96 (ddd, J=13.4, 9.4, 4.5 Hz, 1H), 1.72 (ddd, J=13.0, 10.3, 6.9 Hz, 2H), 1.41-1.35 (m, 3H), 1.35-1.26 (m, 7H), 1.26-1.16 (m, 10H), 1.15-1.10 (m, 2H), 1.06 (s, 9H).

Example 66

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-19-(4-(4-methylthiazol-5-yl)phenyl)-1,17-dioxo-3,10,13-trioxa-2,7,16-triazanonadecan-19-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-066)

CPD-066 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 40%). ¹H NMR (600 MHz, Methanol-d₄) δ8.92 (s, 1H), 7.49-7.42 (m, 5H), 7.39 (ddd, J=8.7, 6.0, 1.8 Hz, 1H), 7.36 (ddd, J=8.4, 2.0, 1.0 Hz, 1H), 7.05 (td, J=9.3, 7.0 Hz, 1H), 6.62 (td, J=8.7, 4.1 Hz, 1H), 5.32 (dd, J=8.3, 6.2 Hz, 1H), 4.73 (dd, J=9.3, 1.2 Hz, 1H), 4.57 (dd, J=9.3, 7.6 Hz, 1H), 4.44 (tt, J=4.0, 1.7 Hz, 1H), 4.06 (t, J=5.3 Hz, 2H), 3.83 (dt, J=11.3, 1.7 Hz, 1H), 3.78-3.71 (m, 3H), 3.52 (td, J=3.7, 3.3, 1.8 Hz, 2H), 3.47 (dd, J=5.1, 3.8 Hz, 2H), 3.37 (qt, J=10.0, 5.8 Hz, 2H), 3.27 (dq, J=9.6, 5.0, 4.1 Hz, 5H), 2.85 (dd, J=14.3, 6.2 Hz, 1H), 2.75 (dd, J=14.3, 8.4 Hz, 1H), 2.47 (s, 3H), 2.20 (ddt, J=13.3, 7.7, 2.0 Hz, 1H), 2.04 (dt, J=10.8, 5.3 Hz, 2H), 1.95 (ddd, J=13.4, 9.4, 4.4 Hz, 1H), 1.42-1.24 (m, 5H), 1.05 (s, 9H).

Example 67

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-22-(4-(4-methylthiazol-5-yl)phenyl)-1,20-dioxo-3,10,13,16-tetraoxa-2,7,19-triazadocosan-22-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-067)

CPD-067 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 40%). ¹H NMR (600 MHz, Methanol-d₄) δ9.00 (s, 1H), 7.50-7.42 (m, 5H), 7.42-7.38 (m, 1H), 7.36 (ddd, J=8.5, 1.9, 1.0 Hz, 1H), 7.05 (td, J=9.1, 6.9 Hz, 1H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 5.32 (dd, J=8.2, 6.2 Hz, 1H), 4.76-4.71 (m, 1H), 4.57 (dd, J=9.3, 7.6 Hz, 1H), 4.44 (tt, J=4.0, 1.8 Hz, 1H), 4.06 (dd, J=5.8, 4.5 Hz, 2H), 3.83 (dt, J=11.3, 1.7 Hz, 1H), 3.79-3.73 (m, 3H), 3.60-3.56 (m, 2H), 3.56-3.53 (m, 2H), 3.53-3.51 (m, 2H), 3.50-3.48 (m, 2H), 3.42 (dt, J=9.9, 5.8 Hz, 1H), 3.38 (ddd, J=9.9, 6.3, 5.1 Hz, 1H), 3.30-3.25 (m, 6H), 2.85 (dd, J=14.2, 6.2 Hz, 1H), 2.79-2.72 (m, 1H), 2.49 (s, 3H), 2.20 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.04 (dt, J=10.9, 5.3 Hz, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.42-1.25 (m, 4H), 1.05 (s, 9H).

Example 68

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-25-(4-(4-methylthiazol-5-yl)phenyl)-1,23-dioxo-3,10,13,16,19-pentaoxa-2,7,22-triazapentacosan-25-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-068)

CPD-068 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 43%). ¹H NMR (600 MHz, Methanol-d₄) δ8.99 (s, 1H), 7.49-7.44 (m, 5H), 7.40 (ddd, J=10.1, 4.6, 2.0 Hz, 1H), 7.37 (ddd, J=8.5, 2.0, 1.0 Hz, 1H), 7.05 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.2 Hz, 1H), 5.32 (dd, J=8.2, 6.1 Hz, 1H), 4.78-4.70 (m, 1H), 4.61-4.53 (m, 1H), 4.45 (tt, J=3.9, 1.7 Hz, 1H), 4.09-4.03 (m, 2H), 3.86-3.81 (m, 1H), 3.79-3.74 (m, 3H), 3.60-3.57 (m, 2H), 3.55 (qd, J=4.7, 3.7, 2.1 Hz, 8H), 3.53-3.49 (m, 2H), 3.44 (ddd, J=9.9, 6.2, 5.3 Hz, 1H), 3.39 (ddd, J=9.9, 6.4, 4.8 Hz, 1H), 3.30-3.24 (m, 6H), 2.84 (dd, J=14.2, 6.2 Hz, 1H), 2.76 (dd, J=14.2, 8.1 Hz, 1H), 2.49 (s, 3H), 2.20 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.04 (dt, J=10.5, 5.2 Hz, 2H), 1.95 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.42-1.25 (m, 4H), 1.06 (s, 9H).

Example 69

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-28-(4-(4-methylthiazol-5-yl)phenyl)-1,26-dioxo-3,10,13,16,19,22-hexaoxa-2,7,25-triazaoctacosan-28-yl)-1-(2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-069)

CPD-069 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 44%). ¹H NMR (600 MHz, Methanol-d₄) δ8.96 (s, 1H), 7.48 (dd, J=10.6, 2.0 Hz, 2H), 7.46 (d, J=1.0 Hz, 3H), 7.42-7.39 (m, 1H), 7.37 (ddd, J=8.4, 2.0, 1.0 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.1 Hz, 1H), 5.32 (dd, J=8.2, 6.1 Hz, 1H), 4.74 (dd, J=9.4, 1.3 Hz, 1H), 4.57 (dd, J=9.3, 7.6 Hz, 1H), 4.44 (dq, J=3.9, 2.1 Hz, 1H), 4.12-4.03 (m, 2H), 3.86-3.81 (m, 1H), 3.79-3.74 (m, 3H), 3.60-3.54 (m, 14H), 3.51 (td, J=4.2, 2.8 Hz, 2H), 3.44 (ddd, J=9.9, 6.3, 5.1 Hz, 1H), 3.39 (ddd, J=9.9, 6.4, 4.8 Hz, 1H), 3.30-3.25 (m, 5H), 2.85 (dd, J=14.1, 6.1 Hz, 1H), 2.76 (dd, J=14.2, 8.2 Hz, 1H), 2.49 (s, 3H), 2.20 (ddt, J=13.3, 7.6, 1.9 Hz, 1H), 2.04 (dt, J=10.3, 5.2 Hz, 2H), 1.96 (ddd, J=13.4, 9.3, 4.4 Hz, 1H), 1.43-1.25 (m, 5H), 1.06 (s, 9H).

Example 70

(2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,11-dioxo-3-oxa-2,7,10-triazadodecan-12-ypoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-070)

CPD-070 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 47%). ¹H NMR (600 MHz, Methanol-d₄) δ8.99 (s, 1H), 7.47 (dd, J=9.3, 3.2 Hz, 1H), 7.44 (dd, J=10.6, 1.9 Hz, 1H), 7.39 (d, J=7.7 Hz, 1H), 7.34 (ddd, J=8.5, 2.0, 0.9 Hz, 1H), 7.24-7.20 (m, 1H), 7.07 (dd, J=7.7, 1.6 Hz, 1H), 6.78 (d, J=1.7 Hz, 1H), 6.62 (td, J=8.7, 3.7 Hz, 1H), 4.74-4.68 (m, 1H), 4.62 (d, J=14.8 Hz, 1H), 4.53 (dd, J=9.4, 7.5 Hz, 1H), 4.49-4.45 (m, 2H), 4.42 (d, J=14.5 Hz, 1H), 4.34 (d, J=14.8 Hz, 1H), 4.06-4.01 (m, 2H), 3.85 (d, J=10.8 Hz, 1H), 3.78 (dd, J=11.0, 3.8 Hz, 1H), 3.75 (q, J=5.6, 4.8 Hz, 1H), 3.70 (dt, J=14.9, 4.9 Hz, 1H), 3.35 (t, J=5.5 Hz, 2H), 2.47 (s, 3H), 2.20 (ddt, J=13.5, 7.8, 2.0 Hz, 1H), 2.05 (qt, J=8.0, 4.4 Hz, 3H), 1.42-1.22 (m, 6H), 0.97 (s, 9H).

Example 71

(2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,12-dioxo-3-oxa-2,7,11-triazatridecan-13-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-071)

CPD-071 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 47%). ¹H NMR (600 MHz, Methanol-d₄) δ9.00 (s, 1H), 7.49-7.45 (m, 1H), 7.42-7.39 (m, 1H), 7.38 (dd, J=5.2, 1.6 Hz, 1H), 7.35-7.32 (m, 1H), 7.11 (dd, J=7.7, 1.6 Hz, 1H), 7.07-7.01 (m, 1H), 6.98 (d, J=1.6 Hz, 1H), 6.61 (td, J=8.7, 4.1 Hz, 1H), 4.73-4.69 (m, 1H), 4.66-4.59 (m, 3H), 4.58-4.54 (m, 1H), 4.48 (tt, J=3.8, 1.7 Hz, 1H), 4.40 (d, J=15.0 Hz, 1H), 4.09-4.03 (m, 2H), 3.84 (d, J=10.9 Hz, 1H), 3.78 (dd, J=11.1, 3.7 Hz, 1H), 3.46 (td, J=6.7, 5.2 Hz, 2H), 3.22 (t, J=5.9 Hz, 2H), 3.12 (t, J=7.4 Hz, 2H), 2.49 (s, 3H), 2.21 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.10-1.98 (m, 5H), 1.41-1.20 (m, 4H), 0.97 (s, 9H).

Example 72

(2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,12-dioxo-3-oxa-2,7,11-triazatridecan-13-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-072)

CPD-072 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 47%). ¹H NMR (600 MHz, Methanol-d₄) δ8.97 (s, 1H), 7.45 (dd, J=10.6, 2.0 Hz, 1H), 7.41 (d, J=7.7 Hz, 1H), 7.38-7.32 (m, 2H), 7.08 (dd, J=7.7, 1.6 Hz, 1H), 7.04-6.97 (m, 1H), 6.94 (d, J=1.6 Hz, 1H), 6.59 (td, J=8.7, 4.3 Hz, 1H), 4.74-4.68 (m, 1H), 4.64-4.52 (m, 4H), 4.48 (tt, J=4.0, 1.8 Hz, 1H), 4.36 (d, J=14.8 Hz, 1H), 4.05 (t, J=5.7 Hz, 2H), 3.84 (d, J=11.0 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.41 (dt, J=13.4, 6.7 Hz, 1H), 3.36-3.32 (m, 1H), 3.23 (t, J=5.8 Hz, 2H), 3.11 (td, J=7.5, 4.1 Hz, 2H), 2.48 (s, 3H), 2.22-2.14 (m, 1H), 2.07-2.00 (m, 3H), 1.83 (p, J=7.7 Hz, 2H), 1.72 (ddd, J=12.9, 10.3, 6.1 Hz, 2H), 1.40-1.23 (m, 4H), 0.99 (s, 9H).

Example 73

(2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,14-dioxo-3-oxa-2,7,13-triazapentadecan-15-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-073)

CPD-073 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 47%). ¹H NMR (600 MHz, Methanol-d₄) δ8.92 (s, 1H), 7.50-7.45 (m, 1H), 7.40 (td, J=9.7, 6.3 Hz, 1H), 7.35 (dt, J=9.2, 1.9 Hz, 1H), 7.10 (dd, J=7.7, 1.6 Hz, 1H), 7.05 (td, J=9.2, 6.9 Hz, 1H), 6.96 (d, J=1.6 Hz, 1H), 6.62 (td, J=8.7, 4.2 Hz, 1H), 6.56 (td, J=8.8, 5.0 Hz, 1H), 4.75-4.69 (m, 1H), 4.65-4.59 (m, 2H), 4.58-4.55 (m, 1H), 4.49-4.46 (m, 1H), 4.43 (d, J=15.0 Hz, 1H), 4.11 (t, J=5.0 Hz, 1H), 4.06 (t, J=5.1 Hz, 1H), 3.84 (d, J=11.1 Hz, 1H), 3.77 (dd, J=11.1, 3.8 Hz, 1H), 3.27 (t, J=5.8 Hz, 1H), 3.23 (t, J=5.8 Hz, 1H), 3.12-3.06 (m, 1H), 3.05-2.98 (m, 2H), 2.48 (s, 3H), 2.23-2.17 (m, 1H), 2.09-2.00 (m, 4H), 1.87 (p, J=8.1 Hz, 1H), 1.76 (p, J=8.0 Hz, 2H), 1.62 (p, J=7.2 Hz, 2H), 1.57-1.51 (m, 1H), 1.43 (p, J=7.7 Hz, 2H), 1.38-1.24 (m, 3H), 1.00 (s, 9H).

Example 74

(2R,4R)-N-(2((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,16-dioxo-3-oxa-2,7,15-triazaheptadecan-17-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-074)

CPD-074 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 42%). ¹H NMR (600 MHz, Methanol-d₄) δ8.96 (s, 1H), 7.49 (d, J=7.7 Hz, 1H), 7.45 (dd, J=10.6, 2.0 Hz, 1H), 7.40 (ddt, J=9.9, 4.6, 2.3 Hz, 1H), 7.36 (ddd, J=8.5, 2.0, 1.0 Hz, 1H), 7.10 (dd, J=7.7, 1.6 Hz, 1H), 7.06 (td, J=9.2, 7.1 Hz, 1H), 6.96 (d, J=1.6 Hz, 1H), 6.62 (td, J=8.7, 4.2 Hz, 1H), 4.75-4.69 (m, 1H), 4.64-4.60 (m, 2H), 4.59-4.55 (m, 2H), 4.48 (tt, J=3.9, 1.7 Hz, 1H), 4.44 (d, J=15.0 Hz, 1H), 4.07 (dd, J=5.7, 4.5 Hz, 2H), 3.88-3.81 (m, 1H), 3.78 (dd, J=11.1, 3.8 Hz, 1H), 3.27 (dd, J=12.5, 7.1 Hz, 2H), 3.23 (t, J=5.9 Hz, 2H), 3.07-2.98 (m, 2H), 2.49 (s, 3H), 2.21 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.07 (dt, J=8.4, 4.3 Hz, 1H), 2.05-2.00 (m, 2H), 1.70 (p, J=7.6 Hz, 2H), 1.55 (p, J=6.6 Hz, 2H), 1.43-1.22 (m, 10H), 1.00 (s, 9H).

Example 75

(2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,17-dioxo-3-oxa-2,7,16-triazaoctadecan-18-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-075)

CPD-075 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.06 g, yield: 47%). ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (s, 1H), 7.48 (d, J=7.7 Hz, 1H), 7.47-7.43 (m, 1H), 7.42-7.39 (m, 1H), 7.36 (ddd, J=8.5, 2.0, 1.0 Hz, 1H), 7.09 (dd, J=7.7, 1.5 Hz, 1H), 7.07-7.03 (m, 1H), 6.96 (d, J=1.6 Hz, 1H), 6.63 (td, J=8.7, 4.3 Hz, 1H), 4.76-4.70 (m, 1H), 4.65-4.59 (m, 2H), 4.59-4.55 (m, 2H), 4.48 (dq, J=4.1, 2.1 Hz, 1H), 4.44 (d, J=15.0 Hz, 1H), 4.10-4.02 (m, 2H), 3.88-3.82 (m, 1H), 3.78 (dd, J=11.1, 3.8 Hz, 1H), 3.28 (dt, J=9.7, 7.1 Hz, 2H), 3.24 (t, J=5.9 Hz, 2H), 3.06-3.00 (m, 2H), 2.49 (s, 3H), 2.20 (ddq, J=11.5, 5.9, 2.0 Hz, 1H), 2.07 (dt, J=8.4, 4.3 Hz, 1H), 2.03 (td, J=7.1, 6.3, 4.4 Hz, 2H), 1.74-1.67 (m, 2H), 1.54 (dd, J=10.0, 4.0 Hz, 2H), 1.42-1.34 (m, 3H), 1.34-1.30 (m, 2H), 1.30-1.25 (m, 7H), 1.01 (s, 9H).

Example 76

(2S,4R)-1-((S)-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-19-(4-(4-methylthiazol-5-yl)phenyl)-1,17-dioxo-3-oxa-2,7,16-triazanonadecan-19-yl)-4-hydroxypyrrolidine-2-carboxamide (CPD-076)

CPD-076 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 42%). ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (s, 1H), 7.46 (dd, J=8.5, 2.2 Hz, 4H), 7.41 (s, 1H), 7.36 (dd, J=8.8, 6.2 Hz, 2H), 7.06 (q, J=8.6 Hz, 1H), 6.63 (td, J=8.6, 4.2 Hz, 1H), 5.33-5.28 (m, 1H), 4.69-4.64 (m, 1H), 4.60-4.55 (m, 1H), 4.45-4.43 (m, 1H), 4.07 (t, J=5.1 Hz, 2H), 3.80 (d, J=11.1 Hz, 1H), 3.74 (dd, J=11.2, 3.7 Hz, 1H), 3.23 (t, J=5.8 Hz, 2H), 3.11 (dt, J=13.8, 7.0 Hz, 1H), 3.05 (t, J=6.9 Hz, 1H), 3.01 (t, J=7.8 Hz, 2H), 2.90-2.82 (m, 1H), 2.74 (dd, J=14.0, 8.5 Hz, 1H), 2.48 (s, 3H), 2.23-2.15 (m, 1H), 2.08-2.00 (m, 2H), 1.95 (ddd, J=13.4, 9.4, 4.3 Hz, 1H), 1.70-1.61 (m, 3H), 1.61-1.54 (m, 3H), 1.39-1.28 (m, 4H), 1.26-1.18 (m, 4H), 1.17-1.12 (m, 2H), 1.05 (s, 9H).

Example 77

(2S,4R)-1-((S)-2-(1-cyanocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-21-(4-(4-methylthiazol-5-yl)phenyl)-1,19-dioxo-3-oxa-2,7,18-triazahenicosan-21-yl)-4-hydroxypyrrolidine-2-carboxamide (CPD-077)

CPD-077 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 41%). ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.48-7.43 (m, 4H), 7.42-7.39 (m, 1H), 7.36 (dd, J=8.6, 4.9 Hz, 2H), 7.06 (q, J=8.6 Hz, 1H), 6.64 (td, J=8.7, 4.2 Hz, 1H), 5.38-5.26 (m, 1H), 4.72-4.63 (m, 1H), 4.61-4.53 (m, 1H), 4.45-4.42 (m, 1H), 4.08 (t, J=5.2 Hz, 2H), 3.80 (d, J=11.1 Hz, 1H), 3.74 (dd, J=11.2, 3.7 Hz, 1H), 3.24 (t, J=5.9 Hz, 2H), 3.11 (dt, J=14.0, 7.2 Hz, 1H), 3.07-2.97 (m, 3H), 2.85 (dd, J=14.0, 5.7 Hz, 1H), 2.74 (dd, J=14.0, 8.7 Hz, 1H), 2.48 (s, 3H), 2.24-2.14 (m, 1H), 2.07-2.01 (m, 2H), 1.95 (ddd, J=13.5, 9.3, 4.3 Hz, 1H), 1.70 (p, J=7.9 Hz, 2H), 1.64 (dt, J=12.8, 6.0 Hz, 1H), 1.61-1.53 (m, 3H), 1.36-1.28 (m, 4H), 1.26-1.15 (m, 8H), 1.14-1.09 (m, 2H), 1.06 (s, 9H).

Example 78

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-19-(4-(4-methylthiazol-5-yl)phenyl)-1,17-dioxo-3-oxa-2,7,16-triazanonadecan-19-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-078)

CPD-078 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 40%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.94 (d, J=2.9 Hz, 1H), 7.49-7.42 (m, 4H), 7.42-7.39 (m, 2H), 7.38-7.34 (m, 1H), 7.06 (q, J=8.7 Hz, 1H), 6.63 (td, J=8.7, 4.2 Hz, 1H), 6.23 (d, J=19.1 Hz, 1H), 5.37-5.24 (m, 1H), 4.59-4.46 (m, 1H), 4.45-4.41 (m, 1H), 4.07 (t, J=5.2 Hz, 2H), 3.92-3.83 (m, 1H), 3.78 (d, J=9.8 Hz, 1H), 3.75-3.64 (m, 1H), 3.59 (t, J=10.5 Hz, 1H), 3.23 (t, J=5.8 Hz, 2H), 3.13-3.05 (m, 1H), 3.05-2.98 (m, 3H), 2.91-2.80 (m, 1H), 2.79-2.68 (m, 1H), 2.48 (s, 3H), 2.45-2.34 (m, 1H), 2.24 (d, J=15.5 Hz, 3H), 2.21-2.11 (m, 1H), 2.02 (dd, J=10.7, 5.3 Hz, 2H), 1.96 (ddd, J=13.2, 8.8, 4.4 Hz, 1H), 1.72-1.61 (m, 2H), 1.36-1.29 (m, 4H), 1.26-1.18 (m, 4H), 1.15 (t, J=7.3 Hz, 2H), 1.06 (dd, J=6.6, 3.2 Hz, 3H), 0.89 (d, J=6.7 Hz, 1H), 0.85 (d, J=6.7 Hz, 1H).

Example 79

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-21-(4-(4-methylthiazol-5-yl)phenyl)-1,19-dioxo-3-oxa-2,7,18-triazahenicosan-21-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-079)

CPD-079 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 49%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.91 (s, 1H), 7.48-7.42 (m, 4H), 7.42-7.38 (m, 2H), 7.37 (dd, J=9.7, 2.4 Hz, 1H), 7.06 (q, J=8.7 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 6.23 (d, J=19.9 Hz, 1H), 5.37-5.25 (m, 1H), 4.52 (dt, J=43.6, 8.1 Hz, 1H), 4.44 (s, 1H), 4.08 (t, J=5.2 Hz, 2H), 3.93-3.84 (m, 1H), 3.78 (d, J=9.8 Hz, 1H), 3.75-3.65 (m, 1H), 3.64-3.56 (m, 1H), 3.24 (t, J=5.9 Hz, 2H), 3.09 (dt, J=14.0, 6.7 Hz, 1H), 3.02 (dt, J=14.1, 7.5 Hz, 3H), 2.93-2.78 (m, 1H), 2.78-2.67 (m, 1H), 2.48 (s, 3H), 2.40 (dt, J=16.3, 6.8 Hz, 1H), 2.27-2.22 (m, 3H), 2.21-2.11 (m, 1H), 2.03 (t, J=5.4 Hz, 2H), 1.95 (td, J=13.4, 5.4 Hz, 1H), 1.70 (p, J=8.0 Hz, 2H), 1.45-1.27 (m, 4H), 1.26-1.09 (m, 10H), 1.06 (dd, J=6.5, 1.9 Hz, 3H), 0.89 (d, J=6.7 Hz, 1H), 0.86 (d, J=6.7 Hz, 1H).

Example 80

(2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-1,15-dioxo-3-oxa-2,7,14-triazahexadecan-16-yl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropane-1-carboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (CPD-080)

CPD-080 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 45%). ¹H NMR (600 MHz, Methanol-d₄) δ9.02 (s, 1H), 7.50-7.43 (m, 2H), 7.40 (ddd, J=8.9, 5.3, 1.7 Hz, 1H), 7.35 (ddd, J=8.5, 1.9, 0.9 Hz, 1H), 7.09 (dd, J=7.7, 1.6 Hz, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.96 (d, J=1.6 Hz, 1H), 6.61 (td, J=8.7, 4.2 Hz, 1H), 4.74-4.70 (m, 1H), 4.63-4.54 (m, 4H), 4.48 (dq, J=4.0, 2.0 Hz, 1H), 4.44 (d, J=15.0 Hz, 1H), 4.09-4.03 (m, 2H), 3.84 (dt, J=11.3, 1.7 Hz, 1H), 3.78 (dd, J=11.1, 3.8 Hz, 1H), 3.30-3.26 (m, 2H), 3.23 (t, J=5.9 Hz, 2H), 3.06-3.00 (m, 2H), 2.49 (s, 3H), 2.20 (ddt, J=13.2, 7.6, 1.9 Hz, 1H), 2.07 (dt, J=8.4, 4.3 Hz, 1H), 2.03 (td, J=7.1, 6.4, 4.5 Hz, 2H), 1.71 (td, J=10.3, 9.1, 6.6 Hz, 2H), 1.58 (p, J=7.2 Hz, 2H), 1.42 (tt, J=9.9, 4.7 Hz, 2H), 1.36 (tdd, J=7.0, 4.7, 1.7 Hz, 2H), 1.34-1.23 (m, 4H), 1.00 (s, 9H).

Example 81

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-13-(4-(4-methylthiazol-5-yl)phenyl)-1,11-dioxo-3-oxa-2,7,10-triazatridecan-13-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-081)

CPD-081 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 42%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ9.02 (s, 1H), 7.46-7.41 (m, 3H), 7.39-7.33 (m, 3H), 7.31 (d, J=8.2 Hz, 1H), 7.01 (tt, J=9.1, 7.2 Hz, 1H), 6.63 (tt, J=8.6, 4.0 Hz, 1H), 6.23 (d, J=18.7 Hz, 1H), 5.32 (ddd, J=34.1, 8.6, 5.5 Hz, 1H), 4.60-4.39 (m, 2H), 4.04 (dp, J=9.9, 4.8 Hz, 2H), 3.92-3.83 (m, 1H), 3.76 (dd, J=24.6, 10.4 Hz, 1H), 3.70-3.61 (m, 1H), 3.59-3.54 (m, 1H), 3.53-3.44 (m, 1H), 3.28 (t, J=5.8 Hz, 1H), 3.26-3.21 (m, 2H), 3.18-3.10 (m, 1H), 2.81-2.75 (m, 1H), 2.74-2.70 (m, 1H), 2.67 (dd, J=14.6, 5.1 Hz, 1H), 2.48 (s, 3H), 2.45-2.36 (m, 1H), 2.25 (s, 1H), 2.23 (s, 1H), 2.18-2.11 (m, 1H), 2.07-1.99 (m, 2H), 1.97-1.92 (m, 1H), 1.04 (dd, J=10.9, 6.6 Hz, 3H), 0.85 (dd, J=15.6, 6.7 Hz, 3H).

Example 82

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-14-(4-(4-methylthiazol-5-yl)phenyl)-1,12-dioxo-3-oxa-2,7,11-triazatetradecan-14-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-082)

CPD-082 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 47%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ9.02 (s, 1H), 7.50-7.43 (m, 4H), 7.42-7.37 (m, 2H), 7.35 (dq, J=8.5, 1.6 Hz, 1H), 7.05 (td, J=9.1, 6.9 Hz, 1H), 6.61 (td, J=8.7, 4.0 Hz, 1H), 6.22 (d, J=8.8 Hz, 1H), 5.41-5.29 (m, 1H), 4.51 (dt, J=52.4, 8.1 Hz, 1H), 4.42 (ddt, J=9.0, 6.9, 3.4 Hz, 1H), 4.09-3.99 (m, J=4.6 Hz, 2H), 3.90-3.81 (m, 1H), 3.81-3.70 (m, 1H), 3.67-3.60 (m, 1H), 3.29-3.25 (m, 1H), 3.18 (td, J=6.7, 6.2, 3.2 Hz, 2H), 3.02-2.87 (m, 2H), 2.86-2.68 (m, 2H), 2.48 (d, J=1.4 Hz, 3H), 2.45-2.35 (m, 1H), 2.23 (d, J=14.5 Hz, 3H), 2.16 (s, 1H), 2.04-1.98 (m, 3H), 1.95-1.82 (m, 3H), 1.05 (dd, J=6.6, 3.9 Hz, 3H), 0.85 (dd, J=14.9, 6.7 Hz, 3H).

Example 83

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-15-(4-(4-methylthiazol-5-yl)phenyl)-1,13-dioxo-3-oxa-2,7,12-triazapentadecan-15-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-083)

CPD-083 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 39%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ9.00 (d, J=2.1 Hz, 1H), 7.49-7.41 (m, 4H), 7.41-7.37 (m, 2H), 7.35 (dt, J=8.4, 1.4 Hz, 1H), 7.05 (tdd, J=9.3, 6.9, 2.6 Hz, 1H), 6.62 (td, J=8.7, 4.1 Hz, 1H), 6.22 (d, J=14.3 Hz, 1H), 5.38-5.25 (m, 1H), 4.51 (dt, J=45.9, 8.1 Hz, 1H), 4.45-4.41 (m, 1H), 4.04 (t, J=5.3 Hz, 2H), 3.91-3.82 (m, 1H), 3.80-3.70 (m, 1H), 3.69-3.59 (m, 1H), 3.22 (t, J=5.8 Hz, 2H), 3.19-3.14 (m, 2H), 3.08-3.02 (m, 2H), 2.86-2.80 (m, 1H), 2.79-2.68 (m, 2H), 2.48 (d, J=1.2 Hz, 3H), 2.41 (dtd, J=9.9, 6.7, 5.1 Hz, 1H), 2.24 (d, J=2.6 Hz, 2H), 2.22 (s, 1H), 2.05-1.98 (m, 2H), 1.97-1.90 (m, 1H), 1.73-1.64 (m, 2H), 1.54 (tt, J=9.7, 4.6 Hz, 2H), 1.05 (dd, J=6.6, 5.5 Hz, 3H), 0.85 (dd, J=19.4, 6.7 Hz, 3H).

Example 84

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-16-(4-(4-methylthiazol-5-yl)phenyl)-1,14-dioxo-3-oxa-2,7,13-triazahexadecan-16-yl)-4-hydroxy-14(R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-084)

CPD-084 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 58%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.91 (d, J=2.4 Hz, 1H), 7.48-7.42 (m, 4H), 7.42-7.37 (m, 2H), 7.35 (ddt, J=8.4, 1.9, 1.0 Hz, 1H), 7.06 (td, J=9.3, 7.0 Hz, 1H), 6.60 (tdd, J=8.8, 4.3, 2.9 Hz, 1H), 6.23 (d, J=14.7 Hz, 1H), 5.37-5.25 (m, 1H), 4.51 (dt, J=48.1, 8.1 Hz, 1H), 4.43 (qd, J=3.7, 3.3, 1.5 Hz, 1H), 4.05 (ddd, J=6.9, 4.7, 2.2 Hz, 2H), 3.91-3.84 (m, 1H), 3.80-3.70 (m, 1H), 3.68-3.59 (m, 1H), 3.19 (dq, J=6.0, 3.4 Hz, 2H), 3.09 (ddd, J=15.0, 13.3, 6.9 Hz, 2H), 3.01-2.95 (m, 2H), 2.89-2.82 (m, 1H), 2.81-2.68 (m, 2H), 2.46 (s, 3H), 2.43-2.36 (m, 1H), 2.25 (d, J=7.2 Hz, 2H), 2.22 (s, 1H), 2.05-1.99 (m, 2H), 1.95 (ddt, J=12.9, 8.4, 4.1 Hz, 1H), 1.69 (ddd, J=15.5, 9.1, 6.8 Hz, 2H), 1.48-1.39 (m, 2H), 1.34-1.24 (m, 2H), 1.08-1.01 (m, 3H), 0.86 (dd, J=18.8, 6.7 Hz, 3H).

Example 85

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-17-(4-(4-methylthiazol-5-yl)phenyl)-1,15-dioxo-3-oxa-2,7,14-triazaheptadecan-17-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-085)

CPD-085 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 49%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.91 (d, J=1.9 Hz, 1H), 7.49-7.42 (m, 4H), 7.41-7.38 (m, 2H), 7.38-7.35 (m, 1H), 7.06 (tdd, J=9.8, 7.9, 1.4 Hz, 1H), 6.62 (td, J=8.7, 4.1 Hz, 1H), 6.23 (d, J=17.0 Hz, 1H), 5.37-5.24 (m, 1H), 4.51 (dt, J=45.0, 8.1 Hz, 1H), 4.44 (tq, J=4.8, 2.3 Hz, 1H), 4.05 (t, J=5.2 Hz, 2H), 3.90-3.84 (m, 1H), 3.79-3.70 (m, 1H), 3.68-3.58 (m, 1H), 3.21 (t, J=5.9 Hz, 2H), 3.15-3.04 (m, 2H), 3.03-2.97 (m, 2H), 2.85 (dd, J=14.2, 6.1 Hz, 1H), 2.81-2.67 (m, 2H), 2.47 (d, J=0.7 Hz, 3H), 2.43-2.37 (m, 1H), 2.25 (d, J=6.4 Hz, 2H), 2.22 (s, 1H), 2.07-1.99 (m, 2H), 1.95 (dddd, J=13.0, 7.9, 4.7, 3.5 Hz, 1H), 1.68 (ddt, J=8.6, 5.9, 3.1 Hz, 2H), 1.43-1.32 (m, 4H), 1.23 (tq, J=7.9, 3.9 Hz, 2H), 1.05 (dd, J=6.6, 5.3 Hz, 3H), 0.87 (dd, J=19.4, 6.7 Hz, 3H).

Example 86

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-18-(4-(4-methylthiazol-5-yl)phenyl)-1,16-dioxo-3-oxa-2,7,15-triazaoctadecan-18-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-086)

CPD-086 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 43%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.91 (d, J=2.5 Hz, 1H), 7.48-7.43 (m, 4H), 7.42-7.39 (m, 2H), 7.38-7.34 (m, 1H), 7.10-7.03 (m, 1H), 6.62 (td, J=8.7, 4.2 Hz, 1H), 6.23 (d, J=18.8 Hz, 1H), 5.31 (ddd, J=35.8, 8.2, 6.1 Hz, 1H), 4.51 (dt, J=44.2, 8.1 Hz, 1H), 4.44 (tq, J=4.8, 2.4 Hz, 1H), 4.11-4.02 (m, 2H), 3.91-3.83 (m, 1H), 3.80-3.70 (m, 1H), 3.68-3.58 (m, 1H), 3.22 (t, J=5.8 Hz, 2H), 3.07 (ddqd, J=20.3, 13.3, 6.9, 2.5 Hz, 2H), 2.98 (td, J=8.4, 7.9, 4.7 Hz, 2H), 2.85 (dd, J=14.0, 5.8 Hz, 1H), 2.81-2.68 (m, 2H), 2.48 (d, J=0.9 Hz, 3H), 2.44-2.37 (m, 1H), 2.26-2.24 (m, 2H), 2.23 (s, 1H), 2.06-2.00 (m, 2H), 1.95 (ddt, J=12.9, 8.5, 4.4 Hz, 1H), 1.71-1.62 (m, 2H), 1.34 (tt, J=15.6, 7.7 Hz, 4H), 1.28-1.22 (m, 2H), 1.20-1.13 (m, 2H), 1.05 (dd, J=6.6, 2.9 Hz, 3H), 0.87 (dd, J=19.0, 6.7 Hz, 3H).

Example 87

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-20-(4-(4-methylthiazol-5-yl)phenyl)-1,18-dioxo-3-oxa-2,7,17-triazaicosan-20-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-087)

CPD-087 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 42%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.95 (d, J=3.1 Hz, 1H), 7.49-7.43 (m, 4H), 7.42-7.39 (m, 2H), 7.38-7.35 (m, 1H), 7.06 (td, J=9.1, 7.0 Hz, 1H), 6.63 (td, J=8.7, 4.3 Hz, 1H), 6.23 (d, J=20.6 Hz, 1H), 5.30 (ddd, J=35.1, 8.1, 5.9 Hz, 1H), 4.52 (dt, J=43.6, 8.1 Hz, 1H), 4.45-4.42 (m, 1H), 4.08 (t, J=5.4 Hz, 2H), 3.90-3.85 (m, 1H), 3.80-3.70 (m, 1H), 3.68-3.56 (m, 1H), 3.24 (t, J=5.8 Hz, 2H), 3.09 (dtd, J=13.8, 7.0, 1.8 Hz, 1H), 3.05-2.98 (m, 3H), 2.88-2.82 (m, 1H), 2.81-2.74 (m, 1H), 2.70 (dt, J=20.9, 7.5 Hz, 1H), 2.48 (d, J=1.0 Hz, 3H), 2.44-2.38 (m, 1H), 2.25 (d, J=5.2 Hz, 2H), 2.23 (s, 1H), 2.03 (tt, J=6.5, 3.4 Hz, 2H), 1.96 (ddt, J=13.1, 8.2, 4.8 Hz, 1H), 1.73-1.64 (m, 2H), 1.32 (qd, J=8.0, 7.3, 3.7 Hz, 4H), 1.27-1.16 (m, 6H), 1.15-1.09 (m, 2H), 1.06 (dd, J=6.6, 2.6 Hz, 3H), 0.87 (dd, J=18.7, 6.7 Hz, 3H).

Example 88

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-23-(4-(4-methylthiazol-5-yl)phenyl)-1,21-dioxo-3-oxa-2,7,20-triazatricosan-23-yl)-4-hydroxy-14(R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-088)

CPD-088 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 41%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.97 (d, J=4.2 Hz, 1H), 7.49-7.43 (m, 4H), 7.43-7.39 (m, 2H), 7.39-7.35 (m, 1H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.64 (td, J=8.7, 4.3 Hz, 1H), 6.23 (d, J=21.0 Hz, 1H), 5.30 (ddd, J=35.2, 8.1, 5.9 Hz, 1H), 4.52 (dt, J=43.4, 8.1 Hz, 1H), 4.44 (tt, J=4.6, 2.3 Hz, 1H), 4.08 (t, J=5.1 Hz, 2H), 3.91-3.85 (m, 1H), 3.80-3.70 (m, 1H), 3.68-3.58 (m, 2H), 3.24 (t, J=5.7 Hz, 2H), 3.13-3.07 (m, 1H), 3.03 (ddd, J=13.3, 8.9, 7.0 Hz, 3H), 2.87-2.77 (m, 1H), 2.77-2.68 (m, 1H), 2.49 (s, 3H), 2.45-2.37 (m, 1H), 2.25 (d, J=4.5 Hz, 2H), 2.23 (s, 1H), 2.03 (tt, J=6.3, 3.3 Hz, 2H), 1.99-1.92 (m, 1H), 1.76-1.68 (m, 2H), 1.38 (p, J=7.8, 7.4 Hz, 2H), 1.35-1.26 (m, 4H), 1.19 (q, J=6.3, 4.2 Hz, 10H), 1.12 (d, J=5.5 Hz, 2H), 1.06 (dd, J=6.6, 1.6 Hz, 3H), 0.87 (dd, J=18.0, 6.7 Hz, 3H).

Example 89

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-16-(4-(4-methylthiazol-5-yl)phenyl)-1,14-dioxo-3,10-dioxa-2,7,13-triazahexadecan-16-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-089)

CPD-089 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 44%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ9.05 (d, J=2.0 Hz, 1H), 7.48-7.40 (m, 4H), 7.40-7.36 (m, 2H), 7.36-7.32 (m, 1H), 7.06-6.99 (m, 1H), 6.60 (tt, J=8.5, 3.9 Hz, 1H), 6.22 (d, J=9.7 Hz, 1H), 5.32 (dt, J=27.8, 7.2 Hz, 1H), 4.56-4.37 (m, 2H), 4.09-4.02 (m, 2H), 3.91-3.83 (m, 1H), 3.80-3.70 (m, 3H), 3.68-3.60 (m, 1H), 3.47 (dt, J=7.8, 5.4 Hz, 2H), 3.29 (t, J=5.9 Hz, 2H), 3.26-3.18 (m, 3H), 2.82 (dd, J=14.5, 6.7 Hz, 1H), 2.77-2.67 (m, 2H), 2.48 (d, J=1.1 Hz, 3H), 2.43-2.37 (m, 1H), 2.24 (d, J=11.1 Hz, 2H), 2.21 (s, 1H), 2.19-2.12 (m, 1H), 2.06 (tt, J=6.5, 3.9 Hz, 2H), 1.93 (ddt, J=13.1, 8.5, 4.5 Hz, 1H), 1.04 (dd, J=8.5, 6.6 Hz, 3H), 0.86 (dd, J=17.3, 6.7 Hz, 3H).

Example 90

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-19-(4-(4-methylthiazol-5-yl)phenyl)-1,17-dioxo-3,10,13-trioxa-2,7,16-triazanonadecan-19-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-090)

CPD-090 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 43%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ9.05 (d, J=2.1 Hz, 1H), 7.49-7.42 (m, 4H), 7.41-7.38 (m, 2H), 7.36 (dt, J=8.5, 1.4 Hz, 1H), 7.04 (tdd, J=9.6, 7.0, 3.1 Hz, 1H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 6.23 (d, J=16.4 Hz, 1H), 5.37-5.22 (m, 1H), 4.51 (dt, J=45.8, 8.1 Hz, 1H), 4.44 (dp, J=4.8, 2.4 Hz, 1H), 4.06 (q, J=5.5 Hz, 2H), 3.91-3.83 (m, 1H), 3.80-3.71 (m, 3H), 3.69-3.58 (m, 1H), 3.54 (dtd, J=6.0, 3.6, 2.9, 1.2 Hz, 2H), 3.49 (td, J=4.6, 3.9, 2.0 Hz, 2H), 3.43-3.36 (m, 2H), 3.30-3.27 (m, 2H), 3.26 (dd, J=6.2, 1.9 Hz, 3H), 2.92-2.82 (m, 1H), 2.80-2.68 (m, 2H), 2.49 (d, J=1.7 Hz, 3H), 2.41 (ddt, J=16.5, 13.6, 6.7 Hz, 1H), 2.25 (d, J=5.4 Hz, 2H), 2.22 (s, 1H), 2.20-2.12 (m, 1H), 2.08-2.02 (m, 2H), 1.95 (ddt, J=13.0, 8.6, 4.5 Hz, 1H), 1.05 (t, J=6.4 Hz, 3H), 0.86 (dd, J=18.3, 6.7 Hz, 3H).

Example 91

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-22-(4-(4-methylthiazol-5-yl)phenyl)-1,20-dioxo-3,10,13,16-tetraoxa-2,7,19-triazadocosan-22-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-091)

CPD-091 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 34%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.96 (s, 1H), 7.49-7.46 (m, 1H), 7.45 (s, 2H), 7.44-7.41 (m, 1H), 7.40-7.35 (m, 3H), 7.05 (tdd, J=9.2, 6.9, 2.2 Hz, 1H), 6.63 (td, J=8.7, 4.1 Hz, 1H), 6.23 (d, J=15.8 Hz, 1H), 5.38-5.23 (m, 1H), 4.51 (dt, J=45.8, 8.1 Hz, 1H), 4.44 (dd, J=4.8, 2.6 Hz, 1H), 4.08-4.03 (m, 2H), 3.90-3.84 (m, 1H), 3.77 (td, J=6.3, 5.4, 2.6 Hz, 2H), 3.74-3.65 (m, 1H), 3.62-3.57 (m, 3H), 3.55 (ddd, J=5.6, 3.9, 1.5 Hz, 2H), 3.51 (ttd, J=5.8, 4.1, 3.6, 2.6 Hz, 4H), 3.45-3.37 (m, 2H), 3.27 (dt, J=10.4, 5.8 Hz, 5H), 2.91-2.82 (m, 1H), 2.81-2.69 (m, 2H), 2.48 (d, J=1.1 Hz, 3H), 2.44-2.37 (m, 1H), 2.25 (d, J=6.9 Hz, 2H), 2.22 (s, 1H), 2.20-2.13 (m, 1H), 2.07-2.01 (m, 2H), 1.95 (ddt, J=12.9, 8.2, 4.3 Hz, 1H), 1.05 (dd, J=6.6, 4.5 Hz, 3H), 0.87 (dd, J=17.6, 6.7 Hz, 3H).

Example 92

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-25-(4-(4-methylthiazol-5-yl)phenyl)-1,23-dioxo-3,10,13,16,19-pentaoxa-2,7,22-triazapentacosan-25-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-092)

CPD-092 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 44%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ9.00 (s, 1H), 7.49-7.46 (m, 1H), 7.45 (s, 2H), 7.44-7.42 (m, 1H), 7.42-7.35 (m, 3H), 7.05 (tdd, J=9.1, 6.9, 2.1 Hz, 1H), 6.64 (td, J=8.7, 4.0 Hz, 1H), 6.23 (d, J=16.5 Hz, 1H), 5.37-5.26 (m, 1H), 4.51 (dt, J=45.2, 8.1 Hz, 1H), 4.44 (tt, J=4.8, 2.4 Hz, 1H), 4.06 (dt, J=5.4, 3.7 Hz, 2H), 3.91-3.83 (m, 1H), 3.77 (dt, J=7.5, 2.3 Hz, 2H), 3.75-3.65 (m, 1H), 3.62-3.57 (m, 3H), 3.57-3.54 (m, 8H), 3.54-3.50 (m, 2H), 3.46-3.38 (m, 2H), 3.30-3.24 (m, 5H), 2.91-2.81 (m, 1H), 2.80-2.70 (m, 2H), 2.49 (d, J=1.0 Hz, 3H), 2.41 (tdq, J=10.0, 6.5, 3.6, 3.1 Hz, 1H), 2.25 (d, J=6.7 Hz, 2H), 2.22 (s, 1H), 2.20-2.13 (m, 1H), 2.07-2.02 (m, 2H), 1.99-1.91 (m, 1H), 1.05 (dd, J=6.6, 5.2 Hz, 3H), 0.87 (dd, J=18.5, 6.7 Hz, 3H).

Example 93

(2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-28-(4-(4-methylthiazol-5-yl)phenyl)-1,26-dioxo-3,10,13,16,19,22-hexaoxa-2,7,25-triazaoctacosan-28-yl)-4-hydroxy-1-((R)-3-methyl-2-(3-methylisoxazol-5-yl)butanoyl)pyrrolidine-2-carboxamide (CPD-093)

CPD-093 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 41%). Two isomers of this spectrum. ¹H NMR (600 MHz, Methanol-d₄) δ8.98 (d, J=1.7 Hz, 1H), 7.50-7.46 (m, 1H), 7.46 (s, 2H), 7.43 (d, J=8.3 Hz, 2H), 7.40-7.35 (m, 2H), 7.09-7.02 (m, 1H), 6.64 (td, J=8.7, 4.0 Hz, 1H), 6.23 (d, J=17.0 Hz, 1H), 5.36-5.25 (m, 1H), 4.52 (dt, J=44.7, 8.1 Hz, 1H), 4.45-4.41 (m, 1H), 4.06 (q, J=4.4, 3.8 Hz, 2H), 3.91-3.84 (m, 1H), 3.80-3.75 (m, 3H), 3.73 (d, J=11.6 Hz, 1H), 3.67 (dd, J=11.0, 4.3 Hz, 1H), 3.63-3.53 (m, 14H), 3.52 (qd, J=4.9, 4.3, 2.4 Hz, 2H), 3.47-3.37 (m, 2H), 3.28 (td, J=7.8, 2.7 Hz, 4H), 2.88-2.82 (m, 1H), 2.80-2.70 (m, 2H), 2.49 (s, 3H), 2.41 (dtd, J=13.5, 6.8, 3.1 Hz, 1H), 2.25 (d, J=6.5 Hz, 2H), 2.22 (s, 1H), 2.14 (d, J=13.6 Hz, 1H), 2.08-2.02 (m, 2H), 1.99-1.93 (m, 1H), 1.05 (dd, J=6.6, 5.1 Hz, 3H), 0.87 (dd, J=18.5, 6.7 Hz, 3H).

Example 94

3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)-N-((1-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12,15-pentaoxa-18-azahenicosan-21-yl)oxy)benzamide (CPD-097)

CPD-094 was synthesized following the same procedures as CPD-001 as described in Example 3. (0.08 g, yield: 44%). ¹H NMR (600 MHz, Methanol-d₄) δ7.45 (d, J=8.4 Hz, 1H), 7.36 (dd, J=10.6, 1.9 Hz, 1H), 7.30 (ddd, J=9.0, 5.3, 1.8 Hz, 1H), 7.26 (dt, J=8.5, 1.4 Hz, 1H), 6.94 (td, J=9.3, 7.0 Hz, 1H), 6.91 (d, J=2.2 Hz, 1H), 6.76 (dd, J=8.4, 2.2 Hz, 1H), 6.53 (td, J=8.7, 4.2 Hz, 1H), 4.95 (dd, J=12.9, 5.5 Hz, 1H), 3.95 (t, J=5.2 Hz, 2H), 3.65 (dd, J=5.7, 4.3 Hz, 2H), 3.59 (t, J=5.3 Hz, 2H), 3.54 (s, 4H), 3.52-3.51 (m, 1H), 3.49 (dd, J=5.9, 2.5 Hz, 2H), 3.48-3.46 (m, 3H), 3.46-3.43 (m, 4H), 3.29 (t, J=5.3 Hz, 2H), 3.21 (p, J=1.6 Hz, 2H), 3.18 (t, J=6.1 Hz, 2H), 3.15 (t, J=5.0 Hz, 2H), 3.03 (s, 3H), 2.79-2.76 (m, 1H), 2.76 (d, J=4.0 Hz, 1H), 2.62-2.48 (m, 1H), 1.97 (ddd, J=9.9, 5.0, 2.9 Hz, 1H), 1.95-1.91 (m, 2H).

Example 95

(2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-7-methyl-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-037)

To a solution of CPD-031 (0.1 g, 0.09 mmol) and formaldehyde (3 mg, 0.1 mmol) in MeOH (1 mL) was added NaBH₃CN (9 mg, 0.14 mmol). The reaction mixture was stirred at room temperature overnight. The reaction was monitored by UPLC. Upon completion, the reaction mixture was purified by preparative HPLC to give CPD-037 (0.05 g, 0.05 mmol, 56% yield) as a white solid. ¹H NMR (800 MHz, Methanol-d₄) δ8.89 (s, 1H), 7.51 (d, J=7.9 Hz, 2H), 7.45 (t, J=10.7 Hz, 3H), 7.39 (s, 1H), 7.36 (d, J=8.7 Hz, 1H), 7.06 (q, J=8.3 Hz, 1H), 6.62 (td, J=8.7, 3.8 Hz, 1H), 5.02 (q, J=7.2 Hz, 1H), 4.55 (t, J=7.4 Hz, 1H), 4.49 (s, 1H), 4.47-4.43 (m, 1H), 4.11 (t, J=7.6 Hz, 1H), 4.06-4.01 (m, 1H), 3.93 (dd, J=10.8, 5.0 Hz, 1H), 3.68 (dd, J=11.1, 3.6 Hz, 1H), 3.45 (q, J=7.7, 6.6 Hz, 1H), 3.04 (td, J=11.9, 5.0 Hz, 1H), 2.89 (s, 3H), 2.49 (s, 3H), 2.27 (dt, J=14.7, 7.9 Hz, 1H), 2.20 (ddd, J=13.7, 9.0, 4.8 Hz, 2H), 2.10 (dt, J=12.8, 5.8 Hz, 3H), 1.80-1.67 (m, 2H), 1.59-1.52 (m, 2H), 1.45 (d, J=7.1 Hz, 3H), 1.36-1.18 (m, 14H), 1.05 (s, 9H).

Example 96

(2R,4S)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-7-methyl-1,18-dioxo-3-oxa-2,7,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-053)

CPD-053 was synthesized following the same procedures as CPD-037 as described in Example 95. (0.08 g, yield: 44%). ¹H NMR (800 MHz, Methanol-d₄) δ8.89 (s, 1H), 7.48 (d, J=10.6 Hz, 1H), 7.44 (d, J=8.0 Hz, 2H), 7.42 (d, 7.9 Hz, 2H), 7.38 (t, J=7.3 Hz, 2H), 7.07 (q, J=8.5 Hz, 1H), 6.64 (td, J=8.7, 3.8 Hz, 1H), 5.00 (q, J=7.2 Hz, 1H), 4.63 (s, 1H), 4.57 (t, J=8.3 Hz, 1H), 4.44 (s, 1H), 4.10 (s, 1H), 4.04 (s, 1H), 3.87 (d, J=11.0 Hz, 1H), 3.75 (dd, J=11.2, 4.1 Hz, 1H), 3.45 (d, J=6.6 Hz, 1H), 3.10-3.00 (m, 1H), 2.90 (s, 31H), 2.48 (s, 3H), 2.29 (dt, J=15.0, 7.7 Hz, 1H), 2.23 (t, 7.2 Hz, 1H), 2.21-2.17 (m, 1H), 2.13-2.08 (m, 2H), 1.96 (ddd, J=13.3, 8.9, 4.6 Hz, 1H), 1.77 (s, 1H), 1.73 (s, 1H), 1.62-1.55 (m, 2H), 1.51 (d, J=7.1 Hz, 3H), 1.39-1.24 (m, 14H), 1.04 (s, 9H).

Example 97

(2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-8-methyl-1,18-dioxo-3-oxa-2,8,19-triazahenicosan-21-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-094)

CPD-094 was synthesized following the same procedures as CPD-037 as described in Example 95. (0.08 g, yield: 44%). ¹H NMR (600 MHz, Methanol-d₄) δ8.97 (s, 1H), 7.49-7.41 (m, 5H), 7.40-7.34 (m, 2H), 7.06 (td, J=9.2, 7.0 Hz, 1H), 6.61 (td, J=8.8, 4.3 Hz, 1H), 5.00 (q, J=6.9 Hz, 1H), 4.63 (d, J=6.4 Hz, 1H), 4.59-4.54 (m, 1H), 4.43 (dp, J=4.3, 2.0 Hz, 1H), 3.92 (p, J=5.0 Hz, 2H), 3.87 (d, J=11.1 Hz, 1H), 3.75 (dd, J=11.0, 4.0 Hz, 1H), 3.34 (ddd, J=9.1, 7.0, 4.5 Hz, 1H), 3.23-3.13 (m, 2H), 3.07 (ddd, J=12.6, 10.3, 6.2 Hz, 1H), 2.87 (s, 3H), 2.49 (s, 3H), 2.29 (ddd, J=14.1, 8.3, 7.1 Hz, 1H), 2.26-2.22 (m, 1H), 2.22-2.15 (m, 2H), 1.99-1.88 (m, 3H), 1.73 (p, J=6.2 Hz, 4H), 1.65-1.56 (m, 2H), 1.51 (d, J=7.0 Hz, 2H), 1.39-1.26 (m, 10H), 1.04 (s, 9H).

Example 98

(2S,4R)-1-((S)-22-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-8-methyl-1,20-dioxo-3-oxa-2,8,21-triazatricosan-23-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-095)

CPD-095 was synthesized following the same procedures as CPD-037 as described in Example 95. (0.07 g, yield: 41%). ¹H NMR (600 MHz, Methanol-d₄) δ8.95 (s, 1H), 7.50-7.40 (m, 5H), 7.40-7.35 (m, 2H), 7.06 (td, J=9.3, 7.0 Hz, 1H), 6.61 (td, J=8.7, 4.3 Hz, 1H), 5.00 (q, J=7.0 Hz, 1H), 4.63 (s, 1H), 4.56 (t, J=8.3 Hz, 1H), 4.43 (dp, J=4.3, 1.9 Hz, 1H), 3.93 (q, J=5.1 Hz, 2H), 3.87 (dt, J=11.2, 1.7 Hz, 1H), 3.75 (dd, J=11.0, 4.0 Hz, 1H), 3.35 (td, J=10.0, 9.2, 4.9 Hz, 1H), 3.18 (dtt, J=12.7, 9.4, 5.9 Hz, 2H), 3.07 (ddd, J=12.8, 10.2, 6.4 Hz, 1H), 2.87 (s, 3H), 2.49 (s, 3H), 2.29 (ddd, J=14.1, 8.3, 7.1 Hz, 1H), 2.24 (dd, J=8.2, 6.3 Hz, 1H), 2.22-2.15 (m, 2H), 1.99-1.88 (m, 3H), 1.73 (p, J=6.2 Hz, 4H), 1.65-1.55 (m, 3H), 1.51 (d, J=7.0 Hz, 2H), 1.42-1.23 (m, 13H), 1.04 (s, 9H).

Example 99

(2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)phenyl)-8-methyl-1,19-dioxo-3-oxa-2,8,20-triazadocosan-22-oyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide (CPD-096)

CPD-096 was synthesized following the same procedures as CPD-037 as described in Example 95. (0.08 g, yield: ¹H NMR (600 MHz, Methanol-d₄) δ8.93 (s, 1H), 7.50-7.40 (m, 5H), 7.40-7.34 (m, 2H), 7.06 (td, J=9.3, 7.0 Hz, 1H), 6.61 (td, J=8.7, 4.3 Hz, 1H), 5.00 (q, J=6.9 Hz, 1H), 4.63 (s, 1H), 4.56 (dd, J=9.1, 7.6 Hz, 1H), 4.43 (dp, J=4.2, 1.9 Hz, 1H), 3.92 (d, J=4.8 Hz, 2H), 3.89-3.85 (m, 1H), 3.75 (dd, J=11.0, 4.0 Hz, 1H), 3.38-3.33 (m, 1H), 3.23-3.12 (m, 2H), 3.07 (ddd, J=12.7, 10.2, 6.2 Hz, 1H), 2.87 (s, 3H), 2.48 (s, 3H), 2.29 (ddd, J=14.1, 8.3, 7.1 Hz, 1H), 2.24 (dd, J=8.1, 6.4 Hz, 1H), 2.22-2.15 (m, 2H), 1.95 (ddt, J=13.2, 8.7, 4.4 Hz, 3H), 1.77-1.69 (m, 4H), 1.65-1.56 (m, 2H), 1.51 (d, J=7.0 Hz, 2H), 1.40-1.26 (m, 12H), 1.04 (s, 9H).

Certain compounds disclosed herein have the structures shown in Table 1.

TABLE 1
CPD Structure
CPD- 001
CPD- 002
CPD- 003
CPD- 004
CPD- 005
CPD- 006
CPD- 007
CPD- 008
CPD- 009
CPD- 010
CPD- 011
CPD- 012
CPD- 013
CPD- 014
CPD- 015
CPD- 016
CPD- 017
CPD- 018
CPD- 019
CPD- 020
CPD- 021
CPD- 022
CPD- 023
CPD- 024
CPD- 025
CPD- 026
CPD- 027
CPD- 028
CPD- 029
CPD- 030
CPD- 031
CPD- 032
CPD- 033
CPD- 034
CPD- 035
CPD- 036
CPD- 037
CPD- 038
CPD- 039
CPD- 040
CPD- 041
CPD- 042
CPD- 043
CPD- 044
CPD- 045
CPD- 046
CPD- 047
CPD- 048
CPD- 049
CPD- 050
CPD- 051
CPD- 052
CPD- 053
CPD- 054
CPD- 055
CPD- 056
CPD- 057
CPD- 058
CPD- 059
CPD- 060
CPD- 061
CPD- 062
CPD- 063
CPD- 064
CPD- 065
CPD- 066
CPD- 067
CPD- 068
CPD- 069
CPD- 070
CPD- 071
CPD- 072
CPD- 073
CPD- 074
CPD- 075
CPD- 076
CPD- 077
CPD- 078
CPD- 079
CPD- 080
CPD- 081
CPD- 082
CPD- 083
CPD- 084
CPD- 085
CPD- 086
CPD- 087
CPD- 088
CPD- 089
CPD- 090
CPD- 091
CPD- 092
CPD- 093
CPD- 094
CPD- 095
CPD- 096
CPD- 097
    CPD     Chemical Name
    CPD-001 (2S,4R)-1-((S)-16-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,14-dioxo-
            3-oxa-2,7,15-triazaheptadecan-17-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-002 (2S,4R)-1-((S)-14-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,12-dioxo-
            3,10-dioxa-2,7,13-triazapentadecan-
            15-oyl)-4-hydroxy-N-(4-(4-
            methylthiazol-5-yl)benzyl)pyrrolidine-
            2-carboxamide
    CPD-003 (2S,4R)-1-((S)-15-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,13-dioxo-
            3,10-dioxa-2,7,14-triazahexadecan-16-
            oyl)-4-hydroxy-N-(4-(4-methylthiazol-
            5-yl)benzyl)pyrrolidine-2-carboxamide
    CPD-004 (2S,4R)-1-((S)-18-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,16-dioxo-
            3,10,13-trioxa-2,7,17-triazanonadecan-
            19-oyl)-4-hydroxy-N-(4-(4-
            methylthiazol-5-yl)benzyl)pyrrolidine-
            2-carboxamide
    CPD-005 (2S,4R)-1-((S)-11-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,9-dioxo-
            3-oxa-2,7,10-triazadodecan-12-oyl)-4-
            hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-006 (2S,4R)-1-((S)-12-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,10-dioxo-
            3-oxa-2,7,11-triazatridecan-13-oyl)-4-
            hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-007 (2S,4R)-1-((S)-14-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,12-dioxo-
            3-oxa-2,7,13-triazapentadecan-15-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-008 (2S,4R)-1-((S)-13-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,11-dioxo-
            3-oxa-2,7,12-triazatetradecan-14-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-009 (2S,4R)-1-((S)-15-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,13-dioxo-
            3-oxa-2,7,14-triazahexadecan-16-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-010 (2S,4R)-1-((S)-18-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,16-dioxo-
            3-oxa-2,7,17-triazanonadecan-19-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-011 (2S,4R)-1-((S)-17-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,15-dioxo-
            3-oxa-2,7,16-triazaoctadecan-18-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-012 (2S,4R)-1-((S)-17-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,5-dioxo-
            3,10,13-trioxa-2,7,16-triazaoctadecan-
            18-oyl)-4-hydroxy-N-(4-(4-
            methylthiazol-5-yl)benzyl)pyrrolidine-
            2-carboxamide
    CPD-013 (2S,4R)-1-((S)-19-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,17-dioxo-
            3-oxa-2,7,18-triazaicosan-20-oyl)-4-
            hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-014 (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,18-dioxo-
            3-oxa-2,7,19-triazahenicosan-21-oyl)-
            4-hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-015 (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,18-dioxo-
            3,10,13,16-tetraoxa-2,7,19-
            triazahenicosan-21-oyl)-4-hydroxy-N-
            (4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-016 (2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,19-dioxo-
            3,10,13,16-tetraoxa-2,7,20-
            triazadocosan-22-oyl)-4-hydroxy-N-(4-
            (4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-017 (2S,4R)-1-((S)-24-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,22-dioxo-
            3,10,13,16,19-pentaoxa-2,7,23-
            triazapentacosan-25-oyl)-4-hydroxy-N-
            (4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-018 (2S,4R)-1-((S)-27-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,25-dioxo-
            3,10,13,16,19,22-hexaoxa-2,7,26-
            triazaoctacosan-28-oyl)-4-hydroxy-N-
            (4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-019 N-(3-((2-(2-((2-(2,6-dioxopiperidin-3-
            yl)-1,3-dioxoisoindolin-4-
            yl)amino)ethoxy)ethyl)amino)propoxy)-
            3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-020 N-(3-((2-(2-(2-((2-(2,6-dioxopiperidin-
            3-yl)-1,3-dioxoisoindolin-4-
            yl)amino)ethoxy)ethoxy)ethyl)amino)
            propoxy)-3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-021 N-((1-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-yl)amino)-3,6,9-
            trioxa-12-azapentadecan-15-yl)oxy)-
            3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-022 N-((1-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-yl)amino)-
            3,6,9,12-tetraoxa-15-azaoctadecan-18-
            yl)oxy)-3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-023 N-((1-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-yl)amino)-
            3,6,9,12,15-pentaoxa-18-azahenicosan-
            21-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-024 N-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)ethyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-025 N-(3-((3-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)propyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-026 N-(3-((4-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)butyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-027 N-(3-((5-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)pentyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-028 N-(3-((6-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)hexyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-029 N-(3-((7-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)heptyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4
            iodophenyl)amino)benzamide
    CPD-030 N-(3-((8-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-4-
            yl)amino)octyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-031 (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,18-dioxo-
            3-oxa-2,7,19-triazahenicosan-21-oyl)-
            4-hydroxy-N-((S)-1-(4-(4-
            methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-032 (2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,19-dioxo-
            3-oxa-2,7,20-triazadocosan-22-oyl)-4-
            hydroxy-N-(4-(4-methylthiazol-5-
            yl)benzyl)pyrrolidine-2-carboxamide
    CPD-033 (2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,19-dioxo-
            3-oxa-2,7,20-triazadocosan-22-oyl)-4-
            hydroxy-N-((S)-1-(4-(4-methylthiazol-
            5-yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-034 (2R,4S)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,18-dioxo-
            3-oxa-2,7,19-triazahenicosan-21-oyl)-
            4-hydroxy-N-((S)-1-(4-(4-
            methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-035 (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,18-dioxo-
            3-oxa-2,8,19-triazahenicosan-21-oyl)-
            4-hydroxy-N-((S)-1-(4-(4-
            methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-036 (2S,4R)-1-((S)-19-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,17-dioxo-
            3-oxa-2,7,18-triazaicosan-20-oyl)-4-
            hydroxy-N-((S)-1-(4-(4-methylthiazol-
            5-yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-037 (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-7-methyl-
            1,18-dioxo-3-oxa-2,7,19-
            triazahenicosan-21-oyl)-4-hydroxy-N-
            ((S)-1-(4-(4-methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-038 (2S,4R)-1-((S)-22-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,20-dioxo-
            3-oxa-2,8,21-triazatricosan-23-oyl)-4-
            hydroxy-N-((S)-1-(4-(4-methylthiazol-
            5-yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-039 (2S,4R)-1-((2S)-21-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,19-dioxo-
            3-oxa-2,8,20-triazadocosan-22-oyl)-4-
            hydroxy-N-((S)-1-(4-(4-methylthiazol-
            5-yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-040 N-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)ethyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-041 N-(3-((3-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)propyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-042 N-(3-((4-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)butyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-043 N-(3-((5-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)pentyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-044 N-(3-((6-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)hexyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-045 N-(3-((7-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)heptyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-046 N-(3-((8-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-
            yl)amino)octyl)amino)propoxy)-3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-047 N-(3-((2-(2-((2-(2,6-dioxopiperidin-3-
            yl)-1,3-dioxoisoindolin-5-
            yl)amino)ethoxy)ethyl)amino)propoxy)-
            3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-048 N-(3-((2-(2-(2-((2-(2,6-dioxopiperidin-
            3-yl)-1,3-dioxoisoindolin-5-
            yl)amino)ethoxy)ethoxy)ethyl)amino)
            propoxy)-3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-049 N-((1-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-yl)amino)-3,6,9-
            trioxa-12-azapentadecan-15-yl)oxy)-
            3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-050 N-((1-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-yl)amino)-
            3,6,9,12-tetraoxa-15-azaoctadecan-18-
            yl)oxy)-3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-051 N-((1-((2-(2,6-dioxopiperidin-3-yl)-
            1,3-dioxoisoindolin-5-yl)amino)-
            3,6,9,12,15-pentaoxa-18-azahenicosan-
            21-yl)oxy)-3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)benzamide
    CPD-052 (2R,4S)-1-((S)-22-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-1,20-dioxo-
            3-oxa-2,8,21-triazatricosan-23-oyl)-4-
            hydroxy-N-((S)-1-(4-(4-methylthiazol-
            5-yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-053 (2R,4S)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-7-methyl-
            1,18-dioxo-3-oxa-2,7,19-
            triazahenicosan-21-oyl)-4-hydroxy-N-
            ((S)-1-(4-(4-methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-054 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            13-(4-(4-methylthiazol-5-yl)phenyl)-
            1,11-dioxo-3-oxa-2,7,10-
            triazatridecan-13-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-055 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            14-(4-(4-methylthiazol-5-yl)phenyl)-
            1,12-dioxo-3-oxa-2,7,11-
            triazatetradecan-14-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-056 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            15-(4-(4-methylthiazol-5-yl)phenyl)-
            1,13-dioxo-3-oxa-2,7,12-
            triazapentadecan-15-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-057 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            16-(4-(4-methylthiazol-5-yl)phenyl)-
            1,14-dioxo-3-oxa-2,7,13-
            triazahexadecan-16-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-058 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            17-(4-(4-methylthiazol-5-yl)phenyl)-
            1,15-dioxo-3-oxa-2,7,14-
            triazaheptadecan-17-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-059 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            18-(4-(4-methylthiazol-5-yl)phenyl)-
            1,16-dioxo-3-oxa-2,7,15-
            triazaoctadecan-18-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-060 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            19-(4-(4-methylthiazol-5-yl)phenyl)-
            1,17-dioxo-3-oxa-2,7,16-
            triazanonadecan-19-yl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-061 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            20-(4-(4-methylthiazol-5-yl)phenyl)-
            1,18-dioxo-3-oxa-2,7,17-triazaicosan-
            20-yl)-1-(2-(1-fluorocyclopropane-1-
            carboxamido)-3,3-dimethylbutanoyl)-
            4-hydroxypyrrolidine-2-carboxamide
    CPD-062 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            21-(4-(4-methylthiazol-5-yl)phenyl)-
            1,19-dioxo-3-oxa-2,7,18-
            triazahenicosan-21-yl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-063 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            22-(4-(4-methylthiazol-5-yl)phenyl)-
            1,20-dioxo-3-oxa-2,7,19-
            triazadocosan-22-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-064 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            16-(4-(4-methylthiazol-5-yl)phenyl)-
            1,14-dioxo-3,10-dioxa-2,7,13-
            triazahexadecan-16-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-065 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            23-(4-(4-methylthiazol-5-yl)phenyl)-
            1,21-dioxo-3-oxa-2,7,20-
            triazatricosan-23-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-066 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            19-(4-(4-methylthiazol-5-yl)phenyl)-
            1,17-dioxo-3,10,13-trioxa-2,7,16-
            triazanonadecan-19-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-067 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            22-(4-(4-methylthiazol-5-yl)phenyl)-
            1,20-dioxo-3,10,13,16-tetraoxa-2,7,19-
            triazadocosan-22-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-068 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            25-(4-(4-methylthiazol-5-yl)phenyl)-
            1,23-dioxo-3,10,13,16,19-pentaoxa-
            2,7,22-triazapentacosan-25-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-069 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            28-(4-(4-methylthiazol-5-yl)phenyl)-
            1,26-dioxo-3,10,13,16,19,22-hexaoxa-
            2,7,25-triazaoctacosan-28-yl)-1-(2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-070 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,11-dioxo-3-oxa-2,7,10-
            triazadodecan-12-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-071 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,12-dioxo-3-oxa-2,7,11-
            triazatridecan-13-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-072 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,13-dioxo-3-oxa-2,7,12-
            triazatetradecan-14-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-073 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,14-dioxo-3-oxa-2,7,13-
            triazapentadecan-15-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-074 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,16-dioxo-3-oxa-2,7,15-
            triazaheptadecan-17-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-075 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,17-dioxo-3-oxa-2,7,16-
            triazaoctadecan-18-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-076 (2S,4R)-1-((S)-2-(1-
            cyanocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-N-((S)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-19-(4-(4-
            methylthiazol-5-yl)phenyl)-1,17-
            dioxo-3-oxa-2,7,16-triazanonadecan-
            19-yl)-4-hydroxypyrrolidine-2-
            carboxamide
    CPD-077 (2S,4R)-1-((S)-2-(1-
            cyanocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-N-((S)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-21-(4-(4-
            methylthiazol-5-yl)phenyl)-1,19-
            dioxo-3-oxa-2,7,18-triazahenicosan-
            21-yl)-4-hydroxypyrrolidine-2-
            carboxamide
    CPD-078 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            19-(4-(4-methylthiazol-5-yl)phenyl)-
            1,17-dioxo-3-oxa-2,7,16-
            triazanonadecan-19-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-079 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            21-(4-(4-methylthiazol-5-yl)phenyl)-
            1,19-dioxo-3-oxa-2,7,18-
            triazahenicosan-21-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-080 (2R,4R)-N-(2-((1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            1,15-dioxo-3-oxa-2,7,14-
            triazahexadecan-16-yl)oxy)-4-(4-
            methylthiazol-5-yl)benzyl)-1-((S)-2-(1-
            fluorocyclopropane-1-carboxamido)-
            3,3-dimethylbutanoyl)-4-
            hydroxypyrrolidine-2-carboxamide
    CPD-081 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            13-(4-(4-methylthiazol-5-yl)phenyl)-
            1,11-dioxo-3-oxa-2,7,10-
            triazatridecan-13-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-082 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            14-(4-(4-methylthiazol-5-yl)phenyl)-
            1,12-dioxo-3-oxa-2,7,11-
            triazatetradecan-14-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-083 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            15-(4-(4-methylthiazol-5-yl)phenyl)-
            1,13-dioxo-3-oxa-2,7,12-
            triazapentadecan-15-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-084 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            16-(4-(4-methylthiazol-5-yl)phenyl)-
            1,14-dioxo-3-oxa-2,7,13-
            triazahexadecan-16-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-085 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            17-(4-(4-methylthiazol-5-yl)phenyl)-
            1,15-dioxo-3-oxa-2,7,14-
            triazaheptadecan-17-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-086 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            18-(4-(4-methylthiazol-5-yl)phenyl)-
            1,16-dioxo-3-oxa-2,7,15-
            triazaoctadecan-18-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-087 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            20-(4-(4-methylthiazol-5-yl)phenyl)-
            1,18-dioxo-3-oxa-2,7,17-triazaicosan-
            20-yl)-4-hydroxy-1-((R)-3-methyl-2-
            (3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-088 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            23-(4-(4-methylthiazol-5-yl)phenyl)-
            1,21-dioxo-3-oxa-2,7,20-
            triazatricosan-23-yl)-4-hydroxy-1-((R)-
            3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-089 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            16-(4-(4-methylthiazol-5-yl)phenyl)-
            1,14-dioxo-3,10-dioxa-2,7,13-
            triazahexadecan-16-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-090 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            19-(4-(4-methylthiazol-5-yl)phenyl)-
            1,17-dioxo-3,10,13-trioxa-2,7,16-
            triazanonadecan-19-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-091 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            22-(4-(4-methylthiazol-5-yl)phenyl)-
            1,20-dioxo-3,10,13,16-tetraoxa-2,7,19-
            triazadocosan-22-yl)-4-hydroxy-1-
            ((R)-3-methyl-2-(3-methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-092 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            25-(4-(4-methylthiazol-5-yl)phenyl)-
            1,23-dioxo-3,10,13,16,19-pentaoxa-
            2,7,22-triazapentacosan-25-yl)-4-
            hydroxy-1-((R)-3-methyl-2-(3-
            methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-093 (2S,4R)-N-((S)-1-(3,4-difluoro-2-((2-
            fluoro-4-iodophenyl)amino)phenyl)-
            28-(4-(4-methylthiazol-5-yl)phenyl)-
            1,26-dioxo-3,10,13,16,19,22-hexaoxa-
            2,7,25-triazaoctacosan-28-yl)-4-
            hydroxy-1-((R)-3-methyl-2-(3-
            methylisoxazol-5-
            yl)butanoyl)pyrrolidine-2-carboxamide
    CPD-094 (2S,4R)-1-((S)-20-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-8-methyl-
            1,18-dioxo-3-oxa-2,8,19-
            triazahenicosan-21-oyl)-4-hydroxy-N-
            ((S)-1-(4-(4-methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-095 (2S,4R)-1-((S)-22-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-8-methyl-
            1,20-dioxo-3-oxa-2,8,21-
            triazatricosan-23-oyl)-4-hydroxy-N-
            ((S)-1-(4-(4-methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-096 (2S,4R)-1-((S)-21-(tert-butyl)-1-(3,4-
            difluoro-2-((2-fluoro-4-
            iodophenyl)amino)phenyl)-8-methyl-
            1,19-dioxo-3-oxa-2,8,20-
            triazadocosan-22-oyl)-4-hydroxy-N-
            ((S)-1-(4-(4-methylthiazol-5-
            yl)phenyl)ethyl)pyrrolidine-2-
            carboxamide
    CPD-097 3,4-difluoro-2-((2-fluoro-4-
            iodophenyl)amino)-N-((1-((2-(1-
            methyl-2,6-dioxopiperidin-3-yl)-1,3-
            dioxoisoindolin-5-yl)amino)-
            3,6,9,12,15-pentaoxa-18-azahenicosan-
            21-yl)oxy)benzamide

As used herein, in case of discrepancy between the structure and chemical name provided for a particular compound, the structure shall control.

Example 100

Selected MEK Degraders Suppressed the Growth of HT-29 Cells (Table 2)

MTT assay was conducted for HT-29 cells after 3 d treatment with indicated compounds with serial dilutions.

Example 101

Selected MEK Degraders Reduced MEK Protein Levels in HT-29 Cells (FIG. 1)

Cells were treated with DMSO or serial dilution of indicated compounds for 24 h. Compound concentrations are 0.3 μM, 1 μM and 3 μM. MEK1/2 protein levels were determined by western blots and normalized with α-tubulin.

Example 102

Selected Compounds Inhibited the Kinase Activity of MEK1 and MEK2 (FIG. 2)

Inhibition value for each concentration point was determined by measuring MEK1/2 kinase activity on ERK phosphorylation and normalized with DMSO control point.

Example 103

CPD-031 Reduces MEK1/2 Protein Levels and Inhibits the Downstream ERK Signaling in a Concentration-Dependent Manner (FIG. 3A-D)

HT-29 (A and C) and SK-MEL-28 (B and D) cells were treated with DMSO or serial dilution of CPD-031 for 24 h. The indicated protein levels were determined by western blots and normalized with α-tubulin.

Example 104

The Effects of PD0325901, CPD-031 and CPD-034 on Reducing MEK1/2 Protein Levels and Inhibiting the Downstream ERK Signaling (FIG. 3E-F)

HT-29 (E) and SK-MEL-28 (F) cells were treated with DMSO or 0.1, 0.3, or 1 μM of PD0325901, CPD-031 and CPD-034 for 24 h.

Example 105

CPD-031 Induced Degradation of MEK1 and MEK2 and Suppresses the Downstream ERK Signaling in a Time-Dependent Manner (FIG. 4A-B)

HT-29 (A) and SK-MEL-28 (B) cells were treated with 0.1 μM or 0.3 μM compound 23 for 24 h. Cells were harvested at indicated time points within 24 h and the indicated protein levels were determined by western blots.

Example 106

CPD-031 Induced MEK1/2 Protein Degradation Through Recruiting the VHL E3 Ubiquitin Ligase and Proteasome-Dependent Proteolysis (FIG. 5)

HT-29 and SK-MEL-28 cells were pretreated with DMSO, PD0325901 (1 μM), MG-132 (3 μM), MLN4924 (1 μM) or VH 032 (10 μM) for 2 h, followed by 10 h treatment with 0.3 μM CPD-031 for rescue experiments. The indicated protein levels were determined by western blots.

Example 107

Global Proteome Analyses of HT-29 Cells Treated with CPD-031, CPD-034 or DMSO Control (FIG. 6A-C)

Cells were harvested for proteome analysis after 10 h treatment with 0.1% DMSO, 0.1 μM CPD-031 or 0.1 μM CPD-034. Volcano plots of the—log10 (P value) versus the log2 ratio are displayed, with proteins outside the significance lines colored in pink or purple (FDR<0.05). P values were calculated from the data of two technical replicates. (A) DMSO compared to CPD-031 treated samples; (B) CPD-034 compared to CPD-031 treated samples; (C) DMSO compared to CPD-034 treated samples.

Example 108

CPD-31 Inhibited Cell Proliferation of HT-29 and SK-MEL-28 Cells (FIG. 7A-D)

MTT assay was conducted for HT-29 (A) and SK-MEL-28 (B) cells after 3 d treatment with DMSO or indicated compounds with serial dilutions. Clonogenic assay was performed in HT-29 (C) and SK-MEL-28 (D) cells for 14 d treatment with DMSO or indicated compounds with 10, 30 and 100 nM, in duplicate, respectively. Cells were then stained by crystal violet.

Example 109

shRNA-Mediated MEK1 and/or MEK2 Knockdown Suppressed Cell Growth (FIG. 7E-F)

shRNA-mediated MEK1/2 knockdown experiments were conducted in HT-29 (E) and SK-MEL-28 (F) cells. MTT assay was used to determine cell viability to assess the effect of MEK1/2 knockdown via shRNAs.

Example 110

CPD-037 and CPD-038 Degraded MEK1 and MEK2 and Inhibited pMEK and pERK in a Concentration-Dependent Manner (FIG. 8A-B)

HT-29 (A) and SK-MEL-28 (B) cells were treated with DMSO or serial dilution of indicated compounds for 24 h. The indicated protein levels were determined by Western blots.

Example 111

Selected MEK Degraders Reduced MEK Protein Levels in HT-29 Cells (FIG. 9A)

Cells were treated with DMSO or serial dilution of indicated compounds for 24 h. Compound concentrations are 0.3 μM, 1 μM and 3 μM. MEK1/2 protein levels were determined by western blots and normalized with a-tubulin.

Example 112

CPD-051 Reduced MEK1/2 Protein Levels and Inhibits the Downstream ERK Signaling in a Concentration-Dependent Manner (FIG. 9B)

HT-29 and SK-MEL-28 cells were treated with DMSO or serial dilution of CPD-051 for 24 h. The indicated protein levels were determined by western blots and normalized with α-tubulin.

Example 113

CPD-037, CPD-038, and CPD-051 Degraded MEK1 and MEK2 and Inhibit pERK Signaling in a Time-Dependent Manner (FIG. 10)

HT-29 cells treated with 0.1 μM of CPD-037 or CPD-038, or 0.3 μM of CPD-051 were harvested at indicated time points. The indicated protein levels were determined by Western blots.

Example 114

Degradation of MEK1/2 Induced by CPD-037, CPD-038, and CPD-051 is Mediated by the Ubiquitin-Proteasome System (FIG. 11)

HT-29 cells were pretreated with DMSO, PD0325901 (1 μM), MG-132 (3 μM), MLN4924 (3 μM), VH 032 (10 μM) or pomalidomide (POMA, 5 μM) for 2 h, before 0.1 μM of CPD-037 or CPD-038, or 0.3 μM of CPD-051 was added. The cells were incubated for another 8 h. The indicated protein levels were determined by Western blots.

Example 115

CPD-038 and CPD-51 Selectively Degraded MEK1 and MEK2 in HT-29 Cells (FIG. 12A-D)

HT-29 cells were treated with 0.1% DMSO, 0.1 μM of CPD-038, 0.3 μM of CPD-051, 0.1 μM of CPD-052 or 0.3 μM of CPD-097 for 8 h before they were harvested for mass spectrometry analysis. Volcano plots of the—log10 (p value) vs the log2 fold change are displayed. Proteins outside the significance lines were labeled with pink or purple color (FDR=0.05, S0=1). P values were calculated from the data of two technical replicates.

Example 116

CPD-037, CPD-038 and CPD-051 Significantly Suppress the Growth of HT-29 and SK-MEL-28 Cells (FIG. 13A-I)

HT-29 (A-C) and SK-MEL-28 (D-F) cells were treated with serial dilutions of indicated compounds for 3 d, followed by WST-8 assay to get live cell signal. (G-I) Clonogenic assay was conducted in HT-29 cells. HT-29 cells were treated with indicated compounds for 10 d. The Petri dish images are representative of two independent experiments. Cells were fixed and stained by crystal violet.

Example 117

Anti-Proliferation Effects of CPD-037 and CPD-038 Versus AZ Compound in Four Different Cancer Cell Lines (FIG. 14A-D)

HT-29 (A), SK-MEL-28 (B), H3122 (C) and SUDHL1 (D) cells were treated with serial dilutions of indicated compounds for 3 d, followed by WST-8 assay to get live cell signal.

Example 118

Concurrent Inhibition of BRAF or PI3K Potentiates Anti-Proliferation Potency of CPD-038 (FIG. 15A-B)

HT-29 (A) and SK-MEL-28 (B) cells were treated with indicated compounds for 3 d, followed by WST-8 assay to get live cell signal.

Example 119

Plasma Concentrations of CPD-031, CPD-037 and CPD-038 Following a Single Intraperitoneal Administration (FIG. 16)

Male Swiss Albino mice were dosed with 50 mg/kg of indicated degraders through intraperitoneal administration. Plasma concentrations of indicated degraders at 0.5, 2 and 8 h are ploted.

Materials and Methods:

General Chemistry Methods:

An Agilent 1200 series system with DAD detector and a 2.1 mm×150 mm Zorbax 300SB-C18 5 μm column with water containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic acid as solvent B at a flow rate of 0.4 mL/min for chromatography were used to obtain high-performance liquid chromatography (HPLC) spectra for all compounds. The gradient program was as follows: 1% B (0-1 min), 1-99% B (1-4 min), and 99% B (4-8 min). A Waters Acquity I-Class Ultra-performance liquid chromatography (UPLC) system with a PDA detector was used to generate UPLC spectra for all compounds. Chromatography was performed using a 2.1×30 mm ACQUITY UPLC BEH C18 1.7 μm column with water containing 3% acetonitrile and 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic acid as solvent B at a flow rate of 0.8 mL/min. The gradient program was as follows: 1-99% B (1-1.5 min), and 99-1% B (1.5-2.5 min). High-resolution mass spectra (HRMS) data were obtained in positive ion mode using an Agilent G1969A API-TOF with an electrospray ionization (ESI) source. Nuclear Magnetic Resonance (NMR) spectra were obtained on a Bruker DRX-600 spectrometer with 600 MHz for proton (¹H NMR) or a Bruker DXI 800 MHz spectrometer with 800 MHz for proton (¹H NMR) or 200 MHz for carbon (¹³C NMR); chemical shifts are reported in ppm (δ). Preparative HPLC was performed using an Agilent Prep 1200 series with UV detector set to 220 nm. Samples were injected into a Phenomenex Luna 75×30 mm, 5 μm, C18 column at room temperature. The flow rate was 40 mL/min. A linear gradient was used with 10% (or 50%) of MeOH (A) in H₂O (with 0.1% TFA) (B) to 100% of MeOH (A). HPLC and UPLC were used to establish the purity of target compounds. All final compounds had >95% purity using the HPLC and UPLC methods described above.

Kinase Inhibition Assay

The inhibition potencies of compounds against MEK1 and MEK2 kinases were determined using the HotSpot kinase assay by Reaction Biology company. This assay measures MEK kinase activity on ERK phosphorylation. Briefly, after incubating the compounds with the kinase reaction mixture of MEK and ERK proteins for 20 min at RT, ³³P-ATP (specific activity 10 μCi/ul) was delivered into the reaction mixture to initiate the reaction for incubation for 2 hours at RT. Radioactivity was then detected by filter-binding method. Kinase activity data was expressed as the percent remaining kinase activity in samples compared to DMSO reactions. Purified kinase proteins, MEK1 (PV3303, Thermo Fisher Scientific) at 100 nM, MEK2 (PV3615, Thermo Fisher Scientific) at 150 nM and ERK kinase-dead mutant K52R (Reaction Biology) at 5 μ□□ were used in the reactions. IC₅₀ was determined using 10-concentration 3-fold serial dilution (top concentrations for PD0325901, compounds 23 and 24 were 3 μM, 30 μM and 30 μM, respectively) with DMSO as control point in two independent experiments.

Cell Culture

Cells were cultivated in DMEM, RPMI-1640 or RPMI-1640 medium supplemented with 10% FBS, 100 units/mL of penicillin and 100 μg/mL of streptomycin. Mycoplasma elimination using LookOut Mycoplasma Elimination Kit (MP0030, Sigma-Aldrich) was conducted before the cells used for experiments.

Western Blot

Cells were lysed on ice for 30 min with the lysis buffer (50 mM Tris pH 7.4, 1% IGEPAL CA-630, 150 mM NaCl, 1 mM EDTA and 1 mM AESBF), supplemented with protease and phosphatase inhibitor cocktail (A32961, Thermo Fisher Scientific). The sample was centrifuged at 12,000 g for 10 min at 4° C. to get supernatant as cell lysate. Protein concentrations were quantified using Pierce rapid gold BCA protein assay kit. The primary antibodies used were MEK1 (2352, CST), MEK2 (9147, CST), pMEK (9121, CST), ERK (4696, CST), pERK (4370, CST), α-tubulin (T6074, Sigma-Aldrich), VHL (68547, CST), CRBN (HPA045910, Sigma-Aldrich), Cullin-9 (A300-098A, Bethyl Laboratories), LENG8 (A304-947A, Bethyl Laboratories). Fluorescence-labeled secondary antibodies (IRDye 680, 800, LI-COR) and OdysseyCLx imaging system (LI-COR) were used to get protein signals which were then analyzed by Image Studio Lite software (LI-COR). DC₅₀ values were obtained with GraphPad Prism 8 from the data of three independent experiments.

Binding affinity assays. For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phase and infected with T7 phage and incubated with shaking at 32° C. until lysis. The lysateswere centrifuged and filtered to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small molecule ligands for 30 min at rt to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with blocking buffer (SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT) to remove unbound ligand and to reduce non-specific binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 111X stocks in 100% DMSO. Kds were determined using an 11-point 3-fold compound dilution series with three DMSO control pointsAll compounds for Kd measurements are distributed by acoustic transfer (non-contact dispensing) in 100% DMSO. The compounds were then diluted directly into the assays such that the final concentration of DMSO was 0.9%. All reactions performed in polypropylene 384-well plate. Each was a final volume of 0.02 mL. The assay plates were incubated at room temperaturewith shaking for 1 h and the affinity beads were washed with wash buffer (1× PBS, 0.05% Tween 20). The beads were then re-suspended in elution buffer (1× PBS, 0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR.

Proteomics Studies

Protein Extraction and Digestion. Cells with indicated treatments were harvested and lysed in lysis buffer (6 M guanidine hydrochloride, 100 mM Tris-HCl pH 8.0). Sonication (5 s on, 5 s off, 2×30 s) was performed to shear genome DNA. Lysate were centrifugated for 30 min at 3,500 g at 4° C. and the supernatant were transferred to a clean tube, diluted 50% with Milli-Q H₂O, then precipitated by addition of cold acetone (four times the original volume), and placed at −20° C. overnight. Precipitated proteins were brought down at 20,000 g at 4° C. for 10 min, and washed with cold acetone after discarding the supernatant. The pellet was air-dried at RT for 5 min and solubilized with 50 mM Tris-HCl (PH 8.0), 8 M urea. Protein concentration was determined (BCA assay) and protein was reduced with 5 mM DTT (dithiothreitol), alkylated with 15 mM IAA (iodoacetamide) in the dark, then diluted with buffer 25 mM Tris (pH 8.0) and 1 mM CaCl₂ (three times the original volume). The final urea concentration is 2 M. Trypsin was added into protein solution with 1:100 ratio (trypsin:protein), and digested 12-16 h or overnight at RT.

Mass Spectrometry Analysis. Peptides were cleaned up by C18 stage tips and the concentration was determined (Peptide assay, 23275, Thermo Fisher Scientific). The clean peptides were dissolved in 0.1% formic acid and analyzed on a Q-Exactive HF-X coupled with an Easy nanoLC 1200 (Thermo Fisher Scientific, San Jose, Calif.). 0.5 μg of peptides were loaded onto an Acclain PepMap RSLC C18 Column (250 mm×75 μm ID, C18, 2 μm, Thermo Fisher Scientific). Analytical separation of all peptides was achieved with 130 min gradient. A linear gradient of 5 to 30% buffer B over 110 min was executed at a 300 nl/min flow rate followed a ramp to 100% B in 5 min, and 15-min wash with 100% B, where buffer A was aqueous 0.1% formic acid, and buffer B was 80% acetonitrile and 0.1% formic acid.

LC-MS experiments were performed in a data-dependent mode with full MS (externally calibrated to a mass accuracy of <5 ppm and a resolution of 60,000 at m/z 200) followed by high energy collision-activated dissociation-MS/MS of the top 20 most intense ions with a resolution of 15,000 at m/z 200. High energy collision-activated dissociation-MS/MS was used to dissociate peptides at a normalized collision energy of 27 eV in the presence of nitrogen bath gas atoms. Dynamic exclusion was 30.0 seconds. Each sample was subjected to two technical LC-MS replicates.

MS Data Analysis. Mass spectra processing and peptide identification were performed on the Andromeda search engine in MaxQuant software (Version 1.6.0.16) against the human UniProt database (UP000005640). All searches were conducted with a defined modification of cysteine carbamidomethylation, with methionine oxidation and protein amino-terminal acetylation as dynamic modifications. Peptides were confidently identified using a target-decoy approach with a peptide false discovery rate (FDR) of 1% and a protein FDR of 1%. A minimum peptide length of 7 amino acids was required, maximally two missed cleavages were allowed, initial mass deviation for precursor ion was up to 7 ppm, and the maximum allowed mass deviation for fragment ions was 0.5 Da. Data processing and statistical analysis were performed on Perseus (Version 1.6.0.7). Protein quantitation was performed on duplicate runs, and a two-sample t-test statistics was used to report statistically significant expression fold-changes.

Cell Viability Assay

Cells (2000 cells per well) were seeded into 96-well microplates. After 20 h, cells were treated with 0.1% DMSO or indicated serial dilutions of compounds in duplicate or triplicate for 3 days. Cell viability was tested using MTT (M6494, Thermo Fisher Scientific) or WST-8 reagent (CK04, Dojindo). Briefly, 12 mM MTT was prepared in PBS or WST-8 reagent was warmed up to room temperature. 20 μL, MTT or CCK-8 was then added to each well and the plates were kept in incubator at 37° C. for 3 h in the dark. For the WST-8 assay, signal was obtained after the incubation. For the MTT assay, cell medium was replaced with 200 μL, of DMSO after the incubation, and then cell plates were kept at 37° C. for another 30 min. Absorbance signals for MTT and WST-8 were read at 540 nm and 450 nm respectively, with 690 nm as reference performed with Infinite F PLEX plate reader (TECAN, Morrisville, N.C., USA). GI₅₀ values were analyzed using GraphPad Prism 8 from the data of at least three independent experiments.

Clonogenic Assay

HT-29 or SK-MEL-28 cells (300 cells per well) were seeded in 12-well plates. After 20 h, cells were treated with DMSO or indicated concentrations of compounds in duplicate for two weeks. Medium containing indicated compounds was changed every 3 days. Cells were then fixed and stained with the solution containing 6% (v/v) glutaraldehyde (G5882, Sigma-Aldrich) and 0.5% (w/v) crystal violet for 1 h. To remove the background color, the plates with stained cells were immersed in running water until clear colonies were observed. The plates were dried at RT. The staining images were obtained with Epson Perfection V600 Photo.

shRNA-Mediated MEK Knockdown

HEK293T cells were transfected with PMD (VSVG)/pCMVΔ8.2/pLK0.1 plasmids for lentivirus packaging. 48 h later, virus was harvested in the medium and filtered. 1.5 mL of virus with 10 μg/mL of polybrene (TR-1003, Sigma-Aldrich) was added into 6-cm dishes to infect HT-29 or SK-MEL-28 cells. After 24 h, medium was changed into fresh full medium with 2 μg/mL of puromycin (P8833, Sigma-Aldrich) for 48 h for selection, and then 2000 cells of shControl, shMEK1 (TRCN0000002329, Sigma-Aldrich), shMEK2 (TRCN0000195037, Sigma-Aldrich), or shMEK1/2 cells, in nonuplicate, were seeded into 96-well plates for 4 d growth. MTT assay was performed every day to get cell viability signals. Meanwhile, knockdown efficiency of each shRNA was examined by western blot.

Mouse PK Study

The in vivo PK studies were conducted for indicated compounds using three male Swiss Albino mice per compound. The mice were administered intraperitoneally with solution formulation (5% NMP, 5% Solutol HS-15, and 90% normal saline) of indicated compounds at a single dose of 50 mg/kg Sixty microliters of blood samples were collected from each mouse at 0.5, 2, and 8 h. Plasma was harvested by centrifugation of blood and stored at −70±10° C. until analysis. Plasma samples were quantified by fit-for-purpose LC-MS/MS method (LLOQ: 5.02 ng/mL for plasma)

Statistic Methods

For all data, number of biologically independent experiments and technical replicates, error bars and P values are described in figure legends, respectively. At least two independent experiments were conducted for all biological studies. The proteomics study was conducted in duplicate. Two-tailed Student's t-tests and two-way ANOVA were used for indicated analysis respectively, P≥0.05, ns; 0.01<P<0.05, *; 0.001<P<0.01, **; P<0.001, ***.

The anti-proliferation results of selected heterobifunctional compounds are set forth in Table 2 below.

TABLE 2
CPD     GI50 (μM) HT-29
CPD-001 1.4 ± 0.2
CPD-002 4.0 ± 0.2
CPD-003 4.8 ± 0.7
CPD-004 1.6 ± 0.3
CPD-005 1.8 ± 0.4
CPD-006 5.0 ± 1.1
CPD-007 3.0 ± 0.5
CPD-008 11 ± 0.9
CPD-009 2.1 ± 0.1
CPD-010 0.6 ± 0.1
CPD-011 0.5 ± 0.2
CPD-012 1.6 ± 0.3
CPD-013 0.5 ± 0.03
CPD-014 0.4 ± 0.2
CPD-015 1.3 ± 0.1
CPD-016 3.3 ± 0.6
CPD-017 1.7 ± 0.1
CPD-019 1.2 ± 0.2
CPD-020 1.3 ± 0.5
CPD-021 0.8 ± 0.2
CPD-022 0.6 ± 0.09
CPD-023 0.6 ± 0.1
CPD-024 0.4 ± 0.01
CPD-025 1.1 ± 0.07
CPD-026 1.9 ± 0.4
CPD-027 1.8 ± 0.5
CPD-028 3.8 ± 1.7
CPD-029 4.5 ± 1.9
CPD-030 3.5 ± 0.9
CPD-031 0.13 ± 0.04
CPD-033 0.099 ± 0.008
CPD-035 0.055 ± 0.005
CPD-036 0.24 ± 0.055
CPD-037 0.032 ± 0.008
CPD-038 0.023 ± 0.005
CPD-039 0.043 ± 0.001
CPD-041 0.5 ± 0.2
CPD-042 1.0 ± 0.4
CPD-043 0.5 ± 0.1
CPD-044 1.1 ± 0.5
CPD-045 0.5 ± 0.2
CPD-046 0.3 ± 0.1
CPD-047 1.4 ± 0.7
CPD-048 1.1 ± 0.3
CPD-049 1.5 ± 0.5
CPD-050 0.5 ± 0.06
CPD-051 0.3 ± 0.06
CPD-052 0.83 ± 0.085
CPD-053 1.3 ± 0.16

GI₅₀ (μM) values of selected compounds in HT-29 cells.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Claims

1. A heterobifunctional compound comprising a mitogen-activated protein kinase kinase (MEK) ligand conjugated to a degradation tag through a linker, according to FORMULA I-1:

2. The heterobifunctional compound of claim 1, according to Formula I-2:

3. The heterobifunctional compound of claim 2, according to one of Formulae I-3-I-8:

4. The heterobifunctional compound of claim 1, wherein Ar2 is

5. The heterobifunctional compound of claim 1, wherein Ar2 is

6. The heterobifunctional compound of claim 3, according to one of Formulae I-9-I-20:

7. (canceled)

8. The heterobifunctional compound of claim 6, according to one of Formulae I-21-I-32:

9. (canceled)

10. The heterobifunctional compound of claim 6, according to one of Formulae I-33-I-38:

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

20. (canceled)

21. (canceled)

22. The heterobifunctional compound of claim 6, according to Formula II:

23. The heterobifunctional compound of claim 1, according to Formula III:

24. The heterobifunctional compound of claim 1, according to Formula IV:

25. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULAE 6A-1, 6B-1, 6C-1, 6A-2, 6B-2, 6C-2, 6A-3, 6B-3, 6C-3, 6A-4, 6B-4, 6C-4, 6A-5, 6B-5, 6C-5, 6A-6, 6B-6, 6C-6, 6A-7, 6B-7, 6C-7, 6A-8, 6B-8, or 6C-8:

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. The heterobifunctional compound of claim 1, wherein RE4 is selected from —N(RE10)RE11, —N(RE10)C(O)RE11,

31. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULAE 6A-9, 6A-10, 6A-11, 6A-12, 6A-13, 6B-9, 6B-10, 6B-11, 6B-12, 6B-13, 6B-14, 6B-15, 6C-9, 6C-10, 6C-11, 6C-12, 6C-13, 6C-14, or 6C-15:

32. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of any of FORMULAE 7A to 7BJ:

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. (canceled)

39. (canceled)

40. (canceled)

41. (canceled)

42. (canceled)

43. The heterobifunctional compound of claim 1, wherein REr, at each occurrence, is selected from Group RE, and Group RE consists of optionally substituted following cyclic groups

44. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety selected from the group consisting of FORMULA 5-1, 5-2, 5-3, 5-4, 5-5 and 5-6, and the degradation tag is connected to the linker moiety of the heterobifunctional compound via a divalent group of ZE;

45. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety selected from the group consisting of FORMULAE 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H, 5I, 5J, 5K, 5L and 5M:

46. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULA 5-1, or FORMULA 5-3,

47. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULA 5A, 5B, 5E, 5F or 5G

48. (canceled)

49. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULA 5-2,

50. (canceled)

51. (canceled)

52. (canceled)

53. (canceled)

54. (canceled)

55. (canceled)

56. (canceled)

57. (canceled)

58. (canceled)

59. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULAE 8A to 8HE:

60. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULA 4A:

61. The heterobifunctional compound of claim 1, wherein the degradation tag is a moiety of FORMULA 4B:

62. (canceled)

63. (canceled)

64. (canceled)

65. The heterobifunctional compound of claim 1, wherein RLr, at each occurrence, is selected from FORMULAE C1, C2, C3, C4, and C5:

66. The heterobifunctional compound of claim 1, wherein RLr, at each occurrence, is selected from Group RLr1 and Group RLr2, and Group RLr1 consists of optionally substituted following cyclic groups

67. The heterobifunctional compound of claim 1, wherein the linker moiety is of FORMULA 9A:

68. The heterobifunctional compound of claim 1, wherein the linker moiety is of FORMULA 9B:

69. The heterobifunctional compound of claim 1, wherein the linker moiety is of FORMULA 9C:

70. A heterobifunctional compound having the following structure:

71. A heterobifunctional compound having the following structure:

72. A pharmaceutical composition, comprising the heterobifunctional compound of claim 1 and a pharmaceutically acceptable excipient, adjuvant or vehicle.

73. A method of treating an MEK-mediated disease, comprising administering to a subject in need thereof, a therapeutically effective amount of a heterobifunctional compound according to claim 1.

74. (canceled)

75. (canceled)